>pdb|4R2R|B Chain B, Wilms Tumor Protein (WT1) zinc fingers in complex with carboxylated DNA
AGCGTGGGNGT
>pdb|4R2Q|C Chain C, Wilms Tumor Protein (WT1) zinc fingers in complex with formylated DNA
TANGCCCACGC
>pdb|4R2Q|B Chain B, Wilms Tumor Protein (WT1) zinc fingers in complex with formylated DNA
AGCGTGGGNGT
>pdb|4R2P|C Chain C, Wilms Tumor Protein (WT1) zinc fingers in complex with hydroxymethylated DNA
TANGCCCACGC
>pdb|4R2P|B Chain B, Wilms Tumor Protein (WT1) zinc fingers in complex with hydroxymethylated DNA
AGCGTGGGNGT
>pdb|4R2E|C Chain C, Wilms Tumor Protein (WT1) zinc fingers in complex with methylated DNA
TANGCCCACGC
>pdb|4R2E|B Chain B, Wilms Tumor Protein (WT1) zinc fingers in complex with methylated DNA
AGCGTGGGNGT
>pdb|4R2D|C Chain C, Egr1/Zif268 zinc fingers in complex with formylated DNA
TANGCCCACGC
>pdb|4R2D|B Chain B, Egr1/Zif268 zinc fingers in complex with formylated DNA
AGCGTGGGNGT
>pdb|4R2C|C Chain C, Egr1/Zif268 zinc fingers in complex with hydroxymethylated DNA
TANGCCCACGC
>pdb|4R2C|B Chain B, Egr1/Zif268 zinc fingers in complex with hydroxymethylated DNA
AGCGTGGGNGT
>pdb|4R2A|C Chain C, Egr1/Zif268 zinc fingers in complex with methylated DNA
TANGCCCACGC
>pdb|4R2A|B Chain B, Egr1/Zif268 zinc fingers in complex with methylated DNA
AGCGTGGGNGT
>pdb|2MNX|B Chain B, Major groove orientation of the (2S)-N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine DNA adduct induced by 1,2-epoxy-3-butene
CTTCTTGTCCG
>pdb|2MNX|A Chain A, Major groove orientation of the (2S)-N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine DNA adduct induced by 1,2-epoxy-3-butene
CGGACNAGAAG
>pdb|4MCE|D Chain D, Crystal structure of the Gas5 GRE Mimic
AAGACTGCCTG
>pdb|4MCE|B Chain B, Crystal structure of the Gas5 GRE Mimic
AAGACTGCCTG
>pdb|4LOX|C Chain C, Crystal structure of the I-SmaMI LAGLIDADG homing endonuclease bound to cleaved DNA
NGGAGGATACC
>pdb|4MFA|P Chain P, Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template O6MG and incoming TTP
GCTGATGCGAT
>pdb|4MF8|P Chain P, Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template O6MG and incoming CTP
GCTGATGCGAC
>pdb|1PYJ|A Chain A, Solution Structure of an O6-[4-oxo-4-(3-pyridyl)butyl]guanine adduct in an 11mer DNA duplex
CCATATNGCCC
>pdb|1S37|A Chain A, Accomodation of Mispair-Aligned N3T-Ethyl-N3T DNA Interstrand Crosslink
CGAAANTTTCG
>pdb|4UN5|D Chain D, Crystal structure of Cas9 bound to PAM-containing DNA target containing mismatches at positions 1-3
TTGTGGTATTG
>pdb|4UN5|C Chain C, Crystal structure of Cas9 bound to PAM-containing DNA target containing mismatches at positions 1-3
CAATACCACAA
>pdb|4UN4|D Chain D, Crystal structure of Cas9 bound to PAM-containing DNA target with mismatches at positions 1-2
ATGTGGTATTG
>pdb|4UN4|C Chain C, Crystal structure of Cas9 bound to PAM-containing DNA target with mismatches at positions 1-2
CAATACCACAT
>pdb|4K4I|N Chain N, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)FTC-TP.
CGGCGGTACTG
>pdb|4K4I|J Chain J, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)FTC-TP.
CGGCGGTACTG
>pdb|4K4I|F Chain F, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)FTC-TP.
CGGCGGTACTG
>pdb|4K4I|B Chain B, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)FTC-TP.
CGGCGGTACTG
>pdb|4K4H|N Chain N, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)3TC-TP.
CGGCGGTACTG
>pdb|4K4H|J Chain J, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)3TC-TP.
CGGCGGTACTG
>pdb|4K4H|F Chain F, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)3TC-TP.
CGGCGGTACTG
>pdb|4K4H|B Chain B, Ternary crystal structures of a human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND (-)3TC-TP.
CGGCGGTACTG
>pdb|4K4G|N Chain N, Ternary crystal structures of human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND L-DCTP.
CGGCGGTACTG
>pdb|4K4G|J Chain J, Ternary crystal structures of human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND L-DCTP.
CGGCGGTACTG
>pdb|4K4G|F Chain F, Ternary crystal structures of human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND L-DCTP.
CGGCGGTACTG
>pdb|4K4G|B Chain B, Ternary crystal structures of human DNA POLYMERASE LAMBDA IN COMPLEX WITH DNA AND L-DCTP.
CGGCGGTACTG
>pdb|4Q8F|T Chain T, Human DNA polymerase eta extending primer immediately after a phenanthriplatin adducted G
ATCNTCACACT
>pdb|1N4B|B Chain B, Solution Structure of the undecamer CGAAAC*TTTCG
CGAAANTTTCG
>pdb|2MHZ|B Chain B, Structure of Exocyclic S,S N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
CTTCTTGTCCG
>pdb|2MHZ|A Chain A, Structure of Exocyclic S,S N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
CGGACNAGAAG
>pdb|2MHX|B Chain B, Structure of Exocyclic R,R N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
CTTCTTGTCCG
>pdb|2MHX|A Chain A, Structure of Exocyclic R,R N6,N6-(2,3-Dihydroxy-1,4-butadiyl)-2'-Deoxyadenosine Adduct Induced by 1,2,3,4-Diepoxybutane in DNA
CGGACNAGAAG
>pdb|4O9M|C Chain C, Human DNA polymerase beta complexed with adenylated tetrahydrofuran (abasic site) containing DNA
GCTGATGCGCC
>pdb|2MIW|B Chain B, Nuclear magnetic resonance studies of N2-guanine adducts derived from the tumorigen dibenzo[a,l]pyrene in DNA: Impact of adduct stereochemistry, size, and local DNA structure on solution conformations
GGTAGCGATGG
>pdb|2MIW|A Chain A, Nuclear magnetic resonance studies of N2-guanine adducts derived from the tumorigen dibenzo[a,l]pyrene in DNA: Impact of adduct stereochemistry, size, and local DNA structure on solution conformations
CCATCGCTACC
>pdb|2MIV|A Chain A, NMR studies of N2-guanine adducts derived from the tumorigen dibenzo[a,l]pyrene in DNA: Impact of adduct stereochemistry, size, and local DNA structure on solution conformations
CCATCGCTACC
>pdb|4NM2|P Chain P, Structure of human DNA polymerase beta complexed with a nicked DNA containing a 8BrG-G at N-1 position and G-C at N position
GCTGATGCGGC
>pdb|4NM1|P Chain P, Structure of human DNA polymerase beta complexed with a nicked DNA containing a 8BrG-C at N-1 position and G-C at N position
GCTGATGCGCC
>pdb|4NLZ|P Chain P, Structure of human DNA polymerase beta complexed with nicked DNA containing a mismatched template 8BrG and incoming GTP
GCTGATGCGAG
>pdb|4NLN|P Chain P, Structure of human DNA polymerase beta complexed with nicked DNA containing a template 8BrG and incoming CTP
GCTGATGCGAC
>pdb|2M44|B Chain B, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer (6AP, 8OG14)
GCNTGGGAGCG
>pdb|2M44|A Chain A, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer (6AP, 8OG14)
CGCTCNCACGC
>pdb|2M43|B Chain B, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer (AP6, 8OG 14)
GCNTGGGAGCG
>pdb|2M43|A Chain A, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer (AP6, 8OG 14)
CGCTCNCACGC
>pdb|2M40|B Chain B, DNA containing a cluster of 8-oxo-guanine and THF lesion
GCGTGGGANCG
>pdb|2M40|A Chain A, DNA containing a cluster of 8-oxo-guanine and THF lesion
CGCTCNCACGC
>pdb|2M3Y|B Chain B, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer
GCGTGGGANCG
>pdb|2M3Y|A Chain A, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: beta anomer
CGCTCNCACGC
>pdb|2M3P|B Chain B, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer
GCGTGGGANCG
>pdb|2M3P|A Chain A, DNA containing a cluster of 8-oxo-guanine and abasic site lesion: alpha anomer
CGCTCNCACGC
>pdb|1X18|A Chain A, Contact sites of ERA GTPase on the THERMUS THERMOPHILUS 30S SUBUNIT
NGATGGCGAAG
>pdb|4C8O|B Chain B, Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair dNaM-d5SICS at the postinsertion site (sequence context 2)
GCCACGGCGCN
>pdb|4C8N|B Chain B, Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair dNaM-d5SICS at the postinsertion site (sequence context 3)
ACCACGGCGCN
>pdb|4C8M|B Chain B, Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the aritificial base pair d5SICS-dNaM at the postinsertion site (sequence context 2)
GCCACGGCGCN
>pdb|4C8L|B Chain B, Binary complex of the large fragment of DNA polymerase I from Thermus Aquaticus with the artificial base pair dNaM-d5SICS at the postinsertion site (sequence context 1)
ACCACGGCGCN
>pdb|4M9V|E Chain E, Zfp57 mutant (E182Q) in complex with 5-carboxylcytosine DNA
ACTGNGGCAAT
>pdb|4M9V|D Chain D, Zfp57 mutant (E182Q) in complex with 5-carboxylcytosine DNA
TATTGCNGCAG
>pdb|4M9V|B Chain B, Zfp57 mutant (E182Q) in complex with 5-carboxylcytosine DNA
ACTGNGGCAAT
>pdb|4M9V|A Chain A, Zfp57 mutant (E182Q) in complex with 5-carboxylcytosine DNA
TATTGCNGCAG
>pdb|4BY9|Z Chain Z, The structure of the Box CD enzyme reveals regulation of rRNA methylation
TCGCCCATCAC
>pdb|4BY9|Y Chain Y, The structure of the Box CD enzyme reveals regulation of rRNA methylation
TCGCCCATCAC
>pdb|4BY9|X Chain X, The structure of the Box CD enzyme reveals regulation of rRNA methylation
TCGCCCATCAC
>pdb|4BY9|W Chain W, The structure of the Box CD enzyme reveals regulation of rRNA methylation
TCGCCCATCAC
>pdb|4BY7|P Chain P, elongating RNA Polymerase II-Bye1 TLD complex
TTCGACCAGGA
>pdb|4BY1|P Chain P, elongating RNA Polymerase II-Bye1 TLD complex soaked with AMPCPP
TTCGACCAGGA
>pdb|4BXX|P Chain P, Arrested RNA polymerase II-Bye1 complex
NCCCCCCCCCC
>pdb|4LD0|F Chain F, T. thermophilus RuvC in complex with Holliday junction substrate
NAAAGCCGATT
>pdb|4KI2|G Chain G, Crystallographic analysis of an RNA-polymerase sigma-subunit fragment complexed with -10 promoter element ssDNA
TGTACAATGGG
>pdb|4KI2|F Chain F, Crystallographic analysis of an RNA-polymerase sigma-subunit fragment complexed with -10 promoter element ssDNA
TGTACAATGGG
>pdb|4KI2|E Chain E, Crystallographic analysis of an RNA-polymerase sigma-subunit fragment complexed with -10 promoter element ssDNA
TGTACAATGGG
>pdb|4KI2|D Chain D, Crystallographic analysis of an RNA-polymerase sigma-subunit fragment complexed with -10 promoter element ssDNA
TGTACAATGGG
>pdb|1TTD|A Chain A, Solution-state Structure Of A Dna Dodecamer Duplex Containing A Cis- Syn Thymine Cyclobutane Dimer
GCACGAANAAG
>pdb|4JUO|G Chain G, A low-resolution three-gate structure of topoisomerase IV from Streptococcus pneumoniae in space group H32
TTTACGTGCAT
>pdb|4JUO|E Chain E, A low-resolution three-gate structure of topoisomerase IV from Streptococcus pneumoniae in space group H32
AGGTCATGAAT
>pdb|4BXO|I Chain I, Architecture and DNA recognition elements of the Fanconi anemia FANCM- FAAP24 complex
TCAGCATCATC
>pdb|4BXO|H Chain H, Architecture and DNA recognition elements of the Fanconi anemia FANCM- FAAP24 complex
GATGATGCTGA
>pdb|2YPB|F Chain F, Structure of the SCL:E47 complex bound to DNA
GAACAGATGGT
>pdb|2YPB|E Chain E, Structure of the SCL:E47 complex bound to DNA
NCCATCTGTTC
>pdb|2YPA|F Chain F, Structure of the SCL:E47:LMO2:LDB1 complex bound to DNA
GAACAGATGGT
>pdb|2YPA|E Chain E, Structure of the SCL:E47:LMO2:LDB1 complex bound to DNA
NCCATCTGTTC
>pdb|4KLU|P Chain P, DNA polymerase beta mismatched product complex with Mn2+, 15 h
GCTGATGCGCA
>pdb|4KLT|P Chain P, DNA polymerase beta mismatched product complex with Mn2+, 30 min
GCTGATGCGCA
>pdb|4KLS|P Chain P, DNA polymerase beta mismatched reactant complex with Mn2+, 10 min
GCTGATGCGCA
>pdb|4KLQ|P Chain P, Observing a DNA polymerase choose right from wrong.
GCTGATGCGCA
>pdb|4KLO|P Chain P, DNA polymerase beta matched nick complex with Mg2+ and PPi, 30 min
GCTGATGCGCC
>pdb|4KLM|P Chain P, DNA polymerase beta matched product complex with Mg2+, 11 h
GCTGATGCGCC
>pdb|4KLL|P Chain P, DNA polymerase beta matched product complex with Mg2+, 45 min
GCTGATGCGCC
>pdb|4KLJ|P Chain P, DNA polymerase beta matched product complex with Mg2+, 5 min
GCTGATGCGCC
>pdb|4KLI|P Chain P, DNA polymerase beta matched product complex with Mg2+, 90 s
GCTGATGCGCC
>pdb|4KLH|P Chain P, DNA polymerase beta matched product complex with Mn2+, 40 s
GCTGATGCGCC
>pdb|4KLG|P Chain P, DNA polymerase beta matched product complex with Mg2+, 40 s
GCTGATGCGCC
>pdb|4KLF|P Chain P, DNA polymerase beta matched reactant complex with Mg2+, 20 s
GCTGATGCGCC
>pdb|4KLE|P Chain P, DNA polymerase beta matched reactant complex with Mg2+, 10 s
GCTGATGCGCC
>pdb|4K0K|Y Chain Y, Crystal structure of the Thermus thermophilus 30S ribosomal subunit complexed with a serine-ASL and mRNA containing a stop codon
NTTNGAAATCT
>pdb|4JRD|B Chain B, Crystal structure of the parallel double-stranded helix of poly(A) RNA
AAAAAAAAAAA
>pdb|4JRD|A Chain A, Crystal structure of the parallel double-stranded helix of poly(A) RNA
AAAAAAAAAAA
>pdb|4JVH|D Chain D, Structure of the star domain of quaking protein in complex with RNA
TTCACTAACAA
>pdb|4B9V|B Chain B, Structure of the high fidelity DNA polymerase I with extending from an oxidative formamidopyrimidine-dG DNA lesion -dA basepair.
NCTGACTCTAA
>pdb|4B9U|B Chain B, Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dG DNA lesion -dA basepair in the post-insertion site.
NCCTGACTCGA
>pdb|4B9T|B Chain B, Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dG DNA lesion -dC basepair in the post-insertion site.
NCCTGACTCGC
>pdb|4B9M|B Chain B, Structure of the high fidelity DNA polymerase I with an oxidative formamidopyrimidine-dA DNA lesion -thymine basepair in the post- insertion site.
NCCTGACTCTT
>pdb|2LWO|D Chain D, Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
GCATGCGTACG
>pdb|2LWN|D Chain D, Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
GCATGCGTACG
>pdb|2LWN|B Chain B, Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
CGTACNCATGC
>pdb|2LWM|D Chain D, Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
GCATGCGTACG
>pdb|2LWM|B Chain B, Solution Structure of Duplex DNA Containing a b-Carba-Fapy-dG Lesion
CGTACNCATGC
>pdb|2LLJ|B Chain B, Structure of a bis-naphthalene bound to a thymine-thymine DNA mismatch
GCACTTCGACG
>pdb|2LLJ|A Chain A, Structure of a bis-naphthalene bound to a thymine-thymine DNA mismatch
CGTCGTAGTGC
>pdb|4IEM|P Chain P, Human apurinic/apyrimidinic endonuclease (APE1) with product DNA and Mg2+
CGATCGGTAGC
>pdb|4IEM|M Chain M, Human apurinic/apyrimidinic endonuclease (APE1) with product DNA and Mg2+
CGATCGGTAGC
>pdb|4IEM|J Chain J, Human apurinic/apyrimidinic endonuclease (APE1) with product DNA and Mg2+
CGATCGGTAGC
>pdb|4IEM|G Chain G, Human apurinic/apyrimidinic endonuclease (APE1) with product DNA and Mg2+
CGATCGGTAGC
>pdb|4HSB|C Chain C, S. pombe 3-methyladenine DNA glycosylase-like protein Mag2 bound to damaged DNA
NCCGTTAGTCC
>pdb|4HSB|B Chain B, S. pombe 3-methyladenine DNA glycosylase-like protein Mag2 bound to damaged DNA
NGACTNACGGG
>pdb|3V7K|T Chain T, Co-crystal structure of K72E variant of rat polymerase beta: Enzyme-DNA binary complex
NAAACTCACAA
>pdb|4B24|X Chain X, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
GCTACNTATCG
>pdb|4B23|Y Chain Y, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
CGATTGGTAGC
>pdb|4B23|X Chain X, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
GCTACNAATCG
>pdb|4B22|Y Chain Y, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
CGATGGGTAGC
>pdb|4B22|X Chain X, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
GCTACNCATCG
>pdb|4B21|X Chain X, Unprecedented sculpting of DNA at abasic sites by DNA glycosylase homolog Mag2
GCTACNGATCG
>pdb|4F50|P Chain P, Y-family DNA polymerase chimera Dbh-Dbh-Dpo4
GGGAAGCCGGC
>pdb|4HJA|B Chain B, Crystal Structure of Schizosaccharomyces pombe Pot1pC bound to ssDNA (ACGGTTACGGT)
ACGGTTACGGT
>pdb|2LZK|B Chain B, NMR solution structure of an N2-guanine DNA adduct derived from the potent tumorigen dibenzo[a,l]pyrene: Intercalation from the minor groove with ruptured Watson-Crick base pairing
GGTAGCGATGG
>pdb|2LZK|A Chain A, NMR solution structure of an N2-guanine DNA adduct derived from the potent tumorigen dibenzo[a,l]pyrene: Intercalation from the minor groove with ruptured Watson-Crick base pairing
CCATCGCTACC
>pdb|2LX1|B Chain B, Major Conformation of the Internal Loop 5'GAGU/3'UGAG
GACGAGTGTCA
>pdb|2LX1|A Chain A, Major Conformation of the Internal Loop 5'GAGU/3'UGAG
GACGAGTGTCA
>pdb|4DR7|W Chain W, Crystal structure of the Thermus thermophilus (HB8) 30S ribosomal subunit with codon, crystallographically disordered near-cognate transfer RNA anticodon stem-loop mismatched at the second codon position, and streptomycin bound
GCCTGGAAAGN
>pdb|4GFH|I Chain I, Topoisomerase II-DNA-AMPPNP complex
NGATGACGATN
>pdb|4GFH|G Chain G, Topoisomerase II-DNA-AMPPNP complex
NCTACTGCTAC
>pdb|4GFH|D Chain D, Topoisomerase II-DNA-AMPPNP complex
NGATGACGATN
>pdb|4GFH|B Chain B, Topoisomerase II-DNA-AMPPNP complex
NCTACTGCTAC
>pdb|4B5M|Z Chain Z, Neisseria AP endonuclease bound to the substrate with a cytosine orphan base
CGATGCGTAGC
>pdb|4B5M|X Chain X, Neisseria AP endonuclease bound to the substrate with a cytosine orphan base
CGATGCGTAGC
>pdb|4B5M|V Chain V, Neisseria AP endonuclease bound to the substrate with a cytosine orphan base
CGATGCGTAGC
>pdb|4B5J|V Chain V, Neisseria AP endonuclease bound to the substrate with an orphan Adenine base
CGATGAGTAGC
>pdb|4B5J|U Chain U, Neisseria AP endonuclease bound to the substrate with an orphan Adenine base
GCTACNCATCG
>pdb|4B5I|V Chain V, Product complex of Neisseria AP endonuclease in presence of metal ions
CGATGGGTAGC
>pdb|4B5H|V Chain V, Substate bound inactive mutant of Neisseria AP endonuclease in presence of metal ions
CGATGGGTAGC
>pdb|4B5H|U Chain U, Substate bound inactive mutant of Neisseria AP endonuclease in presence of metal ions
GCTACNCATCG
>pdb|4B5G|Z Chain Z, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
CGATGGGTAGC
>pdb|4B5G|Y Chain Y, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
GCTACNCATCG
>pdb|4B5G|X Chain X, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
CGATGGGTAGC
>pdb|4B5G|W Chain W, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
GCTACNCATCG
>pdb|4B5G|V Chain V, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
CGATGGGTAGC
>pdb|4B5G|U Chain U, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 2)
GCTACNCATCG
>pdb|4B5F|V Chain V, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 1)
CGATCGGTAGC
>pdb|4B5F|U Chain U, Substrate bound Neisseria AP endonuclease in absence of metal ions (crystal form 1)
GCTACNGATCG
>pdb|2LL9|B Chain B, Solution structure of a DNA containing a thymime-thymine mismatch
GCACTTCGACG
>pdb|2LL9|A Chain A, Solution structure of a DNA containing a thymime-thymine mismatch
CGTCGTAGTGC
>pdb|2LSF|D Chain D, Structure and Stability of Duplex DNA Containing (5'S) 5',8-Cyclo-2'-Deoxyadenosine: An Oxidative Lesion Repair by NER
GCATGTGTACG
>pdb|2LSF|B Chain B, Structure and Stability of Duplex DNA Containing (5'S) 5',8-Cyclo-2'-Deoxyadenosine: An Oxidative Lesion Repair by NER
CGTACNCATGC
>pdb|4FLW|P Chain P, Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
CGATCACGGGG
>pdb|4FLV|P Chain P, Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
CGATCACGGGG
>pdb|4FLU|P Chain P, Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
CGATCACGGGG
>pdb|4FLT|P Chain P, Pyrococcus abyssi B family DNA polymerase bound to a dsDNA, in edition mode
CGATCACGGGG
>pdb|4F02|E Chain E, Crystal structure of the PABP-binding site of eIF4G in complex with RRM1-2 of PABP and poly(A)
NAAAAAAAAAA
>pdb|4F02|B Chain B, Crystal structure of the PABP-binding site of eIF4G in complex with RRM1-2 of PABP and poly(A)
AAAAAAAAAAA
>pdb|4FO6|T Chain T, Crystal structure of the pre-catalytic ternary complex of polymerase lambda with a dATP analog opposite a templating T and an rCMP at the primer terminus.
CGGCTGTACTG
>pdb|4EW4|C Chain C, mouse MBD4 glycosylase domain in complex with DNA containing a ribose sugar
CCATGNGCTGA
>pdb|4EW4|B Chain B, mouse MBD4 glycosylase domain in complex with DNA containing a ribose sugar
TCAGCGCATGG
>pdb|2LT0|D Chain D, NMR structure of duplex DNA containing the beta-OH-PdG dA base pair: A mutagenic intermediate of acrolein
GCATGNGTACG
>pdb|2LT0|B Chain B, NMR structure of duplex DNA containing the beta-OH-PdG dA base pair: A mutagenic intermediate of acrolein
CGTACNCATGC
>pdb|2LSZ|D Chain D, NMR structure of duplex DNA containing the alpha-OH-PdG dA base pair: A mutagenic intermediate of acrolein
GCATGNGTACG
>pdb|2LSZ|B Chain B, NMR structure of duplex DNA containing the alpha-OH-PdG dA base pair: A mutagenic intermediate of acrolein
CGTACNCATGC
>pdb|4ED5|D Chain D, Crystal structure of the two N-terminal RRM domains of HuR complexed with RNA
ATTTTTATTTT
>pdb|4ED5|C Chain C, Crystal structure of the two N-terminal RRM domains of HuR complexed with RNA
ATTTTTATTTT
>pdb|3UQ2|T Chain T, Crystal structure of the post-catalytic product complex of polymerase lambda with an rCMP inserted opposite a templating G and dAMP inserted opposite a templating T at the primer terminus.
CGGCTGTACTG
>pdb|3UQ0|T Chain T, Crystal structure of the post-catalytic product complex of polymerase lambda with an rAMP at the primer terminus.
CGGCTGTACTG
>pdb|3UPQ|T Chain T, Crystal structure of the pre-catalytic ternary complex of polymerase lambda with an rATP analog opposite a templating T.
CGGCTGTACTG
>pdb|4DK9|C Chain C, Crystal Structure of MBD4 Catalytic Domain Bound to Abasic DNA
TGTCCANGTCT
>pdb|4DK9|B Chain B, Crystal Structure of MBD4 Catalytic Domain Bound to Abasic DNA
AAGACGTGGAC
>pdb|3RAD|H Chain H, Quinolone(Clinafloxacin)-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
NACTATGCACG
>pdb|3RAD|F Chain F, Quinolone(Clinafloxacin)-DNA cleavage complex of type IV topoisomerase from S. pneumoniae
NGTCATTCATG
>pdb|4AIL|A Chain A, Crystal Structure of an Evolved Replicating DNA Polymerase
ACGNGTAAGCA
>pdb|3T1Y|X Chain X, Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human anti-codon stem loop (HASL) of transfer RNA Lysine 3 (TRNALYS3) bound to an mRNA with an AAG-codon in the A-site and paromomycin
NACTNTTNANC
>pdb|3T1H|X Chain X, Structure of the Thermus thermophilus 30S ribosomal subunit complexed with a human anti-codon stem loop (HASL) of transfer RNA lysine 3 (tRNALys3) bound to an mRNA with an AAA-codon in the A-site and Paromomycin
NACTNTTNANC
>pdb|3AU6|T Chain T, DNA polymerase X from Thermus thermophilus HB8 ternary complex with primer/template DNA and ddGTP
CGGCCATACTG
>pdb|3SBJ|C Chain C, MutM slanted complex 7
NCTGGTNTACC
>pdb|3SBJ|B Chain B, MutM slanted complex 7
GGTAGACCAGG
>pdb|4ABT|G Chain G, Crystal structure of Type IIF restriction endonuclease NgoMIV with cognate uncleaved DNA
TGCGCCGGCGC
>pdb|4ABT|E Chain E, Crystal structure of Type IIF restriction endonuclease NgoMIV with cognate uncleaved DNA
TGCGCCGGCGC
>pdb|3S6I|F Chain F, Schizosaccaromyces pombe 3-methyladenine DNA glycosylase (Mag1) in complex with abasic-DNA.
AAGACTTGGAC
>pdb|3S6I|E Chain E, Schizosaccaromyces pombe 3-methyladenine DNA glycosylase (Mag1) in complex with abasic-DNA.
TGTCCANGTCT
>pdb|3S6I|C Chain C, Schizosaccaromyces pombe 3-methyladenine DNA glycosylase (Mag1) in complex with abasic-DNA.
AAGACTTGGAC
>pdb|3S6I|B Chain B, Schizosaccaromyces pombe 3-methyladenine DNA glycosylase (Mag1) in complex with abasic-DNA.
TGTCCANGTCT
>pdb|4A3K|N Chain N, RNA Polymerase II initial transcribing complex with a 7nt DNA-RNA hybrid
TAAGTACTTGA
>pdb|3UGP|C Chain C, Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TATAAT)
TGTATAATGGG
>pdb|3UGP|B Chain B, Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TATAAT)
TGTATAATGGG
>pdb|3UGO|C Chain C, Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TACAAT)
TGTACAATGGG
>pdb|3UGO|B Chain B, Crystal structure of RNA-polymerase sigma subunit domain 2 complexed with -10 promoter element ssDNA oligo (TACAAT)
TGTACAATGGG
>pdb|2LGM|2 Chain 2, Structure of DNA Containing an Aristolactam II-dA Lesion
GCATGTGTACG
>pdb|2LGM|1 Chain 1, Structure of DNA Containing an Aristolactam II-dA Lesion
CGTACACATGC
>pdb|2L8F|B Chain B, Structure of a 4X4 Nucleotide RNA Internal Loop from an R2 Retrotransposon
CGGAGGACACT
>pdb|2L8F|A Chain A, Structure of a 4X4 Nucleotide RNA Internal Loop from an R2 Retrotransposon
GTGAAGCCCGT
>pdb|2LD5|C Chain C, Solution NMR-derived complex structure of Hoxa13 DNA binding domain bound to DNA
NATTTTATTTG
>pdb|2LD5|B Chain B, Solution NMR-derived complex structure of Hoxa13 DNA binding domain bound to DNA
CAAATAAAATC
>pdb|3R1D|E Chain E, Crystal structure of GC(8BrG)GCGGCGGC duplex
GCNGCGGCGGC
>pdb|3R1D|D Chain D, Crystal structure of GC(8BrG)GCGGCGGC duplex
GCNGCGGCGGC
>pdb|3R1D|C Chain C, Crystal structure of GC(8BrG)GCGGCGGC duplex
GCNGCGGCGGC
>pdb|3R1D|B Chain B, Crystal structure of GC(8BrG)GCGGCGGC duplex
GCNGCGGCGGC
>pdb|3R1D|A Chain A, Crystal structure of GC(8BrG)GCGGCGGC duplex
GCNGCGGCGGC
>pdb|2KY8|C Chain C, Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target methylated DNA sequence
GAGCNGATNCC
>pdb|2KY8|B Chain B, Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target methylated DNA sequence
GGAATNGGCNC
>pdb|3Q8K|E Chain E, Crystal Structure of Human Flap Endonuclease FEN1 (WT) in complex with product 5'-flap DNA, SM3+, and K+
NGAGGCAGAGT
>pdb|3Q8S|T Chain T, Human DNA polymerase iota incorporating dTTP opposite 8-oxo-guanine
TCANGGGTCCT
>pdb|3Q8R|T Chain T, Human DNA polymerase iota incorporating dGTP opposite 8-oxo-guanine
TCANGGGTCCT
>pdb|3Q8Q|T Chain T, Human DNA polymerase iota incorporating dATP opposite 8-oxo-guanine
TCANGGGTCCT
>pdb|3Q8P|T Chain T, Human DNA polymerase iota incorporating dCTP opposite 8-oxo-guanine
TCANGGGTCCT
>pdb|3PNC|C Chain C, Ternary crystal structure of a polymerase lambda variant with a GT mispair at the primer terminus and sodium at catalytic metal site
CGGCCTTACTG
>pdb|3PMN|B Chain B, ternary crystal structure of polymerase lambda variant with a GT mispair at the primer terminus with Mn2+ in the active site
CGGCCTTACTG
>pdb|3PML|E Chain E, crystal structure of a polymerase lambda variant with a dGTP analog opposite a templating T
CGGCTGTACTG
>pdb|3PML|C Chain C, crystal structure of a polymerase lambda variant with a dGTP analog opposite a templating T
CGGCTGTACTG
>pdb|3OHB|P Chain P, Yeast DNA polymerase eta extending from an 8-oxoG lesion
GTCCTCCCCTN
>pdb|3OHA|P Chain P, Yeast DNA polymerase eta inserting dCTP opposite an 8oxoG lesion
GTCCTCCCCTN
>pdb|3IZE|C Chain C, Model of the small subunit RNA based on a 6.1 A cryo-EM map of Saccharomyces cerevisiae translating 80S ribosome
NAAAGACTNCA
>pdb|2XGQ|U Chain U, Structure of yeast DNA polymerase eta in complex with C8-N-acetyl-2- aminoanthracene containing DNA
CNCTCATCCAC
>pdb|2XGQ|T Chain T, Structure of yeast DNA polymerase eta in complex with C8-N-acetyl-2- aminoanthracene containing DNA
CNCTCATCCAC
>pdb|2XGP|U Chain U, Yeast DNA polymerase eta in complex with C8-2-acetylaminofluorene containing DNA
CNCTCATCCAC
>pdb|2XGP|T Chain T, Yeast DNA polymerase eta in complex with C8-2-acetylaminofluorene containing DNA
CNCTCATCCAC
>pdb|3L1Q|B Chain B, The crystal structure of the undecamer d(TGGCCTTAAGG)
TGGCCTTAAGG
>pdb|3L1Q|A Chain A, The crystal structure of the undecamer d(TGGCCTTAAGG)
TGGCCTTAAGG
>pdb|3L2P|B Chain B, Human DNA Ligase III Recognizes DNA Ends by Dynamic Switching Between Two DNA Bound States
CGGGATGCGTC
>pdb|3MR3|T Chain T, Human DNA polymerase eta - DNA ternary complex with the 3'T of a CPD in the active site (TT1)
CANATGACGCT
>pdb|3L4K|B Chain B, Topoisomerase II-DNA cleavage complex, metal-bound
NCTACTGCTAC
>pdb|3L4J|B Chain B, Topoisomerase II-DNA cleavage complex, apo
NCTACTGCTAC
>pdb|3MGI|T Chain T, Ternary complex of a DNA polymerase lambda loop mutant
CGGCAATACTG
>pdb|3MGH|E Chain E, Binary complex of a DNA polymerase lambda loop mutant
CGGCAGTACTG
>pdb|3MGH|T Chain T, Binary complex of a DNA polymerase lambda loop mutant
CGGCAGTACTG
>pdb|3MDC|T Chain T, DNA polymerase lambda in complex with dFdCTP
CGGCGGTACTG
>pdb|3MDA|T Chain T, DNA polymerase lambda in complex with araC
CGGCGGTACTG
>pdb|2X6V|D Chain D, Crystal structure of human TBX5 in the DNA-bound and DNA-free form
TAAGGTGTGAG
>pdb|2X6V|C Chain C, Crystal structure of human TBX5 in the DNA-bound and DNA-free form
TCTCACACCTT
>pdb|3AEV|C Chain C, Crystal structure of a/eIF2alpha-aDim2p-rRNA complex from Pyrococcus horikoshii OT3
GGATCACCTCC
>pdb|3G6Y|T Chain T, Ternary complex of DNA Polymerase iota:DNA:dTTP with an abasic site at the templating position
TCTNGGGTCCT
>pdb|3G6X|T Chain T, Ternary complex of DNA Polymerase iota:DNA:dGTP with an abasic site at the templating position
TCTNGGGTCCT
>pdb|3GOX|D Chain D, Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I in the absence of EDTA
TACGTCGAGTC
>pdb|3GOX|C Chain C, Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I in the absence of EDTA
CTCGACGTAGA
>pdb|3FC3|D Chain D, Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I
TACGTCGAGTC
>pdb|3FC3|C Chain C, Crystal structure of the beta-beta-alpha-Me type II restriction endonuclease Hpy99I
CTCGACGTAGA
>pdb|3FTM|C Chain C, Class II ligase ribozyme product-template duplex, structure 1
GTGTGAGGCTG
>pdb|3FTM|A Chain A, Class II ligase ribozyme product-template duplex, structure 1
GTGTGAGGCTG
>pdb|3FS0|B Chain B, Class II ligase ribozyme product-template duplex, structure 2
CCAGTCGGAAC
>pdb|2W36|F Chain F, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
CGATCTGTAGC
>pdb|2W36|E Chain E, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
GCNACNGANCG
>pdb|2W36|D Chain D, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
CGATCTGTAGC
>pdb|2W36|C Chain C, Structures of endonuclease V with DNA reveal initiation of deaminated adenine repair
GCNACNGANCG
>pdb|3EXL|C Chain C, Crystal Structure of a p53 Core Tetramer Bound to DNA
GAGCATGCTCA
>pdb|3EXJ|C Chain C, Crystal Structure of a p53 Core Tetramer Bound to DNA
NAGCATGCTCA
>pdb|3EQ4|C Chain C, Model of tRNA(Leu)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
NGGCGAAGTCG
>pdb|3EQ3|C Chain C, Model of tRNA(Trp)-EF-Tu in the ribosomal pre-accommodated state revealed by cryo-EM
NGGCGAAGTCG
>pdb|3EP2|C Chain C, Model of Phe-tRNA(Phe) in the ribosomal pre-accommodated state revealed by cryo-EM
NGGCGAAGTCG
>pdb|2VUM|P Chain P, Alpha-amanitin inhibited complete RNA polymerase II elongation complex
AAAGACCAGGC
>pdb|2JXS|A Chain A, NMR structure of RNA duplex containing single adenosine bulge
GCAGAAGAGCG
>pdb|3C0X|C Chain C, I-SceI in complex with a top nicked DNA substrate
NAGGGTAATAC
>pdb|3BSX|D Chain D, Crystal Structure of Human Pumilio 1 in complex with Puf5 RNA
TTGTAATATTA
>pdb|3BSX|C Chain C, Crystal Structure of Human Pumilio 1 in complex with Puf5 RNA
TTGTAATATTA
>pdb|3BQ2|P Chain P, Post-insertion binary complex of Dbh DNA polymerase
GAAGCCGGCGG
>pdb|2R1G|X Chain X, Coordinates of the thermus thermophilus 30S components neighboring RbfA as obtained by fitting into the CRYO-EM map of A 30S-RBFA complex
NGAAGTCGTAA
>pdb|2R1G|E Chain E, Coordinates of the thermus thermophilus 30S components neighboring RbfA as obtained by fitting into the CRYO-EM map of A 30S-RBFA complex
NGCCCGTCACG
>pdb|2R9L|D Chain D, Polymerase Domain from Mycobacterium tuberculosis Ligase D in complex with DNA
GCCGCAACGCA
>pdb|2R8J|T Chain T, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
NGCTCATCCAC
>pdb|2R8J|U Chain U, Structure of the Eukaryotic DNA Polymerase eta in complex with 1,2-d(GpG)-cisplatin containing DNA
NGCTCATCCAC
>pdb|2NUG|F Chain F, Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 1.7-Angstrom Resolution
NGTGGCCTTGC
>pdb|2NUG|D Chain D, Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 1.7-Angstrom Resolution
NAGGTCATTCG
>pdb|2NUG|E Chain E, Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 1.7-Angstrom Resolution
NGTGGCCTTGC
>pdb|2NUG|C Chain C, Crystal structure of RNase III from Aquifex aeolicus complexed with ds-RNA at 1.7-Angstrom Resolution
NAGGTCATTCG
>pdb|248D|A Chain A, Crystal Structures Of An A-Form Duplex With Single-Adenosine Bulges And A Conformational Basis For Site Specific Rna Self-Cleavage
GCGNNNNNCGC
>pdb|247D|A Chain A, Crystal Structures Of An A-Form Duplex With Single- Adenosine Bulges And A Conformational Basis For Site Specific Rna Self-Cleavage
GCGNNNNNCGC
>pdb|1QCU|D Chain D, Crystal Structure Of An 18 Base Pair Copy Control Related Rna Duplex
NGGGGGGGGGG
>pdb|1QCU|C Chain C, Crystal Structure Of An 18 Base Pair Copy Control Related Rna Duplex
NCCCCCCCCCC
>pdb|1QCU|B Chain B, Crystal Structure Of An 18 Base Pair Copy Control Related Rna Duplex
NCCCCCCCCCC
>pdb|1QCU|A Chain A, Crystal Structure Of An 18 Base Pair Copy Control Related Rna Duplex
NGGGGGGGGGG
>pdb|1I2Y|F Chain F, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2Y|E Chain E, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2Y|D Chain D, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2Y|C Chain C, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2Y|B Chain B, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2Y|A Chain A, 1.66 A Structure Of A-Duplex With Bulged Adenosine, Spermine Form
GCGNNNNACGT
>pdb|1I2X|D Chain D, 2.4 A Structure Of A-Duplex With Bulged Adenosine, Spermidine Form
GCGNNNNACGT
>pdb|1I2X|C Chain C, 2.4 A Structure Of A-Duplex With Bulged Adenosine, Spermidine Form
GCGNNNNACGT
>pdb|1I2X|B Chain B, 2.4 A Structure Of A-Duplex With Bulged Adenosine, Spermidine Form
GCGNNNNACGT
>pdb|1I2X|A Chain A, 2.4 A Structure Of A-Duplex With Bulged Adenosine, Spermidine Form
GCGNNNNACGT
>pdb|1HLO|D Chain D, The Crystal Structure Of An Intact Human Max-Dna Complex: New Insights Into Mechanisms Of Transcriptional Control
ACCACGTGGTG
>pdb|1HLO|C Chain C, The Crystal Structure Of An Intact Human Max-Dna Complex: New Insights Into Mechanisms Of Transcriptional Control
CACCACGTGGT
>pdb|2Q10|F Chain F, RESTRICTION ENDONUCLEASE BcnI (WILD TYPE)-COGNATE DNA SUBSTRATE COMPLEX
CTCCGGGTTGT
>pdb|2Q10|E Chain E, RESTRICTION ENDONUCLEASE BcnI (WILD TYPE)-COGNATE DNA SUBSTRATE COMPLEX
AACCCGGAGAC
>pdb|2Q10|D Chain D, RESTRICTION ENDONUCLEASE BcnI (WILD TYPE)-COGNATE DNA SUBSTRATE COMPLEX
CTCCGGGTTGT
>pdb|2Q10|C Chain C, RESTRICTION ENDONUCLEASE BcnI (WILD TYPE)-COGNATE DNA SUBSTRATE COMPLEX
AACCCGGAGAC
>pdb|2HRI|B Chain B, A parallel stranded human telomeric quadruplex in complex with the porphyrin TMPyP4
TAGGGTTAGGG
>pdb|2HRI|A Chain A, A parallel stranded human telomeric quadruplex in complex with the porphyrin TMPyP4
TAGGGTTAGGG
>pdb|2P66|C Chain C, Human DNA Polymerase beta complexed with tetrahydrofuran (abasic site) containing DNA
GCTGATGCGCC
>pdb|2P0J|D Chain D, Structure of restriction endonuclease BstYI bound to non-cognate DNA
TATGGATTCAT
>pdb|2P0J|C Chain C, Structure of restriction endonuclease BstYI bound to non-cognate DNA
ATGAATCCATA
>pdb|2ODI|F Chain F, Restriction Endonuclease BCNI-Cognate DNA Substrate Complex
CTCCGGGTTGT
>pdb|2ODI|E Chain E, Restriction Endonuclease BCNI-Cognate DNA Substrate Complex
AACCCGGAGAC
>pdb|2ODI|D Chain D, Restriction Endonuclease BCNI-Cognate DNA Substrate Complex
CTCCGGGTTGT
>pdb|2ODI|C Chain C, Restriction Endonuclease BCNI-Cognate DNA Substrate Complex
AACCCGGAGAC
>pdb|2OAA|F Chain F, Restriction endonuclease MvaI-cognate DNA substrate complex
CATCCAGGTAC
>pdb|2OAA|E Chain E, Restriction endonuclease MvaI-cognate DNA substrate complex
GGTACCTGGAT
>pdb|2OAA|D Chain D, Restriction endonuclease MvaI-cognate DNA substrate complex
CATCCAGGTAC
>pdb|2OAA|C Chain C, Restriction endonuclease MvaI-cognate DNA substrate complex
GGTACCTGGAT
>pdb|2JA8|P Chain P, CPD lesion containing RNA Polymerase II elongation complex D
TTCGACCAGAT
>pdb|2JA7|6 Chain 6, CPD lesion containing RNA Polymerase II elongation complex C
TTCGACCAGGA
>pdb|2JA7|3 Chain 3, CPD lesion containing RNA Polymerase II elongation complex C
TTCGACCAGGA
>pdb|2JA6|P Chain P, CPD lesion containing RNA Polymerase II elongation complex B
NTCGACCAGGA
>pdb|2JA5|P Chain P, CPD lesion containing RNA Polymerase II elongation complex A
TTCGACCAGGA
>pdb|2HW3|B Chain B, T:O6-methyl-guanine pair in the polymerase postinsertion site (-1 basepair position)
GCGATCAGCTT
>pdb|2HHU|B Chain B, C:O6-methyl-guanine in the polymerase postinsertion site (-1 basepair position)
GCGATCAGCCC
>pdb|2FLL|T Chain T, Ternary complex of human DNA polymerase iota with DNA and dTTP
TCTAGGGTCCT
>pdb|2FLP|T Chain T, Binary complex of the catalytic core of human DNA polymerase iota with DNA (template G)
TCTGGGGTCCT
>pdb|2FLN|T Chain T, binary complex of catalytic core of human DNA polymerase iota with DNA (template A)
TCTAGGGTCCT
>pdb|2GWS|N Chain N, Crystal Structure of human DNA Polymerase lambda with a G/G mismatch in the primer terminus
CGGCAGCGCAC
>pdb|2GWS|J Chain J, Crystal Structure of human DNA Polymerase lambda with a G/G mismatch in the primer terminus
CGGCAGCGCAC
>pdb|2GWS|F Chain F, Crystal Structure of human DNA Polymerase lambda with a G/G mismatch in the primer terminus
CGGCAGCGCAC
>pdb|2GWS|T Chain T, Crystal Structure of human DNA Polymerase lambda with a G/G mismatch in the primer terminus
CGGCAGCGCAC
>pdb|2AVJ|F Chain F, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVJ|E Chain E, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVJ|D Chain D, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVJ|C Chain C, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVJ|B Chain B, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVJ|A Chain A, G4(Br)UTTG4 dimeric quadruplex
GGGGNTTGGGG
>pdb|2AVH|A Chain A, G4T3G4 dimeric quadruplex structure
GGGGTTTGGGG
>pdb|2B0E|D Chain D, EcoRV Restriction Endonuclease/GAAUTC/Ca2+
AAAGAANTCTT
>pdb|2B0E|C Chain C, EcoRV Restriction Endonuclease/GAAUTC/Ca2+
AAAGAANTCTT
>pdb|2B0D|D Chain D, EcoRV Restriction Endonuclease/GAATTC/Ca2+
AAAGAATTCTT
>pdb|2B0D|C Chain C, EcoRV Restriction Endonuclease/GAATTC/Ca2+
AAAGAATTCTT
>pdb|1XCI|B Chain B, Mispair Aligned N3T-Butyl-N3T Interstrand Crosslink
CGAAANTTTCG
>pdb|1XCI|A Chain A, Mispair Aligned N3T-Butyl-N3T Interstrand Crosslink
CGAAANTTTCG
>pdb|1YLS|C Chain C, Crystal structure of selenium-modified Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
NGAGCNCGCNC
>pdb|1YLS|A Chain A, Crystal structure of selenium-modified Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
NGAGCNCGCNC
>pdb|1YKV|C Chain C, Crystal structure of the Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
NGAGCTCGCCC
>pdb|1YKV|A Chain A, Crystal structure of the Diels-Alder ribozyme complexed with the product of the reaction between N-pentylmaleimide and covalently attached 9-hydroxymethylanthracene
NGAGCTCGCCC
>pdb|1YKQ|C Chain C, Crystal structure of Diels-Alder ribozyme
GGAGCTCGCCC
>pdb|1YKQ|A Chain A, Crystal structure of Diels-Alder ribozyme
GGAGCTCGCCC
>pdb|1XSL|N Chain N, Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap
CGGCAGCGCAC
>pdb|1XSL|J Chain J, Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap
CGGCAGCGCAC
>pdb|1XSL|F Chain F, Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap
CGGCAGCGCAC
>pdb|1XSL|B Chain B, Crystal Structure of human DNA polymerase lambda in complex with a one nucleotide DNA gap
CGGCAGCGCAC
>pdb|1S37|B Chain B, Accomodation of Mispair-Aligned N3T-Ethyl-N3T DNA Interstrand Crosslink
CGAAATTTTCG
>pdb|1EXL|B Chain B, Structure Of An 11-Mer Dna Duplex Containing The Carbocyclic Nucleotide Analog: 2'-Deoxyaristeromycin
GTNACTCACTG
>pdb|1EXL|A Chain A, Structure Of An 11-Mer Dna Duplex Containing The Carbocyclic Nucleotide Analog: 2'-Deoxyaristeromycin
CAGTGNGTCAC
>pdb|1XNR|X Chain X, Crystal Structure of an Inosine-Cytosine Wobble Base Pair in the Context of the Decoding Center
GGCTNCGAACC
>pdb|1XNQ|X Chain X, Structure of an Inosine-Adenine Wobble Base Pair Complex in the Context of the Decoding Center
GGCTNCGAACC
>pdb|1XMQ|X Chain X, Crystal Structure of t6A37-ASLLysUUU AAA-mRNA Bound to the Decoding Center
GACTTTTNATC
>pdb|1XMO|X Chain X, Crystal Structure of mnm5U34t6A37-tRNALysUUU Complexed with AAG-mRNA in the Decoding Center
GACTNTTNATC
>pdb|1TEZ|K Chain K, COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS
ATCGGCTNCGC
>pdb|1TEZ|I Chain I, COMPLEX BETWEEN DNA AND THE DNA PHOTOLYASE FROM ANACYSTIS NIDULANS
ATCGGCTNCGC
>pdb|1TVA|P Chain P, Human Dna Polymerase Beta Complexed With Nicked Dna Containing A Mismatched Template Thymidine And Incoming Cytidine
GCTGATGCGCC
>pdb|1TV9|P Chain P, Human Dna Polymerase Beta Complexed With Nicked Dna Containing A Mismatched Template Adenine And Incoming Cytidine
GCTGATGCGCC
>pdb|1UA1|B Chain B, Structure of aminofluorene adduct paired opposite cytosine at the polymerase active site.
AGGGATGGTGC
>pdb|1U49|B Chain B, Adenine-8oxoguanine mismatch at the polymerase active site
GCCTGACTCGA
>pdb|1U1R|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTTAG(2PR)G); A Human Telomeric Repeat Containing 2-aminopurine
TAGGGTTAGNG
>pdb|1U1Q|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTTA(DI)GG); A Human Telomeric Repeat Containing Inosine
TAGGGTTANGG
>pdb|1U1O|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTTAG(DI)G); A Human Telomeric Repeat Containing Inosine
TAGGGTTAGNG
>pdb|1U1N|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTTA (PRN)GG); A Human Telomeric Repeat Containing Nebularine
TAGGGTTANGG
>pdb|1U1M|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTTA 7GU GG); A Human Telomeric Repeat Containing 7-deaza-guanine
TAGGGTTANGG
>pdb|1U1L|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTT PRN GGG); A Human Telomeric Repeat Containing nebularine
TAGGGTTNGGG
>pdb|1U1K|B Chain B, Crystal Structure of UP1 Complexed With d(TTAGGGTT 7DA GGG); A Human Telomeric Repeat Containing 7-deaza-adenine
TAGGGTTNGGG
>pdb|1TFY|G Chain G, How CCA is added to the 3' end of immature tRNA without the use of an oligonucleotide template
CGGATCCGCAC
>pdb|1PYJ|B Chain B, Solution Structure of an O6-[4-oxo-4-(3-pyridyl)butyl]guanine adduct in an 11mer DNA duplex
GGGCCATATGG
>pdb|1NJY|B Chain B, Thymine-Thymine Mismatch At The Polymerase Active Site
GCGATCACGTT
>pdb|1NJW|B Chain B, Guanine-Thymine Mismatch At The Polymerase Active Site
GCGATCAGCGG
>pdb|1RZT|N Chain N, Crystal structure of DNA polymerase lambda complexed with a two nucleotide gap DNA molecule
CGGCAACGCAC
>pdb|1RZT|J Chain J, Crystal structure of DNA polymerase lambda complexed with a two nucleotide gap DNA molecule
CGGCAACGCAC
>pdb|1RZT|F Chain F, Crystal structure of DNA polymerase lambda complexed with a two nucleotide gap DNA molecule
CGGCAACGCAC
>pdb|1RZT|B Chain B, Crystal structure of DNA polymerase lambda complexed with a two nucleotide gap DNA molecule
CGGCAACGCAC
>pdb|1PO6|B Chain B, Crystal Structure of UP1 Complexed With d(TAGG(6MI)TTAGGG): A Human Telomeric Repeat Containing 6-methyl-8-(2-deoxy-beta-ribofuranosyl)isoxanthopteridine (6MI)
TAGGNTTAGGN
>pdb|1N4B|A Chain A, Solution Structure of the undecamer CGAAAC*TTTCG
CGAAACTTTCG
>pdb|1P59|C Chain C, Structure of a non-covalent Endonuclease III-DNA Complex
TGNCCANGNCT
>pdb|1P59|B Chain B, Structure of a non-covalent Endonuclease III-DNA Complex
AAGACGNGGAC
>pdb|1NUV|H Chain H, The Leadzyme Ribozyme Bound to Mg(H2O)6(II) and Sr(II) at 1.8 A resolution
GCTGGGAGTCC
>pdb|1NUV|F Chain F, The Leadzyme Ribozyme Bound to Mg(H2O)6(II) and Sr(II) at 1.8 A resolution
GCTGGGAGTCC
>pdb|1NUV|D Chain D, The Leadzyme Ribozyme Bound to Mg(H2O)6(II) and Sr(II) at 1.8 A resolution
GCTGGGAGTCC
>pdb|1NUV|B Chain B, The Leadzyme Ribozyme Bound to Mg(H2O)6(II) and Sr(II) at 1.8 A resolution
GCTGGGAGTCC
>pdb|1NUJ|H Chain H, THE LEADZYME STRUCTURE BOUND TO MG(H20)6(II) AT 1.8 A RESOLUTION
GCTGGGAGTCC
>pdb|1NUJ|F Chain F, THE LEADZYME STRUCTURE BOUND TO MG(H20)6(II) AT 1.8 A RESOLUTION
GCTGGGAGTCC
>pdb|1NUJ|D Chain D, THE LEADZYME STRUCTURE BOUND TO MG(H20)6(II) AT 1.8 A RESOLUTION
GCTGGGAGTCC
>pdb|1NUJ|B Chain B, THE LEADZYME STRUCTURE BOUND TO MG(H20)6(II) AT 1.8 A RESOLUTION
GCTGGGAGTCC
>pdb|1KD5|B Chain B, The Crystal Structure of r(GGUCACAGCCC)2 metal free form
GGTCACAGCCC
>pdb|1KD5|A Chain A, The Crystal Structure of r(GGUCACAGCCC)2 metal free form
GGTCACAGCCC
>pdb|1KD4|B Chain B, The Crystal Structure of r(GGUCACAGCCC)2, Barium form
GGTCACAGCCC
>pdb|1KD4|A Chain A, The Crystal Structure of r(GGUCACAGCCC)2, Barium form
GGTCACAGCCC
>pdb|1KD3|B Chain B, The Crystal Structure of r(GGUCACAGCCC)2, Thallium form
GGTCACAGCCC
>pdb|1KD3|A Chain A, The Crystal Structure of r(GGUCACAGCCC)2, Thallium form
GGTCACAGCCC
>pdb|1E3O|B Chain B, Crystal structure of Oct-1 POU dimer bound to MORE
TCCTCATGCAT
>pdb|1E3O|A Chain A, Crystal structure of Oct-1 POU dimer bound to MORE
ATGCATGAGGA
>pdb|1F27|B Chain B, Crystal Structure Of A Biotin-Binding Rna Pseudoknot
AAAAAGTCCTC
>pdb|1EON|D Chain D, ECORV BOUND TO 3'-S-PHOSPHOROTHIOLATE DNA AND CA2+
CAAGANATCTT
>pdb|1EON|C Chain C, ECORV BOUND TO 3'-S-PHOSPHOROTHIOLATE DNA AND CA2+
AAAGANATCTT
>pdb|1EO4|D Chain D, ECORV BOUND TO MN2+ AND COGNATE DNA CONTAINING A 3'S SUBSTITION AT THE CLEAVAGE SITE
CAAGANATCTT
>pdb|1EO4|C Chain C, ECORV BOUND TO MN2+ AND COGNATE DNA CONTAINING A 3'S SUBSTITION AT THE CLEAVAGE SITE
CAAGANATCTT
>pdb|1EO3|D Chain D, INHIBITION OF ECORV ENDONUCLEASE BY DEOXYRIBO-3'-S-PHOSPHOROTHIOLATES: A HIGH RESOLUTION X-RAY CRYSTALLOGRAPHIC STUDY
CAAGANATCTT
>pdb|1EO3|C Chain C, INHIBITION OF ECORV ENDONUCLEASE BY DEOXYRIBO-3'-S-PHOSPHOROTHIOLATES: A HIGH RESOLUTION X-RAY CRYSTALLOGRAPHIC STUDY
CAAGANATCTT
>pdb|1B60|B Chain B, 3,N4-Etheno-2'-Deoxycytidine Opposite Cytidine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics
GCATGCGTACG
>pdb|1B60|A Chain A, 3,N4-Etheno-2'-Deoxycytidine Opposite Cytidine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics
CGTACNCATGC
>pdb|1DE8|V Chain V, Human ApurinicAPYRIMIDINIC ENDONUCLEASE-1 (Ape1) Bound To Abasic Dna
CGATCGGTAGC
>pdb|1DE8|U Chain U, Human ApurinicAPYRIMIDINIC ENDONUCLEASE-1 (Ape1) Bound To Abasic Dna
GCTACNGATCG
>pdb|1DE8|Y Chain Y, Human ApurinicAPYRIMIDINIC ENDONUCLEASE-1 (Ape1) Bound To Abasic Dna
CGATCGGTAGC
>pdb|1DE8|X Chain X, Human ApurinicAPYRIMIDINIC ENDONUCLEASE-1 (Ape1) Bound To Abasic Dna
GCTACNGATCG
>pdb|1CVJ|T Chain T, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|S Chain S, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|R Chain R, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|Q Chain Q, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|P Chain P, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|O Chain O, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|N Chain N, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|1CVJ|M Chain M, X-Ray Crystal Structure Of The Poly(A)-Binding Protein In Complex With Polyadenylate Rna
AAAAAAAAAAA
>pdb|476D|B Chain B, Calcium Form Of B-Dna Undecamer Gcgaattcgcg
GCGAATTCGCG
>pdb|476D|A Chain A, Calcium Form Of B-Dna Undecamer Gcgaattcgcg
GCGAATTCGCG
>pdb|2UP1|B Chain B, STRUCTURE OF UP1-TELOMERIC DNA COMPLEX
NAGGGTTAGGG
>pdb|2SSP|B Chain B, Leucine-272-alanine Uracil-dna Glycosylase Bound To Abasic Site- Containing Dna
AAAGATAACAG
>pdb|1SSP|B Chain B, Wild-Type Uracil-Dna Glycosylase Bound To Uracil-Containing Dna
AAAGATAACAG
>pdb|429D|D Chain D, Crystal Structure Of A Leadzyme; Metal Binding And Implications For Catalysis
GCTGGGAGTCC
>pdb|429D|B Chain B, Crystal Structure Of A Leadzyme; Metal Binding And Implications For Catalysis
GCTGGGAGTCC
>pdb|1B94|D Chain D, RESTRICTION ENDONUCLEASE ECORV WITH CALCIUM
AAAGATATCTT
>pdb|1B94|C Chain C, RESTRICTION ENDONUCLEASE ECORV WITH CALCIUM
AAAGATATCTT
>pdb|1B5K|B Chain B, 3,n4-etheno-2'-deoxycytidine Opposite Thymidine In An 11-mer Duplex, Solution Structure From Nmr And Molecular Dynamics
GCATGTGTACG
>pdb|1B5K|A Chain A, 3,n4-etheno-2'-deoxycytidine Opposite Thymidine In An 11-mer Duplex, Solution Structure From Nmr And Molecular Dynamics
CGTACNCATGC
>pdb|1B6Y|B Chain B, 3,N4-Etheno-2'-Deoxycytidine Opposite Adenine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics, 2 Structures
GCATGAGTACG
>pdb|1B6Y|A Chain A, 3,N4-Etheno-2'-Deoxycytidine Opposite Adenine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics, 2 Structures
CGTACNCATGC
>pdb|1B6X|B Chain B, 3,N4-Etheno-2'-Deoxycytidine Opposite Guanine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics, 4 Structures
GCATGGGTACG
>pdb|1B6X|A Chain A, 3,N4-Etheno-2'-Deoxycytidine Opposite Guanine In An 11-Mer Duplex, Solution Structure From Nmr And Molecular Dynamics, 4 Structures
CGTACNCATGC
>pdb|1BC7|B Chain B, Serum Response Factor Accessory Protein 1a (Sap-1)DNA Complex
CACATCCTGTC
>pdb|1BC7|A Chain A, Serum Response Factor Accessory Protein 1a (Sap-1)DNA Complex
GACAGGATGTG
>pdb|1RV5|D Chain D, COMPLEX OF ECORV ENDONUCLEASE WITH D(AAAGAT)/D(ATCTT)
AAAGATATCTT
>pdb|1RV5|C Chain C, COMPLEX OF ECORV ENDONUCLEASE WITH D(AAAGAT)/D(ATCTT)
AAAGATATCTT
>pdb|1BSU|D Chain D, STRUCTURAL AND ENERGETIC ORIGINS OF INDIRECT READOUT IN SITE-SPECIFIC DNA CLEAVAGE BY A RESTRICTION ENDONUCLEASE
AAAGANNTCTT
>pdb|1A9J|B Chain B, Apyrimidinic Dna With Bound Water At The Damaged Site, Beta Form, Nmr, 1 Structure
GGCGTATCGCG
>pdb|1A9J|A Chain A, Apyrimidinic Dna With Bound Water At The Damaged Site, Beta Form, Nmr, 1 Structure
CGCGANACGCC
>pdb|1A9I|B Chain B, Apyrimidinic Dna With Bound Water At The Damaged Site, Alpha Form, Nmr, 1 Structure
GGCGTATCGCG
>pdb|1A9I|A Chain A, Apyrimidinic Dna With Bound Water At The Damaged Site, Alpha Form, Nmr, 1 Structure
CGCGANACGCC
>pdb|1A9H|B Chain B, Apurinic Dna With Bound Water At The Damaged Site And O2 Of Cytosine, Beta Form, Nmr, 1 Structure
GGCGTCTCGCN
>pdb|1A9H|A Chain A, Apurinic Dna With Bound Water At The Damaged Site And O2 Of Cytosine, Beta Form, Nmr, 1 Structure
CGCGANACGCC
>pdb|1A9G|B Chain B, Apurinic Dna With Bound Water At The Damaged Site And N3 Of Cytosine, Beta Form, Nmr, 1 Structure
GGCGTCTCGCN
>pdb|1A9G|A Chain A, Apurinic Dna With Bound Water At The Damaged Site And N3 Of Cytosine, Beta Form, Nmr, 1 Structure
CGCGANACGCC
>pdb|1A3Q|D Chain D, Human Nf-Kappa-B P52 Bound To Dna
GGGGATTCCCC
>pdb|1A3Q|C Chain C, Human Nf-Kappa-B P52 Bound To Dna
GGGGAATCCCC
>pdb|364D|A Chain A, 3.0 A Structure Of Fragment I From E. Coli 5s Rrna
TGCNTGGCGGC
>pdb|1AG5|B Chain B, THE SOLUTION STRUCTURE OF AN AFLATOXIN B1 EPOXIDE ADDUCT AT THE N7 POSITION OF GUANINE OPPOSITE AN ADENINE IN THE COMPLEMENTARY STRAND OF AN OLIGODEOXYNUCLEOTIDE DUPLEX, NMR, MINIMIZED AVERAGE STRUCTURE
GGATCAGATGG
>pdb|1BPZ|P Chain P, Human Dna Polymerase Beta Complexed With Nicked Dna
GCTGATGCGTG
>pdb|1NFK|D Chain D, STRUCTURE OF THE NUCLEAR FACTOR KAPPA-B (NF-KB) P50 HOMODIMER
TGGGAATTCCC
>pdb|1NFK|C Chain C, STRUCTURE OF THE NUCLEAR FACTOR KAPPA-B (NF-KB) P50 HOMODIMER
TGGGAATTCCC
>pdb|6VDD|E Chain E, POL domain of Pol1 from M. smegmatis complex with DNA primer-template and dNTP
GCGATCACGTA
>pdb|6VDD|B Chain B, POL domain of Pol1 from M. smegmatis complex with DNA primer-template and dNTP
GCGATCACGTA
>pdb|6CQI|B Chain B, 2.42A Crystal structure of Mycobacterium tuberculosis Topoisomerase I in complex with an oligonucleotide MTS2-11
NTCCGCTTGAC
>pdb|5VAJ|C Chain C, BhRNase H - amide-RNA/DNA complex
GACACCTGANC
>pdb|5HK3|C Chain C, Crystal structure of M. tuberculosis MazF-mt3 T52D-F62D mutant in complex with DNA
AGNCNCCNNNC
>pdb|5HK0|F Chain F, Crystal structure of M. tuberculosis MazF-mt3 (Rv1991c) in complex with RNA
AGTCNCCTTTC
>pdb|5HK0|E Chain E, Crystal structure of M. tuberculosis MazF-mt3 (Rv1991c) in complex with RNA
AGTCNCCTTTC
>pdb|5HJZ|C Chain C, Structure of M. tuberculosis MazF-mt1 (Rv2801c) in complex with RNA
CATCNACCTGA
>pdb|5DWA|D Chain D, Crystal structure of pre-specific restriction endonuclease AgeI-DNA complex
TCGACCGGTCG
>pdb|5DWA|C Chain C, Crystal structure of pre-specific restriction endonuclease AgeI-DNA complex
TCGACCGGTCG
>pdb|3NDH|D Chain D, Restriction endonuclease in complex with substrate DNA
CCATCGCGTAC
>pdb|3NDH|C Chain C, Restriction endonuclease in complex with substrate DNA
GGTACGCGATG
>pdb|3GXQ|D Chain D, Structure of ArtA and DNA complex
ACATGTCATGT
>pdb|2I0Q|D Chain D, Crystal structure of a telomere single-strand DNA-protein complex from O. nova with full-length alpha and beta telomere proteins
GGGTTTTGGGG
>pdb|2ASB|B Chain B, Structure of a Mycobacterium tuberculosis NusA-RNA complex
GAACTCAATAG
>pdb|1PH7|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End-Binding Protein Complexed With Noncognate Ssdna Ggggttttgigg
GGGTTTTGNGG
>pdb|1PH6|D Chain D, Crystal Structure of THE OXYTRICHA NOVA TELOMERE END-BINDING PROTEIN COMPLEXED WITH NONCOGNATE SSDNA GGGGTTTTGTGG
GGGTTTTGTGG
>pdb|1PH5|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End- Binding Protein Complexed With Noncognate Ssdna Ggggttttg(3dr)gg
GGGTTTTGNGG
>MD390236.1 WO 2020090822-A/2: Suppressing agent for non-specific binding of nucleic acid, agent for hybridization of nucleic acid, and method for hybridization of nucleic acid
GGGGGGGGGGG
>LY802844.1 KR 1020200014099-A/36: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CTAAGGGTGGG
>LY802841.1 KR 1020200014099-A/33: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CGTCGCGCAAC
>LY802840.1 KR 1020200014099-A/32: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
TGTCGCGCAAC
>LY802839.1 KR 1020200014099-A/31: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
TGTCGTGCGAC
>LY802838.1 KR 1020200014099-A/30: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
TGTCGCGCAAT
>LY802837.1 KR 1020200014099-A/29: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
AGTCGCSCAAC
>LY802836.1 KR 1020200014099-A/28: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
AGTCGCCCAAC
>LY802835.1 KR 1020200014099-A/27: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
AGTCGTGCAAC
>LY802834.1 KR 1020200014099-A/26: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
TGTCGCGCGAC
>LY802833.1 KR 1020200014099-A/25: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
AGTCGCGCAAC
>LY802832.1 KR 1020200014099-A/24: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACTATTAG
>LY802831.1 KR 1020200014099-A/23: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACTNTTAG
>LY802830.1 KR 1020200014099-A/22: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACTCTTCG
>LY802829.1 KR 1020200014099-A/21: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACTCTTTG
>LY802828.1 KR 1020200014099-A/20: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACCCTTAG
>LY802827.1 KR 1020200014099-A/19: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACTCTTAG
>LY802826.1 KR 1020200014099-A/18: BIOMARKER COMPOSIOTION FOR CLASSIFYING PSEUDOSTELLARIA HETEROPHYLLA, KIT COMPRISING SAME AND METHOD FOR CLASSIFIYING PSEUDOSTELLARIA HETEROPHYLLA USING SAME
CCCACACTTGG
>LY836213.1 KR 1020200015570-A/9: VIRUS LIKE PARTICLE
GAAAAAAGGAG
>LY834663.1 KR 1020200005660-A/864: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACCGCAAGCA
>LY834662.1 KR 1020200005660-A/863: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCGTTCAGCC
>LY834661.1 KR 1020200005660-A/862: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGGATCCTACA
>LY834660.1 KR 1020200005660-A/861: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTTATGTCTC
>LY834659.1 KR 1020200005660-A/860: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCGCATGAACC
>LY834658.1 KR 1020200005660-A/859: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCTATGTCGGA
>LY834657.1 KR 1020200005660-A/858: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCGAATAATCG
>LY834656.1 KR 1020200005660-A/857: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGACACCTCG
>LY834655.1 KR 1020200005660-A/856: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATTGACGCAC
>LY834654.1 KR 1020200005660-A/855: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTAGACGGTCT
>LY834653.1 KR 1020200005660-A/854: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCTATAGGACC
>LY834652.1 KR 1020200005660-A/853: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGGTTACATG
>LY834651.1 KR 1020200005660-A/852: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTGGCTCATG
>LY834650.1 KR 1020200005660-A/851: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCAGACATTAA
>LY834649.1 KR 1020200005660-A/850: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTGTGTCCGA
>LY834648.1 KR 1020200005660-A/849: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTGCGTTAGT
>LY834647.1 KR 1020200005660-A/848: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGGCCTAGATG
>LY834646.1 KR 1020200005660-A/847: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGTCTAGCCAT
>LY834645.1 KR 1020200005660-A/846: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGAACGACACA
>LY834644.1 KR 1020200005660-A/845: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACCTGGTCAGT
>LY834643.1 KR 1020200005660-A/844: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGAGAACATAA
>LY834642.1 KR 1020200005660-A/843: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGAATGGACTT
>LY834641.1 KR 1020200005660-A/842: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGGACTGTGTC
>LY834640.1 KR 1020200005660-A/841: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCAACTCTAC
>LY834639.1 KR 1020200005660-A/840: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGCCACAGCA
>LY834638.1 KR 1020200005660-A/839: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTACGAGCTT
>LY834637.1 KR 1020200005660-A/838: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGAACGAGACA
>LY834636.1 KR 1020200005660-A/837: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTGATCGTAG
>LY834635.1 KR 1020200005660-A/836: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTCAGTACAAG
>LY834634.1 KR 1020200005660-A/835: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCGTTATACTT
>LY834633.1 KR 1020200005660-A/834: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCAGGAGATAC
>LY834632.1 KR 1020200005660-A/833: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGAGCAGTGA
>LY834631.1 KR 1020200005660-A/832: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCTACCTAAG
>LY834630.1 KR 1020200005660-A/831: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGGATTGCTCA
>LY834629.1 KR 1020200005660-A/830: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CATGAGGCTTG
>LY834628.1 KR 1020200005660-A/829: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAAGTGTTAC
>LY834627.1 KR 1020200005660-A/828: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCCTCTTCATA
>LY834626.1 KR 1020200005660-A/827: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCTAGGACAG
>LY834625.1 KR 1020200005660-A/826: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTCAGCGTCA
>LY834624.1 KR 1020200005660-A/825: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCTTAGGTGTG
>LY834623.1 KR 1020200005660-A/824: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATGGATCTGG
>LY834622.1 KR 1020200005660-A/823: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCAGATGAATC
>LY834621.1 KR 1020200005660-A/822: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CACACTACTGG
>LY834620.1 KR 1020200005660-A/821: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACTTCACGCA
>LY834619.1 KR 1020200005660-A/820: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAAGGACCGTA
>LY834618.1 KR 1020200005660-A/819: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTTCCAACGTT
>LY834617.1 KR 1020200005660-A/818: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTTGGATCTTG
>LY834616.1 KR 1020200005660-A/817: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAACGTTACGC
>LY834615.1 KR 1020200005660-A/816: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGTGAACAAC
>LY834614.1 KR 1020200005660-A/815: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CACCAGAATGT
>LY834613.1 KR 1020200005660-A/814: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACCAGCACTAT
>LY834612.1 KR 1020200005660-A/813: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCGTGAAGTG
>LY834611.1 KR 1020200005660-A/812: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTCTTGCCTCA
>LY834610.1 KR 1020200005660-A/811: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTAGAGGTTGG
>LY834609.1 KR 1020200005660-A/810: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGTAACGTGG
>LY834608.1 KR 1020200005660-A/809: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGCCTGATGT
>LY834607.1 KR 1020200005660-A/808: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGTAATCGCC
>LY834606.1 KR 1020200005660-A/807: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACCGTTGCCAT
>LY834605.1 KR 1020200005660-A/806: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACCGACTACA
>LY834604.1 KR 1020200005660-A/805: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGAGATTACAA
>LY834603.1 KR 1020200005660-A/804: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACACGAGCAA
>LY834602.1 KR 1020200005660-A/803: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCAATGTTGAA
>LY834601.1 KR 1020200005660-A/802: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTACTCGACGT
>LY834600.1 KR 1020200005660-A/801: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAGTCACGACA
>LY834599.1 KR 1020200005660-A/800: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATTACCGTCT
>LY834598.1 KR 1020200005660-A/799: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCGAATAGTCG
>LY834597.1 KR 1020200005660-A/798: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCACGCAACC
>LY834596.1 KR 1020200005660-A/797: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAAGCACACGT
>LY834595.1 KR 1020200005660-A/796: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCGTCAGCTG
>LY834594.1 KR 1020200005660-A/795: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGATCGATGG
>LY834593.1 KR 1020200005660-A/794: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGCCAACATT
>LY834592.1 KR 1020200005660-A/793: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCCTCAGTGAA
>LY834591.1 KR 1020200005660-A/792: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTACGCTGATC
>LY834590.1 KR 1020200005660-A/791: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCGATACAGAG
>LY834589.1 KR 1020200005660-A/790: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAACTCGTTG
>LY834588.1 KR 1020200005660-A/789: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAAGCTTACTA
>LY834587.1 KR 1020200005660-A/788: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCAACGTGCAG
>LY834586.1 KR 1020200005660-A/787: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAGAAGGTTCA
>LY834585.1 KR 1020200005660-A/786: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGTCACAAGG
>LY834584.1 KR 1020200005660-A/785: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCCAGTTGGC
>LY834583.1 KR 1020200005660-A/784: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGCTAGCTACT
>LY834582.1 KR 1020200005660-A/783: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCTTAATGCAT
>LY834581.1 KR 1020200005660-A/782: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACATTCGCACA
>LY834580.1 KR 1020200005660-A/781: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGCTTATCGT
>LY834579.1 KR 1020200005660-A/780: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCAGATGTCCG
>LY834578.1 KR 1020200005660-A/779: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGTCGAACTT
>LY834577.1 KR 1020200005660-A/778: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AACGCCTATAA
>LY834576.1 KR 1020200005660-A/777: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACCATCGCCT
>LY834575.1 KR 1020200005660-A/776: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATCCTCGTAAG
>LY834574.1 KR 1020200005660-A/775: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTCCACAGGA
>LY834573.1 KR 1020200005660-A/774: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGAATATGTG
>LY834572.1 KR 1020200005660-A/773: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAGTCGAAGC
>LY834571.1 KR 1020200005660-A/772: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAGTCACTGT
>LY834570.1 KR 1020200005660-A/771: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTATTCACAGT
>LY834569.1 KR 1020200005660-A/770: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCGATAGTCGT
>LY834568.1 KR 1020200005660-A/769: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTACACTATGC
>LY832697.1 KR 1020200006111-A/303: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTGGAC
>LY832696.1 KR 1020200006111-A/302: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTGCTC
>LY832695.1 KR 1020200006111-A/301: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTCGTC
>LY832694.1 KR 1020200006111-A/300: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGAGGTC
>LY832693.1 KR 1020200006111-A/299: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTCTGGTC
>LY832692.1 KR 1020200006111-A/298: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATGTTGTGGTC
>LY832691.1 KR 1020200006111-A/297: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GTGCTTCTGTA
>LY832690.1 KR 1020200006111-A/296: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTGGTC
>LY832680.1 KR 1020200006111-A/286: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ACTCGAGTGGC
>LY832679.1 KR 1020200006111-A/285: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GTGTGGTGTGC
>LY832677.1 KR 1020200006111-A/283: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTGGTC
>LY832676.1 KR 1020200006111-A/282: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
CCGCAAGTGGC
>LY832667.1 KR 1020200006111-A/273: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GGGGGCRTATG
>LY832665.1 KR 1020200006111-A/271: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
KMGTRWRTCNW
>LY832663.1 KR 1020200006111-A/269: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
HGGRGSAGTGG
>LY832662.1 KR 1020200006111-A/268: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TGTRCWNKNWW
>LY832654.1 KR 1020200006111-A/260: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TAGCGRGTGCG
>LY832651.1 KR 1020200006111-A/257: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
SKMDRGTGGCY
>LY832645.1 KR 1020200006111-A/251: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
AWCTTGTGGTC
>LY832643.1 KR 1020200006111-A/249: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ACWCGAGWKGC
>LY832642.1 KR 1020200006111-A/248: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
SSSCAAGTGGC
>LY832640.1 KR 1020200006111-A/246: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
DWWNGTTGGRD
>LY832635.1 KR 1020200006111-A/241: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
DDRGKTAGGGK
>LY832626.1 KR 1020200006111-A/232: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
CCYNKVRAHCC
>LY832601.1 KR 1020200006111-A/207: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ATCTTGTGGTC
>LY997671.1 KR 1020200043542-A/104: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATGTCAGAGT
>LY997668.1 KR 1020200043542-A/101: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TGAGACTGTAC
>LY996768.1 KR 1020200044145-A/36: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>LY996756.1 KR 1020200044145-A/24: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>LY996540.1 KR 1020200054278-A/3: NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
TAAATATTTTA
>LY927684.1 KR 1020200024905-A/3051: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRRRR
>LY927668.1 KR 1020200024905-A/3035: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRRRC
>LY982307.1 KR 1020200035130-A/116: NUCLEIC ACID MOLECULES AND USES THEREOF
CTAGCGCCACC
>LY845608.1 KR 1020200026874-A/36: A HTP GENOMIC ENGINEERING PLATFORM FOR IMPROVING ESCHERICHIA COLI
CGGGCTGCTGC
>LY927639.1 KR 1020200024905-A/3006: NOVEL NUCLEIC ACID MOLECULES
GGGTTTTTGGG
>LY927628.1 KR 1020200024905-A/2995: NOVEL NUCLEIC ACID MOLECULES
GGTTTTTTTGG
>LY821917.1 KR 1020200062063-A/10: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
CTCGTTCGTTC
>LY819424.1 KR 1020200012786-A/10: A gene editing of anticoagulant factors
AAAGAGTTTGC
>LY819422.1 KR 1020200012786-A/8: A gene editing of anticoagulant factors
AAATTTCTACT
>LY818582.1 KR 1020200011899-A/10: Genome editing for treating autoimmune disease
AAAGAGTTTGC
>LY818580.1 KR 1020200011899-A/8: Genome editing for treating autoimmune disease
AAATTTCTACT
>LY920993.1 KR 1020200038236-A/735: COMPOSITIONS COMPRISING CURONS AND USES THEREOF
CGGCGGCGGCG
>MD245224.1 JP 2020103258-A/106: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TNTAANANCTG
>MD245201.1 JP 2020103258-A/83: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TNTAANATCTG
>MD245200.1 JP 2020103258-A/82: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TNTAANANCTG
>MD245199.1 JP 2020103258-A/81: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TNTAANANCTG
>MD245197.1 JP 2020103258-A/79: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TNTAANANCTG
>MD245155.1 JP 2020103258-A/37: Method for identifying positions of post transcription modification of uridine or citidine in RNA
GAAGAGAGAGT
>MD245154.1 JP 2020103258-A/36: Method for identifying positions of post transcription modification of uridine or citidine in RNA
GAAGAGAGAGT
>MD245152.1 JP 2020103258-A/34: Method for identifying positions of post transcription modification of uridine or citidine in RNA
GGAGAGGGAGC
>MD245142.1 JP 2020103258-A/24: Method for identifying positions of post transcription modification of uridine or citidine in RNA
ACNCNCTTAAG
>MD245125.1 JP 2020103258-A/7: Method for identifying positions of post transcription modification of uridine or citidine in RNA
CTCCAATAGCG
>LY765667.1 KR 1020190118688-A/111: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765666.1 KR 1020190118688-A/110: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765665.1 KR 1020190118688-A/109: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765664.1 KR 1020190118688-A/108: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765663.1 KR 1020190118688-A/107: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765662.1 KR 1020190118688-A/106: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765661.1 KR 1020190118688-A/105: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765660.1 KR 1020190118688-A/104: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765659.1 KR 1020190118688-A/103: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765658.1 KR 1020190118688-A/102: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765657.1 KR 1020190118688-A/101: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765656.1 KR 1020190118688-A/100: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765655.1 KR 1020190118688-A/99: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765654.1 KR 1020190118688-A/98: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765653.1 KR 1020190118688-A/97: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765652.1 KR 1020190118688-A/96: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765651.1 KR 1020190118688-A/95: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765612.1 KR 1020190118688-A/56: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY765577.1 KR 1020190118688-A/21: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
GATTAGCATTA
>LY727708.1 KR 1020190096989-A/191: METHODS FOR PROCESSING NUCLEIC ACID SAMPLES
ACACTCTTTCC
>LY727679.1 KR 1020190096989-A/100: METHODS FOR PROCESSING NUCLEIC ACID SAMPLES
ACACTCTTTCC
>LY760010.1 KR 1020190129896-A/21: TGF-B-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF
GGGSGGGSGGG
>LY759926.1 KR 1020190112855-A/171: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY759925.1 KR 1020190112855-A/170: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY759924.1 KR 1020190112855-A/169: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY759923.1 KR 1020190112855-A/168: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY722758.1 KR 1020190128618-A/59: IMMUNOMODULATORY FUSION PROTEINS
TAAAAAAAAAT
>LY793715.1 KR 1020190140950-A/36: HUMAN GENE CORRECTION
CGGGTGGAGTT
>LY721015.1 KR 1020190078555-A/18: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
CGGGTCAAAGA
>LY721007.1 KR 1020190078555-A/10: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
CGGGTCAAAGA
>LY720989.1 KR 1020190076944-A/18: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
CGGGTCAAAGA
>LY720981.1 KR 1020190076944-A/10: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
CGGGTCAAAGA
>LY757184.1 KR 1020190119107-A/24: NUCLEIC ACID BASED DATA STORAGE
GCNNNNNNNGC
>LY757183.1 KR 1020190119107-A/23: NUCLEIC ACID BASED DATA STORAGE
GCCNNNNNGGC
>LY757182.1 KR 1020190119107-A/22: NUCLEIC ACID BASED DATA STORAGE
GCANNNNNTGC
>LY757179.1 KR 1020190119107-A/19: NUCLEIC ACID BASED DATA STORAGE
GACNNNNNGTC
>LY757175.1 KR 1020190119107-A/15: NUCLEIC ACID BASED DATA STORAGE
CCTNNNNNAGG
>LY757174.1 KR 1020190119107-A/14: NUCLEIC ACID BASED DATA STORAGE
CCNNNNNNNGG
>LY757173.1 KR 1020190119107-A/13: NUCLEIC ACID BASED DATA STORAGE
CCANNNNNTGG
>LY757166.1 KR 1020190119107-A/6: NUCLEIC ACID BASED DATA STORAGE
ACNNNNNCTCC
>LY757165.1 KR 1020190119107-A/5: NUCLEIC ACID BASED DATA STORAGE
ACNNNNGTAYC
>LY756161.1 KR 1020190109587-A/4765: Abtibody libraries
CTAACTGGGGA
>LY716645.1 KR 1020190143663-A/1: One-step isothermal detection method of gene mutation using hairpins formed on a gold nanoshell
CAGCTCCAACA
>LY787805.1 KR 1020190130608-A/10546: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
TAGGTTCTGGT
>LY787803.1 KR 1020190130608-A/10544: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
ATAGACTCAGA
>LY787802.1 KR 1020190130608-A/10543: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
CACCACAGCTA
>LY787799.1 KR 1020190130608-A/10540: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
AGAGTACAAAG
>LY787796.1 KR 1020190130608-A/10537: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
GATCAACTAGG
>LY713839.1 KR 1020190096149-A/20: Skin-penetrating Delivery Carrier Comprising Nucleic Acid Complex and Uses thereof
TGTAGTCGGTG
>LY750350.1 KR 1020190128634-A/30: MULTIPLE TRANSGENE RECOMBINANT ADENOVIRUS
TAAAAAAAAAT
>LY750230.1 KR 1020190113879-A/801: METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES
CTTCCGAATGC
>LY748881.1 KR 1020190115019-A/197: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
TAAKNNNNGTC
>LY748864.1 KR 1020190115019-A/180: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
ACANNNNNGTG
>LY748862.1 KR 1020190115019-A/178: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAYNNNNNRTC
>LY748851.1 KR 1020190115019-A/167: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNRTAA
>LY748849.1 KR 1020190115019-A/165: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CAGNNNNNGAT
>LY748846.1 KR 1020190115019-A/162: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AAGNNNNNCTT
>LY748843.1 KR 1020190115019-A/159: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCANNNNNNTC
>LY748839.1 KR 1020190115019-A/155: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GACNNNNNGGT
>LY748838.1 KR 1020190115019-A/154: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GATGNNNNTGT
>LY748828.1 KR 1020190115019-A/144: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCCNNNNNCTC
>LY748825.1 KR 1020190115019-A/141: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
ATTCNNNNCTG
>LY748798.1 KR 1020190115019-A/114: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CACNNNNNTAC
>LY748797.1 KR 1020190115019-A/113: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNRTG
>LY748796.1 KR 1020190115019-A/112: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GATGNNNNTGT
>LY748788.1 KR 1020190115019-A/104: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GATNNNNRTAC
>LY748784.1 KR 1020190115019-A/100: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AGGNNNNNGAT
>LY748767.1 KR 1020190115019-A/83: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GACNNNNNTGA
>LY748765.1 KR 1020190115019-A/81: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNTAC
>LY748755.1 KR 1020190115019-A/71: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCTNNNNNAGG
>LY748702.1 KR 1020190115019-A/18: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNTCC
>LY748688.1 KR 1020190115019-A/4: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AACNNNNCTTT
>LY748687.1 KR 1020190115019-A/3: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CACNNNNGTAY
>LY747629.1 KR 1020190115447-A/18: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
CGAATTCATGC
>LY747628.1 KR 1020190115447-A/17: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
GCATGAATTCG
>LY747601.1 KR 1020190100425-A/51: OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLES
ACAGAAAGACA
>LY746465.1 KR 1020190095965-A/2464: PLASMA KALLIKREIN BINDING PROTEINS
CCTNNNNNAGG
>LY746462.1 KR 1020190095965-A/2461: PLASMA KALLIKREIN BINDING PROTEINS
CGTCTCNNNNN
>LY746459.1 KR 1020190095965-A/2458: PLASMA KALLIKREIN BINDING PROTEINS
CCANNNNNTGG
>LY746457.1 KR 1020190095965-A/2456: PLASMA KALLIKREIN BINDING PROTEINS
GACNNNNNGTC
>LY746456.1 KR 1020190095965-A/2455: PLASMA KALLIKREIN BINDING PROTEINS
GACNNNNNGTC
>LY746455.1 KR 1020190095965-A/2454: PLASMA KALLIKREIN BINDING PROTEINS
NNNNNGAGACC
>LY746454.1 KR 1020190095965-A/2453: PLASMA KALLIKREIN BINDING PROTEINS
GGTCTCNNNNN
>LY746453.1 KR 1020190095965-A/2452: PLASMA KALLIKREIN BINDING PROTEINS
GCCNNNNNGGC
>LY746446.1 KR 1020190095965-A/2445: PLASMA KALLIKREIN BINDING PROTEINS
GCANNNNNTGC
>LY745199.1 KR 1020190102259-A/45: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
AAGAGGGATTT
>LY744992.1 KR 1020190104191-A/94: TREATMENT OF SODIUM CHANNEL VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ABTISENSE TRANSCRIPT TO SCNA
GCCAGTCACAA
>LY744706.1 KR 1020190100967-A/963: OPTIMIZED STRATEGY FOR EXON SKIPPING MODIFICATIONS USING CRISPR/CAS9 WITH TRIPLE GUIDE SEQUENCES
CTTTCTTTCAC
>LY743112.1 KR 1020190092611-A/13: METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY
AGTCGAAAAAC
>LY743101.1 KR 1020190092611-A/2: METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY
AGCTGATATTG
>LY743033.1 KR 1020190110554-A/88: SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO
TAATTTTAGGT
>LY742948.1 KR 1020190110554-A/3: SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO
GTTTTAGAGCT
>MD243540.1 JP 2020513777-A/45: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
AAGAGGGATTT
>MD232780.1 JP 2020510612-A/137: Substances for targeting various selected organs or tissues
ATTCTCAGGAA
>MD232804.1 JP 2020510612-A/161: Substances for targeting various selected organs or tissues
ATCCTGTAGGA
>MD232803.1 JP 2020510612-A/160: Substances for targeting various selected organs or tissues
AGCATCCTGTA
>MD232801.1 JP 2020510612-A/158: Substances for targeting various selected organs or tissues
AGTTTCTTCCA
>MD232724.1 JP 2020510612-A/81: Substances for targeting various selected organs or tissues
NNNNNGNNGGN
>MD232723.1 JP 2020510612-A/80: Substances for targeting various selected organs or tissues
NGNNNNNNGNN
>MD232721.1 JP 2020510612-A/78: Substances for targeting various selected organs or tissues
NGNNNNNNNNN
>MD232700.1 JP 2020510612-A/57: Substances for targeting various selected organs or tissues
NNNNNNNGGNN
>MD232601.1 JP 2020510403-A/801: METHOD FOR SYNTHESIS OF ENCODED LIBRARIES
CTTCCGAATGC
>MD230036.1 JP 2020074683-A/23: MicroRNA detection system using novel sPCR primers
TAAAGTGCTTA
>MD230035.1 JP 2020074683-A/22: MicroRNA detection system using novel sPCR primers
TAAGGTGCATC
>MD230034.1 JP 2020074683-A/21: MicroRNA detection system using novel sPCR primers
CAAAGTGCTTA
>MV293467.1 Sequence 20 from patent US 10662473
CCTTCCCCGGN
>MV293465.1 Sequence 18 from patent US 10662473
GGGGGAGGCCN
>MV293446.1 Sequence 1 from patent US 10662472
ACGTACGACGT
>MV292728.1 Sequence 8 from patent US 10662437
CCAGTGAGGAG
>MV283135.1 Sequence 83 from patent US 10662256
CTAACTGGGGC
>MV153549.1 Sequence 3 from patent US 10658069
AACGCTTACGA
>MV152934.1 Sequence 8 from patent US 10655165
CATCCTCCTCC
>MV150360.1 Sequence 18 from patent US 10653800
CTCGTACGTTC
>MV150358.1 Sequence 16 from patent US 10653800
CTCGTTCGTTC
>MV150357.1 Sequence 15 from patent US 10653800
CTCGTTCGTTC
>MV150348.1 Sequence 6 from patent US 10653800
CTCGATCGTTC
>MV150347.1 Sequence 5 from patent US 10653800
CTCGTTCGTTC
>MV150346.1 Sequence 4 from patent US 10653800
CTCGAACGTTC
>MV121047.1 Sequence 1 from patent US 10633700
ACGTACGACGT
>MV119253.1 Sequence 7 from patent US 10633657
TAAGCACTTTG
>MV098837.1 Sequence 6 from patent US 10626446
AATTGTTGCCC
>MV098836.1 Sequence 5 from patent US 10626446
GCCCTTGACTG
>MV098835.1 Sequence 4 from patent US 10626446
ACTGAATTGAA
>MV098719.1 Sequence 4 from patent US 10626439
GGGATCCTACC
>MV097103.1 Sequence 11 from patent US 10626395
GGTTCACTGTG
>MV095291.1 Sequence 39 from patent US 10624349
GTTTTTGTACT
>MV095284.1 Sequence 25 from patent US 10624349
AATCATTTGAG
>MV095283.1 Sequence 24 from patent US 10624349
TTTCATTTGAG
>MV094289.1 Sequence 56 from patent US 10619219
CTCGTTCGTTC
>MV094288.1 Sequence 55 from patent US 10619219
CTCGTTCGTTC
>MV094287.1 Sequence 54 from patent US 10619219
CTCGTTCGTTC
>MV094286.1 Sequence 53 from patent US 10619219
CTCGTTCGTTC
>MV094285.1 Sequence 52 from patent US 10619219
CTCGTTCGTTC
>MV094284.1 Sequence 51 from patent US 10619219
CTCGTTCGTTC
>MV094282.1 Sequence 49 from patent US 10619219
CTCGTTCGTTC
>MV094281.1 Sequence 48 from patent US 10619219
CTCGTTCGTTC
>MV094275.1 Sequence 42 from patent US 10619219
CTCGATCGTTC
>MV094274.1 Sequence 41 from patent US 10619219
CTCGTTCGTTC
>MV094273.1 Sequence 40 from patent US 10619219
CTCGAACGTTC
>MV094269.1 Sequence 36 from patent US 10619219
CTCGTACGTTC
>MV094264.1 Sequence 24 from patent US 10619219
TTTTTTTTTTT
>MV094263.1 Sequence 19 from patent US 10619219
TATTATTTTTT
>MV094262.1 Sequence 18 from patent US 10619219
TGTTGTTTTTT
>MV094261.1 Sequence 17 from patent US 10619219
TTTTTTTTTTT
>MV094260.1 Sequence 16 from patent US 10619219
TTTTTTTTTTT
>MV094259.1 Sequence 15 from patent US 10619219
CCCCTTCCCCC
>MV094258.1 Sequence 14 from patent US 10619219
TTTTTTTTTTT
>MV094257.1 Sequence 11 from patent US 10619219
TTTTTTTTTTT
>MV094256.1 Sequence 10 from patent US 10619219
TTTTTTTTTTT
>MV094255.1 Sequence 9 from patent US 10619219
TTTTTTTTTTT
>MV094254.1 Sequence 8 from patent US 10619219
TTTTTTTTTTT
>MV094253.1 Sequence 7 from patent US 10619219
TTTTTTTTTTT
>MV094251.1 Sequence 5 from patent US 10619219
TTTTTTTTTTT
>MV092393.1 Sequence 4 from patent US 10619205
GTAGTAGTACG
>MV092389.1 Sequence 10 from patent US 10619204
NNNNGAAGACG
>MV092388.1 Sequence 9 from patent US 10619204
GCTCTTCNNNN
>MV146829.1 Sequence 1 from patent US 10648028
ACGTACGACGT
>MV146093.1 Sequence 38 from patent US 10648019
TGGAGCTGTTG
>MV146092.1 Sequence 37 from patent US 10648019
TGGAGCTGATG
>MV142610.1 Sequence 4 from patent US 10646504
GGGATCCTACC
>MV139906.1 Sequence 34 from patent US 10640822
CAAGTACGTGA
>MV139732.1 Sequence 232 from patent US 10640820
TAACCAGCCCT
>MV139495.1 Sequence 12 from patent US 10640818
NNNNGAAGAGC
>MV139494.1 Sequence 11 from patent US 10640818
GCTCTTCNNNN
>MV139491.1 Sequence 8 from patent US 10640818
NNNNNGAGACG
>MV139490.1 Sequence 7 from patent US 10640818
CGTCTCNNNNN
>MV139489.1 Sequence 6 from patent US 10640818
NNNNNGAGACC
>MV139488.1 Sequence 5 from patent US 10640818
GGTCTCNNNNN
>MV138299.1 Sequence 140 from patent US 10640789
GCCCCTTCTTC
>MV136699.1 Sequence 290 from patent US 10640780
CTTGTTGGTTA
>MV136698.1 Sequence 289 from patent US 10640780
GCTTGTTAGTT
>MV136691.1 Sequence 282 from patent US 10640780
TGTAAGCACTA
>MV130861.1 Sequence 461 from patent US 10639332
GRTVDGTVVSD
>MV130860.1 Sequence 461 from patent US 10639331
GRTVDGTVVSD
>MV085678.1 Sequence 120 from patent US 10619153
GGTCTCNCCTG
>MV085677.1 Sequence 119 from patent US 10619153
AGCANGAGACC
>MV085676.1 Sequence 118 from patent US 10619153
CAGGNGAGACC
>MV085675.1 Sequence 117 from patent US 10619153
GGTCTCNTGCT
>MV085674.1 Sequence 116 from patent US 10619153
CCTGTGAGACC
>MV085673.1 Sequence 115 from patent US 10619153
GGTCTCAAGCA
>MV085672.1 Sequence 114 from patent US 10619153
GGTCTCACAGG
>MV085671.1 Sequence 113 from patent US 10619153
TGCTTGAGACC
>MV084003.1 Sequence 44 from patent US 10617709
TGAGAGGCCGC
>MV084001.1 Sequence 42 from patent US 10617709
GCGACCGTAAC
>MV083995.1 Sequence 35 from patent US 10617709
TGAAGGGCTCT
>MV083974.1 Sequence 10 from patent US 10617709
CTTCCCTCCCA
>MO965016.1 Sequence 79 from patent US 10597658
TAGCATACTTA
>MO965015.1 Sequence 78 from patent US 10597658
TGGCCATCAAT
>MO965014.1 Sequence 77 from patent US 10597658
ACCAAAAGAAT
>MO965008.1 Sequence 69 from patent US 10597658
TAGCATACTTA
>MO965007.1 Sequence 68 from patent US 10597658
TGGCCATCAAT
>MO965006.1 Sequence 67 from patent US 10597658
ACCAAAAGAAT
>MO964994.1 Sequence 55 from patent US 10597658
TAGCATACTTA
>MO964993.1 Sequence 54 from patent US 10597658
TGGCCATCAAT
>MO964992.1 Sequence 53 from patent US 10597658
ACCAAAAGAAT
>MO964988.1 Sequence 47 from patent US 10597658
TAGCATACTTA
>MO964987.1 Sequence 46 from patent US 10597658
TGGCCATCAAT
>MO964986.1 Sequence 45 from patent US 10597658
ACCAAAAGAAT
>MO961247.1 Sequence 357 from patent US 10596252
GGGTTTTTGGG
>MO961237.1 Sequence 346 from patent US 10596252
GGTTTTTTTGG
>MO959459.1 Sequence 214 from patent US 10590489
GCCGCCTGAAA
>MO957737.1 Sequence 6 from patent US 10590461
CTAATCGGATC
>MO957736.1 Sequence 5 from patent US 10590461
GTCAGTCAATG
>MO957735.1 Sequence 4 from patent US 10590461
ACGTAGGGTCA
>MO957734.1 Sequence 3 from patent US 10590461
TAGCCTAGTAA
>MO957733.1 Sequence 2 from patent US 10590461
ACTGTCAGTAG
>MO950114.1 Sequence 2301 from patent US 10590413
CAGGTAAGTAT
>MV083408.1 Sequence 979 from patent US 10614353
TAAAGGAGGAA
>MV083407.1 Sequence 976 from patent US 10614353
AGAGGTGGTGT
>MV083406.1 Sequence 975 from patent US 10614353
AAAGGAGGTGT
>MV083358.1 Sequence 925 from patent US 10614353
AGGAGGTCATC
>MV081773.1 Sequence 1 from patent US 10612091
CGATCGATCGA
>MV081769.1 Sequence 10 from patent US 10612090
AAATTCCGGCA
>MV081768.1 Sequence 9 from patent US 10612090
GGATCAAGCTA
>MV081767.1 Sequence 8 from patent US 10612090
ATCCTTTAAGC
>MV081265.1 Sequence 30 from patent US 10612082
CTCGCAGGAAC
>MV079979.1 Sequence 7 from patent US 10612043
ATCTGGNNNNN
>MV067134.1 Sequence 8 from patent US 10612018
GGGCACTGTAC
>MV067133.1 Sequence 7 from patent US 10612018
GGGCACTGTAC
>MV067078.1 Sequence 52 from patent US 10612011
AAATSGGGGAA
>MV065925.1 Sequence 60 from patent US 10610605
TGGAGAAAGGT
>MV065924.1 Sequence 59 from patent US 10610605
ACCTTTCTCCA
>MV065368.1 Sequence 32 from patent US 10610521
TCACTGCTGAA
>MV058640.1 Sequence 207 from patent US 10604755
GGATGAAGAAG
>MV058562.1 Sequence 129 from patent US 10604755
CTTCTTCATCC
>MV044953.1 Sequence 8 from patent US 10603385
CCCACCACCAC
>MV044952.1 Sequence 7 from patent US 10603385
ACACCGACGGC
>MO996689.1 Sequence 1 from patent US 10600499
CATAGGGTGTA
>MC403646.1 JP 2018164458-A/4: TERMINALLY MODIFIED RNA
AAAAAGCAAAA
>MC403644.1 JP 2018164458-A/2: TERMINALLY MODIFIED RNA
TTTTGCTTTTT
>MC403057.1 JP 2018157825-A/35: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAACTCC
>MC403056.1 JP 2018157825-A/34: Compositions and Methods for Regulating Cell Osmolarity
GGAGTTTTCCA
>MC403055.1 JP 2018157825-A/33: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAAACAC
>MC403054.1 JP 2018157825-A/32: Compositions and Methods for Regulating Cell Osmolarity
TGGAAATCTCC
>MC403053.1 JP 2018157825-A/31: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATTTT
>MC403052.1 JP 2018157825-A/30: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAGTTTT
>MC403051.1 JP 2018157825-A/29: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAGTTCC
>MC403050.1 JP 2018157825-A/28: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAGTTAC
>MC403049.1 JP 2018157825-A/27: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATTAC
>MC403047.1 JP 2018157825-A/25: Compositions and Methods for Regulating Cell Osmolarity
TGGAATTCTAT
>MC403046.1 JP 2018157825-A/24: Compositions and Methods for Regulating Cell Osmolarity
ATAGAATTCCA
>MC403045.1 JP 2018157825-A/23: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAACTAC
>MC403044.1 JP 2018157825-A/22: Compositions and Methods for Regulating Cell Osmolarity
CGGAAAATCCC
>MC403043.1 JP 2018157825-A/21: Compositions and Methods for Regulating Cell Osmolarity
CGGAAAATACC
>MC403042.1 JP 2018157825-A/20: Compositions and Methods for Regulating Cell Osmolarity
CGGAAAAAACC
>MC403041.1 JP 2018157825-A/19: Compositions and Methods for Regulating Cell Osmolarity
AGGAAAATCAC
>MC403040.1 JP 2018157825-A/18: Compositions and Methods for Regulating Cell Osmolarity
TGGAAATTTAC
>MC403039.1 JP 2018157825-A/17: Compositions and Methods for Regulating Cell Osmolarity
TGGAATATTAC
>MC403038.1 JP 2018157825-A/16: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATTAC
>MC403037.1 JP 2018157825-A/15: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATCAC
>MC403036.1 JP 2018157825-A/14: Compositions and Methods for Regulating Cell Osmolarity
CGGAAAATCAC
>MC403035.1 JP 2018157825-A/13: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATCAC
>MC403034.1 JP 2018157825-A/12: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAAATTT
>MC403033.1 JP 2018157825-A/11: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAAATAT
>MC403032.1 JP 2018157825-A/10: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAAGTCC
>MC403031.1 JP 2018157825-A/9: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATCAC
>MC403027.1 JP 2018157825-A/5: Compositions and Methods for Regulating Cell Osmolarity
TGGAAATTTGT
>MC403026.1 JP 2018157825-A/4: Compositions and Methods for Regulating Cell Osmolarity
HGGAAANNHNH
>MC403023.1 JP 2018157825-A/1: Compositions and Methods for Regulating Cell Osmolarity
HGGAAWNNHNH
>MC402209.1 JP 2019508037-A/18: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
NTTTNTTTTNT
>MC422857.1 JP 2018174942-A/2: METHODS FOR PURIFICATION OF MESSENGER RNA
GGGATCCTACC
>MD225152.1 JP 2020508639-A/14: VHH-containing heavy chain antibody and production thereof
CTAACTGGAGC
>MC033761.1 JP 2018534939-A/3: PURIFICATION OF POLYMERASE COMPLEXES
ATGTGACCTAT
>MC033407.1 JP 2018532412-A/190: BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
GGCTCATCTGG
>MC032951.1 JP 2018530560-A/3411: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
ATCCTGTAGGA
>MC032927.1 JP 2018530560-A/3387: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
ATTCTCAGGAA
>MC032948.1 JP 2018530560-A/3408: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
AGTTTCTTCCA
>MC032950.1 JP 2018530560-A/3410: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
AGCATCCTGTA
>MC032870.1 JP 2018530560-A/3330: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NGNNNNNNGNN
>MC032871.1 JP 2018530560-A/3331: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NNNNNGNNGGN
>MC032868.1 JP 2018530560-A/3328: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NGNNNNNNNNN
>MC032847.1 JP 2018530560-A/3307: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NNNNNNNGGNN
>MC414568.1 JP 2018164462-A/74: Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences
CTAACTGGGGA
>MC414490.1 JP 2018183178-A/144: Antisense Nucleic Acid
CCTGGAGTTCC
>MC414492.1 JP 2018183178-A/146: Antisense Nucleic Acid
ACAGTTTGCCG
>MC183485.1 JP 2018535695-A/59: ANTI-CANCER AND ANTI-INFLAMMATORY THERAPEUTICS AND METHODS THEREOF
GAAAGGGGCTG
>MC182928.1 JP 2019505209-A/37: GENE MODIFICATION ASSAYS
TGCTTGGAAAG
>MC031097.1 JP 2018530560-A/1557: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
CTGTTGAGAAA
>MC183361.1 JP 2019503385-A/1: MODULATORS OF ROR-GAMMA
AAAGTAGGTCA
>MC028114.1 JP 2018533955-A/23: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
TTTGCTTAGAA
>MC028105.1 JP 2018533955-A/14: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
AAAACATACCA
>MC409812.1 JP 2018183155-A/33: RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE
GGAAAGTCCCC
>MC409739.1 JP 2018171070-A/10: Aptamers for use against autoantibody-associated diseases
GGTGGTGGTGG
>MD217844.1 JP 2020065482-A/1: Diagnostics for Parkinson disease and model animal
TGATCMGTTTG
>MC435439.1 JP 2019004914-A/22: A method for DNA amplification with a blocking oligonucleotide
TAGGTCGTCAT
>MC244217.1 JP 2018535651-A/14: Diagnostic Methods and Devices
GCGGGCCAAAC
>MC016117.1 JP 2020042813-A/11: METHODS AND SYSTEMS FOR ALIGNING SEQUENCES
TTGGATATGGG
>MC015964.1 JP 2020043794-A/22: Primer set, and amplification method of target nucleotide sequence using it
GAAGGCGGGAA
>MC015961.1 JP 2020043794-A/19: Primer set, and amplification method of target nucleotide sequence using it
GATCAGATTGT
>MP563855.1 Sequence 99 from Patent EP3625244
SYASDMVSDTV
>MP464435.1 Sequence 13 from Patent WO2019243888
GTACATGAGAC
>MP462957.1 Sequence 149 from Patent EP3597744
CTTGTTGGTTA
>MP462956.1 Sequence 148 from Patent EP3597744
GCTTGTTAGTT
>MP462949.1 Sequence 141 from Patent EP3597744
TGTAAGCACTA
>MP366414.1 Sequence 2 from Patent EP3556764
AAGAAGAAGAA
>MP366413.1 Sequence 1 from Patent EP3556764
TTCTTCTTCTT
>MP459888.1 Sequence 6 from Patent EP3597748
ACTNNNNGATT
>MP459886.1 Sequence 4 from Patent EP3597748
TCGNNNNGATT
>MP459884.1 Sequence 2 from Patent EP3597748
CGCNNNNGATT
>MP457035.1 Sequence 56 from Patent EP3594339
AGCTTCTCAAA
>MP457907.1 Sequence 11 from Patent EP3592847
AAAAAAAAAAA
>MP457681.1 Sequence 8 from Patent EP3597657
GNGNGCNNNAG
>MP457677.1 Sequence 4 from Patent EP3597657
CNGNCTNNNAC
>MP619978.1 Sequence 84 from Patent WO2019204743
CGATCGATCCC
>MP619947.1 Sequence 53 from Patent WO2019204743
GGGATCGATCG
>MP619952.1 Sequence 58 from Patent WO2019204743
ATCNATCNATC
>MP543953.1 Sequence 24 from Patent WO2020033951
TTTNTTTNTNT
>MP454249.1 Sequence 3 from Patent EP3592344
AAAGTACACGA
>MP454248.1 Sequence 2 from Patent EP3592344
AAAGTAGGTTA
>MP454247.1 Sequence 1 from Patent EP3592344
AAAGTAGGTCA
>MP540257.1 Sequence 4 from Patent WO2020047007
AAAAAAAAAAA
>MP452354.1 Sequence 148 from Patent EP3591036
ACGCCGTCATT
>MP359796.1 Sequence 214 from Patent EP3551767
GGAGCTGTGAT
>MP359772.1 Sequence 190 from Patent EP3551767
GGAGCTAGTGG
>MP539718.1 Sequence 4 from Patent WO2020047184
CTTTCTCTCTG
>MP359587.1 Sequence 5 from Patent EP3551767
GGAGCTGTTGG
>MP359586.1 Sequence 4 from Patent EP3551767
GGAGCTGATGG
>MP358393.1 Sequence 24 from Patent EP3551193
GGGATCCTACC
>MP539521.1 Sequence 166 from Patent WO2020047282
AGATGGTGTCA
>MP539512.1 Sequence 157 from Patent WO2020047282
CAGTTCTTCCT
>MP614455.1 Sequence 2 from Patent WO2019191122
ATTGGAGTCCT
>MP449573.1 Sequence 5 from Patent WO2019238873
WWWATTTAWWW
>MP537009.1 Sequence 5 from Patent EP3618856
ATAGCCATGGC
>MP537008.1 Sequence 4 from Patent EP3618856
RYMRMVATGGC
>MP353037.1 Sequence 34 from Patent WO2019200171
CCCCCACAACC
>MP443260.1 Sequence 21 from Patent EP3589663
GGGSGGGSGGG
>MP350374.1 Sequence 6 from Patent EP3550032
AATTGTTGCCC
>MP350373.1 Sequence 5 from Patent EP3550032
GCCCTTGACTG
>MP350372.1 Sequence 4 from Patent EP3550032
ACTGAATTGAA
>MP441658.1 Sequence 14 from Patent EP3583201
ATTACGCCACC
>MP441398.1 Sequence 13 from Patent EP3582790
GGGATCCTACC
>MP608894.1 Sequence 122 from Patent WO2020086742
ATCGGGCTAGC
>MP523231.1 Sequence 60 from Patent EP3600671
AGCGATAGTAC
>MP523226.1 Sequence 55 from Patent EP3600671
AGCGATAGTAC
>MP343280.1 Sequence 6 from Patent WO2019195166
TTTTTTTTTTT
>MP340304.1 Sequence 26 from Patent WO2019186274
CAGCAGTGCCT
>MP340144.1 Sequence 13 from Patent EP3546578
ATGCAAAGCAT
>MP338104.1 Sequence 13 from Patent WO2019185732
ATGCAAAGCAT
>MP427420.1 Sequence 12 from Patent EP3580354
ACGAGCTACGA
>MP335338.1 Sequence 96 from Patent WO2019186175
TAACACCGGTG
>MP427418.1 Sequence 10 from Patent EP3580354
TCGTAGCTCGT
>MP333264.1 Sequence 160 from Patent EP3539980
AAATTTCTACT
>MP333269.1 Sequence 165 from Patent EP3539980
AAAGAGTTTGC
>MP333263.1 Sequence 159 from Patent EP3539980
AAAGAGTTTGC
>MP424801.1 Sequence 6 from Patent EP3580675
CTGGAACTATG
>MP424800.1 Sequence 5 from Patent EP3580675
AGCTTGCAGGC
>MP424799.1 Sequence 4 from Patent EP3580675
GCTGATCTGAA
>MP424798.1 Sequence 3 from Patent EP3580675
GGAGCTCCTAC
>MP424797.1 Sequence 2 from Patent EP3580675
CTGCTAGGAAT
>MP424796.1 Sequence 1 from Patent EP3580675
AGCGTTAAGGG
>MP327821.1 Sequence 188 from Patent EP3536809
CTTGCCCAGGC
>MP326809.1 Sequence 44 from Patent EP3536776
TTCTGCCTGTG
>MP511974.1 Sequence 38 from Patent EP3612547
CAAACCGCGCG
>MP326631.1 Sequence 188 from Patent EP3536810
CTTGCCCAGGC
>MP416078.1 Sequence 6 from Patent EP3578663
AAAAAAAAAAT
>MP317698.1 Sequence 25 from Patent EP3535404
CAAAGGGACAA
>MP317679.1 Sequence 6 from Patent EP3535404
GCCACCCCTCA
>MP316461.1 Sequence 15 from Patent EP3541952
AGCTCTCGAGT
>MP408207.1 Sequence 2 from Patent WO2019219581
CTGCCCAGAGT
>MP596337.1 Sequence 2 from Patent EP3640346
TACGTCATGCT
>MP596336.1 Sequence 1 from Patent EP3640346
ATGCCTGAATC
>MP593082.1 Sequence 989 from Patent EP3634496
RRAAVNRRAAV
>MP313947.1 Sequence 8 from Patent EP3541940
AGCTCTCGAGT
>MP311046.4 Sequence 8 from Patent EP3538662
CAABTTBBTBT
>MP311045.4 Sequence 7 from Patent EP3538662
CATBBTTBTBT
>MP311048.3 Sequence 10 from Patent EP3538662
TACBTBBTBTB
>MP311047.3 Sequence 9 from Patent EP3538662
CTABTBTBTBT
>MP311094.1 Sequence 18 from Patent EP3534916
AAATCCAGTGA
>MP588064.1 Sequence 4 from Patent WO2020070105
CGGAACAGCGG
>MP588059.1 Sequence 50 from Patent EP3624842
CCGCCRCCAGG
>MP401548.1 Sequence 13 from Patent EP3562958
AGTCGAAAAAC
>MP401537.1 Sequence 2 from Patent EP3562958
AGCTGATATTG
>MP400974.1 Sequence 2 from Patent EP3571616
TTGGCATGACT
>MP400690.1 Sequence 9 from Patent EP3572530
ACTACRGTCAA
>MP400689.1 Sequence 8 from Patent EP3572530
CGTACKAAGAG
>MP585611.1 Sequence 11 from Patent WO2020081768
GGTCTCGYYYY
>MP585606.1 Sequence 6 from Patent WO2020081768
CCAGAGCAAGG
>MP585568.1 Sequence 1 from Patent WO2020081398
TCNNNCGNNCG
>MP398521.1 Sequence 83 from Patent EP3568470
TCCGCGGCCGC
>MP398520.1 Sequence 82 from Patent EP3568470
GTCGTTTGGGT
>MP635657.1 Sequence 116 from Patent WO2020033863
CTAGCGCCACC
>MP485364.1 Sequence 140 from Patent EP3603679
GCCCCTTCTTC
>MP484327.1 Sequence 29 from Patent WO2020020471
CTGCACCTGCC
>MP397205.1 Sequence 36 from Patent EP3572072
GTTAGGGTTAG
>MP397193.1 Sequence 24 from Patent EP3572072
GTTAGGGTTAG
>MP396945.1 Sequence 44 from Patent EP3565891
GGCGCCATNTT
>MP482907.1 Sequence 406 from Patent WO2020023864
AACACACAGAG
>MP482904.1 Sequence 403 from Patent WO2020023864
ATTCAACACAC
>MP482898.1 Sequence 397 from Patent WO2020023864
AACACACAGAG
>MP482897.1 Sequence 396 from Patent WO2020023864
TCAACACACAG
>MP482892.1 Sequence 391 from Patent WO2020023864
AACACACAGAG
>MP479968.1 Sequence 48 from Patent EP3604558
GGTCAGGAGTT
>MP479020.1 Sequence 12 from Patent WO2020007953
ACNNNNNCTCC
>MP631149.1 Sequence 330 from Patent EP3573448
CCTTTTGTCNC
>MP631148.1 Sequence 329 from Patent EP3573448
CCTTTTGTCTC
>MP631147.1 Sequence 328 from Patent EP3573448
CCTCGTGTCTC
>MP631127.1 Sequence 308 from Patent EP3573448
CCTTTTGTCGG
>MP391039.1 Sequence 71 from Patent EP3569252
TCTCAGATGGT
>MP391024.1 Sequence 56 from Patent EP3569252
TCCTTCTGATT
>MP391023.1 Sequence 55 from Patent EP3569252
CTCTTCCTTTT
>MP391022.1 Sequence 54 from Patent EP3569252
ATACTGTCCAA
>MP391021.1 Sequence 53 from Patent EP3569252
GGTGCTCAAAC
>MP391020.1 Sequence 52 from Patent EP3569252
AGAGTTCAAGG
>MP391018.1 Sequence 50 from Patent EP3569252
ATCCACACAAG
>MP391017.1 Sequence 49 from Patent EP3569252
CTCTTAATGAT
>MP391015.1 Sequence 47 from Patent EP3569252
TGTTTCACCAT
>MP391014.1 Sequence 46 from Patent EP3569252
GGTTTGCCAAG
>MP391013.1 Sequence 45 from Patent EP3569252
TGTTTCATACG
>MP391010.1 Sequence 42 from Patent EP3569252
ATATACCTCAT
>MP391009.1 Sequence 41 from Patent EP3569252
TCCTGCATCAT
>MP391008.1 Sequence 40 from Patent EP3569252
GTATATGCCAT
>MP391007.1 Sequence 39 from Patent EP3569252
TTCTGATTCAT
>MP391006.1 Sequence 38 from Patent EP3569252
ACATCTGTCAT
>MP391005.1 Sequence 37 from Patent EP3569252
CATTGAGATTT
>MP391004.1 Sequence 36 from Patent EP3569252
CTACTGGTCAT
>MP391003.1 Sequence 35 from Patent EP3569252
GACTTAATCAA
>MP391002.1 Sequence 34 from Patent EP3569252
GGTGCAGTCAT
>MP391000.1 Sequence 32 from Patent EP3569252
TGTTAAAGAGC
>MP390999.1 Sequence 31 from Patent EP3569252
AATTCGAGCAT
>MP390998.1 Sequence 30 from Patent EP3569252
TGTTTGATCAT
>MP390997.1 Sequence 29 from Patent EP3569252
ACGCTAATCAT
>MP390996.1 Sequence 28 from Patent EP3569252
TTTCCAGCCAT
>MP390995.1 Sequence 27 from Patent EP3569252
TTCCCTGCCAT
>MP390994.1 Sequence 26 from Patent EP3569252
TTTTGCTCCAT
>MP390993.1 Sequence 25 from Patent EP3569252
TCATCTTTGCT
>MP390991.1 Sequence 23 from Patent EP3569252
AATGAGGCCAT
>MP390990.1 Sequence 22 from Patent EP3569252
TCAAATGAGGC
>MP390989.1 Sequence 21 from Patent EP3569252
TCTTTGGCCAT
>MP390988.1 Sequence 20 from Patent EP3569252
ATGATACGCAT
>MP390987.1 Sequence 19 from Patent EP3569252
CTTAGACATGG
>MP390986.1 Sequence 18 from Patent EP3569252
GGCAGACTCGG
>MP390985.1 Sequence 17 from Patent EP3569252
CTATTCTCCAA
>MP390984.1 Sequence 16 from Patent EP3569252
ACTCGGGACAT
>MP390983.1 Sequence 15 from Patent EP3569252
AAATTTATCCA
>MP390982.1 Sequence 14 from Patent EP3569252
AATTTATCCAT
>MP390981.1 Sequence 13 from Patent EP3569252
CATTTAGTTTG
>MP390980.1 Sequence 12 from Patent EP3569252
ATCCATTTAGT
>MP390979.1 Sequence 11 from Patent EP3569252
GCTTTTTTCAT
>MP390978.1 Sequence 10 from Patent EP3569252
TTGATAGTCAT
>MP390977.1 Sequence 9 from Patent EP3569252
AGAAAACCCAT
>MP390976.1 Sequence 8 from Patent EP3569252
GCACGTTTCAT
>MP390975.1 Sequence 7 from Patent EP3569252
TTATCTACCAT
>MP390973.1 Sequence 5 from Patent EP3569252
TTGCCATTAGC
>MP390972.1 Sequence 4 from Patent EP3569252
CACAGGAATTC
>MP390971.1 Sequence 3 from Patent EP3569252
ATTCTCCTCAT
>MP390970.1 Sequence 2 from Patent EP3569252
ATATCGCTCAC
>MP390969.1 Sequence 1 from Patent EP3569252
CTTCGATAGTG
>MP631052.1 Sequence 233 from Patent EP3573448
TACACTTTTGG
>MP631027.1 Sequence 208 from Patent EP3573448
TAAGAGCCGCC
>MP630991.1 Sequence 172 from Patent EP3573448
CCATTTTTAGT
>MP573395.1 Sequence 45 from Patent WO2020065303
TGGTGGGGCCC
>MP573394.1 Sequence 44 from Patent WO2020065303
TGGTGAGGCCC
>MP573393.1 Sequence 43 from Patent WO2020065303
TGGTAAGGCCC
>MP388653.1 Sequence 4 from Patent WO2019209946
CGCACTTCAAT
>MP572029.1 Sequence 6 from Patent EP3636758
ACTNNNNGATT
>MP572027.1 Sequence 4 from Patent EP3636758
TCGNNNNGATT
>MP572025.1 Sequence 2 from Patent EP3636758
CGCNNNNGATT
>MP385642.1 Sequence 135 from Patent EP3567122
CCTCCGACCGT
>MP471894.1 Sequence 1 from Patent EP3595710
GCGGCCGCAAC
>MP568106.1 Sequence 95 from Patent EP3636778
TACTCCTATGA
>MP568104.1 Sequence 93 from Patent EP3636778
TAATCCAATCA
>MP568103.1 Sequence 92 from Patent EP3636778
TAATTGAATCA
>MP568102.1 Sequence 91 from Patent EP3636778
TACTTTTATGA
>MP568101.1 Sequence 90 from Patent EP3636778
TAATTTAATCA
>MP568100.1 Sequence 89 from Patent EP3636778
TAAYBBAATCA
>MP510408.1 Sequence 14 from Patent EP3610003
TAAAAAAAAAT
>MP510086.1 Sequence 22 from Patent EP3610025
TAAAAAAAAAT
>MP403640.1 Sequence 30 from Patent EP3574090
TAAAAAAAAAT
>MP389766.1 Sequence 27 from Patent WO2019209859
AGGATAAGTGA
>MP389750.1 Sequence 11 from Patent WO2019209859
CTGGAAAATGT
>MO938900.1 Sequence 13 from patent US 10584337
CCTGACCCAGT
>MO933638.1 Sequence 39 from patent US 10582712
GTTTTTGTACT
>MO933631.1 Sequence 25 from patent US 10582712
AATCATTTGAG
>MO933630.1 Sequence 24 from patent US 10582712
TTTCATTTGAG
>MO932490.1 Sequence 1 from patent US 10577652
ACGTACGACGT
>MO931731.1 Sequence 782 from patent US 10577630
CCNNNNNNNGG
>MO929392.1 Sequence 116 from patent US 10577609
TCTGATTTTGT
>MO929344.1 Sequence 60 from patent US 10577609
CGTTGACTTAT
>MO928108.1 Sequence 32 from patent US 10577605
AATGCTGGCAG
>MO928107.1 Sequence 31 from patent US 10577605
AATGCTGGCAG
>MO928106.1 Sequence 30 from patent US 10577605
AATGCTGGCAG
>MO928105.1 Sequence 29 from patent US 10577605
AATGCTGGCAG
>MO928104.1 Sequence 28 from patent US 10577605
AATGCTGGCAG
>MO928103.1 Sequence 27 from patent US 10577605
AATGCTGGCAG
>MO928102.1 Sequence 26 from patent US 10577605
AATGCTGGCAG
>MO927633.1 Sequence 63 from patent US 10577430
CTAACTGGGGA
>MO900269.1 Sequence 69 from patent US 10568958
GGGTTTTTGGG
>MO900259.1 Sequence 58 from patent US 10568958
GGTTTTTTTGG
>MO899883.1 Sequence 461 from patent US 10568909
GRTVDGTVVSD
>MO890647.1 Sequence 167 from patent US 10563215
AGTGGGAAGTG
>MO890645.1 Sequence 165 from patent US 10563215
CTGATGTAAAG
>MO890643.1 Sequence 163 from patent US 10563215
AATGAGAATGA
>MO890641.1 Sequence 161 from patent US 10563215
GGCTCCGCCAC
>MO890639.1 Sequence 159 from patent US 10563215
TTTTGGTTCTC
>MO890638.1 Sequence 158 from patent US 10563215
GAACTCACCTT
>MO890637.1 Sequence 157 from patent US 10563215
ATGAAGGAGTG
>MO890636.1 Sequence 156 from patent US 10563215
TCCCTGTCGTC
>MO890634.1 Sequence 154 from patent US 10563215
GTGGGAAGTGA
>MO890632.1 Sequence 152 from patent US 10563215
CCTTAATGAAA
>MO890631.1 Sequence 151 from patent US 10563215
CATGGATGAGA
>MO890627.1 Sequence 147 from patent US 10563215
TAACACAACCC
>MO890626.1 Sequence 146 from patent US 10563215
GCATCCCCTGA
>MO890623.1 Sequence 143 from patent US 10563215
TGTGCCATCTG
>MO890618.1 Sequence 138 from patent US 10563215
TTCTCCTTCTG
>MO890617.1 Sequence 137 from patent US 10563215
GATCTTATACA
>MO890615.1 Sequence 135 from patent US 10563215
TTGTCCTGGCA
>MO890613.1 Sequence 133 from patent US 10563215
TTCAATGAGAA
>MO890611.1 Sequence 131 from patent US 10563215
CAGCAGGGGTG
>MO890608.1 Sequence 128 from patent US 10563215
GCCATGGATGA
>MO890607.1 Sequence 127 from patent US 10563215
TTGAGCTAACA
>MO890606.1 Sequence 126 from patent US 10563215
GCGTCATATTT
>MO890605.1 Sequence 125 from patent US 10563215
CCGTTCTGGGA
>MO890604.1 Sequence 124 from patent US 10563215
CAGGGCTGTAT
>MO890603.1 Sequence 123 from patent US 10563215
TGAGAGAGAAA
>MO890602.1 Sequence 122 from patent US 10563215
AGGAGTGGGAA
>MO890601.1 Sequence 121 from patent US 10563215
AGCCATGGATG
>MO890600.1 Sequence 120 from patent US 10563215
ATGCCAACCCG
>MO890598.1 Sequence 118 from patent US 10563215
TGCGGTTCTCG
>MO890595.1 Sequence 115 from patent US 10563215
CATCACTTTTG
>MO890594.1 Sequence 114 from patent US 10563215
AGCTTCCCTTA
>MO890593.1 Sequence 113 from patent US 10563215
GGTTCTCGGAG
>MO890591.1 Sequence 111 from patent US 10563215
CAGGGCTGTAT
>MO890589.1 Sequence 109 from patent US 10563215
CGGAGCAGCTT
>MO890588.1 Sequence 108 from patent US 10563215
CATCTGGTCTC
>MO890586.1 Sequence 106 from patent US 10563215
GGCCTGGAATT
>MO890585.1 Sequence 105 from patent US 10563215
CTACTGCTGCA
>MO890581.1 Sequence 101 from patent US 10563215
TCAGGCAGGTG
>MO890579.1 Sequence 99 from patent US 10563215
AGCTGAGAGGG
>MO890578.1 Sequence 98 from patent US 10563215
CCTTCTCTGCG
>MO890577.1 Sequence 97 from patent US 10563215
TTTGATAGCTG
>MO890572.1 Sequence 92 from patent US 10563215
CTGATGTAAAG
>MO890571.1 Sequence 91 from patent US 10563215
CTGGTGAGCTT
>MO890569.1 Sequence 89 from patent US 10563215
GAGTAGTGCCA
>MO890567.1 Sequence 87 from patent US 10563215
CTTCAACCTAA
>MO890566.1 Sequence 86 from patent US 10563215
TTCTCAAGAAA
>MO890564.1 Sequence 84 from patent US 10563215
GACTCATCACT
>MO890563.1 Sequence 83 from patent US 10563215
ATTGCATATTG
>MO890561.1 Sequence 81 from patent US 10563215
CATTGCCATGG
>MO890559.1 Sequence 79 from patent US 10563215
GAATCGCTTCT
>MO890557.1 Sequence 77 from patent US 10563215
AACTGGGAATT
>MO890556.1 Sequence 76 from patent US 10563215
TTGTGTCACAT
>MO890555.1 Sequence 75 from patent US 10563215
GACAATGGCCG
>MO890553.1 Sequence 73 from patent US 10563215
TTCATGAAATA
>MO890552.1 Sequence 72 from patent US 10563215
CCCTTGGTTAG
>MO890549.1 Sequence 69 from patent US 10563215
TGCGACAGCAG
>MO890546.1 Sequence 66 from patent US 10563215
ACCAGAAGGCC
>MO890544.1 Sequence 64 from patent US 10563215
TCAAGGCTGCT
>MO890543.1 Sequence 63 from patent US 10563215
GAGTACATTGG
>MO890540.1 Sequence 60 from patent US 10563215
GTATCCAGATA
>MO890539.1 Sequence 59 from patent US 10563215
CTGTCACTCAA
>MO890538.1 Sequence 58 from patent US 10563215
GGTCGTAGAAA
>MO890537.1 Sequence 57 from patent US 10563215
CGGTTTGGTAG
>MO890536.1 Sequence 56 from patent US 10563215
ACCAGCTTGTG
>MO890535.1 Sequence 55 from patent US 10563215
CCATATTATTC
>MO890534.1 Sequence 54 from patent US 10563215
CTGGTTTGTTC
>MO890532.1 Sequence 52 from patent US 10563215
GTGTCACATTA
>MO890530.1 Sequence 50 from patent US 10563215
GACAATGGCCG
>MO890529.1 Sequence 49 from patent US 10563215
TGGAATCGCTT
>MO890528.1 Sequence 48 from patent US 10563215
TGGATCAGCTG
>MO890527.1 Sequence 47 from patent US 10563215
TGGATCAGCTG
>MO890525.1 Sequence 45 from patent US 10563215
ATAAAGGTGGT
>MO890522.1 Sequence 42 from patent US 10563215
CCAAGGGAGTT
>MO890521.1 Sequence 41 from patent US 10563215
CGGTTTGGTAG
>MO890517.1 Sequence 37 from patent US 10563215
TTCTGGTTTGT
>MO890515.1 Sequence 35 from patent US 10563215
TATAATCTCGG
>MO890514.1 Sequence 34 from patent US 10563215
CAATAATACCG
>MO890513.1 Sequence 33 from patent US 10563215
CTTTGTTGGCC
>MO890512.1 Sequence 32 from patent US 10563215
AATCTCGGCTT
>MO890508.1 Sequence 28 from patent US 10563215
GCTTTGTTGGC
>MO890504.1 Sequence 24 from patent US 10563215
TATAATCTCGG
>MO890503.1 Sequence 23 from patent US 10563215
CAAAGTCGATA
>MO890496.1 Sequence 16 from patent US 10563215
AAGTTATCCCA
>MO890495.1 Sequence 15 from patent US 10563215
CTCTGCTCGAG
>MO890444.1 Sequence 281 from patent US 10563212
ACAAAGAGGCA
>MO890443.1 Sequence 280 from patent US 10563212
ACAAACAGGCA
>MO890442.1 Sequence 279 from patent US 10563212
CCGTCGAGGTT
>MO890441.1 Sequence 278 from patent US 10563212
CCGTCTAGGTT
>MO890440.1 Sequence 277 from patent US 10563212
GGCCTCCTCGT
>MO890439.1 Sequence 276 from patent US 10563212
GGCCTTCTCGT
>MO890438.1 Sequence 275 from patent US 10563212
AAAGTCTTACC
>MO890437.1 Sequence 274 from patent US 10563212
AAAGTATTACC
>MO890436.1 Sequence 273 from patent US 10563212
TTAACCTCCCC
>MO890435.1 Sequence 272 from patent US 10563212
TTAACTTCCCC
>MO890434.1 Sequence 271 from patent US 10563212
CCTGTGAACTC
>MO890433.1 Sequence 270 from patent US 10563212
CCTGTAAACTC
>MO890432.1 Sequence 269 from patent US 10563212
TATAGCGGTTC
>MO890431.1 Sequence 268 from patent US 10563212
TATAGTGGTTC
>MO890430.1 Sequence 267 from patent US 10563212
CGCTTTGCCTG
>MO890429.1 Sequence 266 from patent US 10563212
CGCTTCGCCTG
>MO890428.1 Sequence 265 from patent US 10563212
AATTCTACTCT
>MO890427.1 Sequence 264 from patent US 10563212
AATTCGACTCT
>MO890426.1 Sequence 263 from patent US 10563212
AGAAGGAAGGA
>MO890425.1 Sequence 262 from patent US 10563212
AGAAGCAAGGA
>MO890364.1 Sequence 201 from patent US 10563212
AGAAAAATCCC
>MO890360.1 Sequence 197 from patent US 10563212
ACGAGCGGAGG
>MO890356.1 Sequence 193 from patent US 10563212
AGAAAAATCCC
>MO890355.1 Sequence 192 from patent US 10563212
AGTTTCCGGCT
>MO890353.1 Sequence 190 from patent US 10563212
CCTCCGTACAA
>MO890352.1 Sequence 189 from patent US 10563212
AGAAAAATCCC
>MO890349.1 Sequence 186 from patent US 10563212
AGTTTCCGGCT
>MO890348.1 Sequence 185 from patent US 10563212
CCTCCGTACAA
>MO889614.1 Sequence 68 from patent US 10563202
CTCCTTCCTCC
>MO889441.1 Sequence 357 from patent US 10563199
CAGTGTTTGTG
>MO889172.1 Sequence 88 from patent US 10563199
CCTGGGTTCAT
>MO889170.1 Sequence 86 from patent US 10563199
GTAGGAGTCTC
>MO889169.1 Sequence 85 from patent US 10563199
CACAAACACTG
>MO887007.1 Sequence 39 from patent US 10561148
GTTTTTGTACT
>MO887000.1 Sequence 25 from patent US 10561148
AATCATTTGAG
>MO886999.1 Sequence 24 from patent US 10561148
TTTCATTTGAG
>MO908002.1 Sequence 1 from patent US 10570446
ACGTACGACGT
>MO908001.1 Sequence 1 from patent US 10570444
CGATACTGACG
>MO904052.1 Sequence 8 from patent US 10570395
CCTGACCCAGT
>MO841608.1 Sequence 176 from patent US 10557146
ACCCAATCTCC
>MO763639.1 Sequence 3 from patent US 10550429
TTTTTTTTTTT
>MO763638.1 Sequence 2 from patent US 10550429
AAAAAAAAAAA
>MO750239.1 Sequence 47 from patent US 10545144
GGGGGGGGGGG
>MO750233.1 Sequence 40 from patent US 10545144
TTTTTTTTTTT
>MO749693.1 Sequence 1 from patent US 10544464
CCCCTTCCGGG
>MO747285.1 Sequence 334 from patent US 10544433
GAAGCTGGAGG
>MO747284.1 Sequence 333 from patent US 10544433
GAAGCTGGAGG
>MO747265.1 Sequence 314 from patent US 10544433
TCAACCGGTGG
>MO746812.1 Sequence 9 from patent US 10544431
CTTCTACCCGT
>MO746811.1 Sequence 8 from patent US 10544431
TTTTTCTTATT
>MO746765.1 Sequence 17 from patent US 10544429
AGCCACCATGG
>MO746546.1 Sequence 5 from patent US 10544422
GACCCAAGAGA
>MO746544.1 Sequence 2 from patent US 10544421
GAGGGCCGGGA
>MC006773.1 JP 2020500513-A/42: COMPOSITIONS AND METHODS FOR DETECTING OR QUANTIFYING HEPATITIS B VIRUS
CACTGAACAAA
>MC006554.1 JP 2020501517-A/252: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
GCCCCAGGACG
>MC006509.1 JP 2020501517-A/207: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
TGGGAGCCCTG
>MC006368.1 JP 2020501517-A/66: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
AGCAGCTCGAA
>MB494765.1 JP 2020018287-A/29: Screening vector
TCTAGAGATCT
>MB494661.1 JP 2020019718-A/18: agent and method for promoting cardiac differentiation
GGGTTAGGGTT
>MB494660.1 JP 2020019718-A/17: agent and method for promoting cardiac differentiation
GTTAGGGTTAG
>MB487886.1 JP 2020002136-A/36: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>MB487874.1 JP 2020002136-A/24: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>MB487246.1 JP 2020000051-A/142: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGGGCGGGCGG
>MB487241.1 JP 2020000051-A/137: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGGGGAGGAGG
>MB487209.1 JP 2020000051-A/105: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGTGGCGGAGG
>MB487167.1 JP 2020000051-A/63: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGTGGGGGGGG
>MB494371.1 JP 2019535245-A/6: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR SCREENING MICROORGANISMS AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
CTAATCGGATC
>MB494370.1 JP 2019535245-A/5: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR SCREENING MICROORGANISMS AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
GTCAGTCAATG
>MB494369.1 JP 2019535245-A/4: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR SCREENING MICROORGANISMS AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
ACGTAGGGTCA
>MB494368.1 JP 2019535245-A/3: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR SCREENING MICROORGANISMS AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
TAGCCTAGTAA
>MB494367.1 JP 2019535245-A/2: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR SCREENING MICROORGANISMS AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
ACTGTCAGTAG
>MB486999.1 JP 2019531730-A/6: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR BACTERIAL COMMUNITY RELATIONSHIP DETERMINATION AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
CTAATCGGATC
>MB486998.1 JP 2019531730-A/5: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR BACTERIAL COMMUNITY RELATIONSHIP DETERMINATION AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
GTCAGTCAATG
>MB486997.1 JP 2019531730-A/4: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR BACTERIAL COMMUNITY RELATIONSHIP DETERMINATION AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
ACGTAGGGTCA
>MB486996.1 JP 2019531730-A/3: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR BACTERIAL COMMUNITY RELATIONSHIP DETERMINATION AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
TAGCCTAGTAA
>MB486995.1 JP 2019531730-A/2: HIGH RESOLUTION SYSTEMS, KITS, APPARATUS, AND METHODS FOR BACTERIAL COMMUNITY RELATIONSHIP DETERMINATION AND OTHER HIGH THROUGHPUT MICROBIOLOGY APPLICATIONS
ACTGTCAGTAG
>MB483787.1 JP 2019213508-A/3: A method for determining an adverse effect of Trastuzumab and a kit therefor
TAGTTCAGAGC
>MB483786.1 JP 2019213508-A/2: A method for determining an adverse effect of Trastuzumab and a kit therefor
TAGTTTAGAGC
>MB483365.1 JP 2019528312-A/26: MRNA-MEDIATED IMMUNIZATION METHODS
NNNANNATGNC
>MB483360.1 JP 2019528312-A/21: MRNA-MEDIATED IMMUNIZATION METHODS
AAAAAATGTCT
>MB480623.1 JP 2019193662-A/27: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
ACGGGTAGGAC
>MB480601.1 JP 2019193662-A/5: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
TTAAGAAAAAA
>MO684762.1 Sequence 12 from patent US 10533163
TAACTATAACG
>MO638542.1 Sequence 30 from patent US 10526641
AAGCTTGAAGA
>MO635462.1 Sequence 1178 from patent US 10526602
GTGCCTTAAAT
>MO635423.1 Sequence 1139 from patent US 10526602
GGTGAATGCCA
>MO635422.1 Sequence 1138 from patent US 10526602
TTAAGGCACGC
>MO635416.1 Sequence 1132 from patent US 10526602
TAGCTCGTGGT
>MO635415.1 Sequence 1131 from patent US 10526602
TGGCAGTGTCT
>MO635408.1 Sequence 1124 from patent US 10526602
TATAGGCACGC
>MO635402.1 Sequence 1118 from patent US 10526602
GGTGAATGCCA
>MO635401.1 Sequence 1117 from patent US 10526602
TTAAGGCACGC
>MO635395.1 Sequence 1111 from patent US 10526602
TTAAGGCACGC
>MO635394.1 Sequence 1110 from patent US 10526602
GGTGAATGCCA
>MO635379.1 Sequence 1095 from patent US 10526602
GGTGAATGCCA
>MO631557.1 Sequence 39 from patent US 10524477
GTTTTTGTACT
>MO631550.1 Sequence 25 from patent US 10524477
AATCATTTGAG
>MO631549.1 Sequence 24 from patent US 10524477
TTTCATTTGAG
>MO630698.1 Sequence 50 from patent US 10519508
TACTACTACTA
>MO630317.1 Sequence 15 from patent US 10519487
ATTAGCATTAA
>MO630315.1 Sequence 13 from patent US 10519487
CCCCTATCACG
>MO629875.1 Sequence 171 from patent US 10519468
AATTTCTACTG
>MO629874.1 Sequence 170 from patent US 10519468
AATTTCTACTG
>MO629873.1 Sequence 169 from patent US 10519468
AATTTCTACTG
>MO629872.1 Sequence 168 from patent US 10519468
AATTTCTACTG
>MO628928.1 Sequence 108 from patent US 10519458
CACATGCATCC
>MO628926.1 Sequence 106 from patent US 10519458
TCTATAACTGA
>MO628923.1 Sequence 103 from patent US 10519458
CGATTAACTGC
>MO628922.1 Sequence 102 from patent US 10519458
AACATGCATTT
>MO628921.1 Sequence 101 from patent US 10519458
CACCAAACCTG
>MO628918.1 Sequence 98 from patent US 10519458
GACATGCATAT
>MO628916.1 Sequence 96 from patent US 10519458
ACCATGCATAT
>MO628913.1 Sequence 93 from patent US 10519458
AACATGCAAAT
>MO628912.1 Sequence 92 from patent US 10519458
TCCATGCAAAA
>MO628911.1 Sequence 91 from patent US 10519458
AACCTACCTCT
>MO628903.1 Sequence 83 from patent US 10519458
CGGGCCAGCTG
>MO628901.1 Sequence 81 from patent US 10519458
GGGGCCGCCCG
>MO628899.1 Sequence 79 from patent US 10519458
AGGTTAATTAC
>MO628898.1 Sequence 78 from patent US 10519458
CACCAAACATT
>MO628897.1 Sequence 77 from patent US 10519458
TATTTGCTTAA
>MO628875.1 Sequence 55 from patent US 10519458
GGGGCCAGGTC
>MO628872.1 Sequence 52 from patent US 10519458
TGGGCTCGATC
>MO628871.1 Sequence 51 from patent US 10519458
CGGGCCCCAAC
>MO628870.1 Sequence 50 from patent US 10519458
GGGGCCCGGAC
>MO628862.1 Sequence 42 from patent US 10519458
TGCATGCAGCC
>MO628861.1 Sequence 41 from patent US 10519458
TGCATGCAGGT
>MO628860.1 Sequence 40 from patent US 10519458
AGGGCCGAGGC
>MO628858.1 Sequence 38 from patent US 10519458
TGGGCCGCGCG
>MO628857.1 Sequence 37 from patent US 10519458
GGGGCCATTCA
>MO628855.1 Sequence 35 from patent US 10519458
CACCAACCAGC
>MO628854.1 Sequence 34 from patent US 10519458
ATCATGCATCT
>MO628844.1 Sequence 24 from patent US 10519458
CGCATGCATTG
>MO628842.1 Sequence 22 from patent US 10519458
ACCATGCATAC
>MO627160.1 Sequence 146 from patent US 10519450
TTTACCTGGTT
>MO625867.1 Sequence 25 from patent US 10519436
CTACTCCTACC
>MO625865.1 Sequence 23 from patent US 10519436
AACCCAATCCC
>MO625864.1 Sequence 22 from patent US 10519436
ACGTGTCTACC
>MO625862.1 Sequence 20 from patent US 10519436
CGCCCGGACTC
>MO625586.1 Sequence 41 from patent US 10519426
ACGGGTAGGAC
>MO625565.1 Sequence 13 from patent US 10519426
TTAAGAAAAAA
>MO619862.1 Sequence 20 from patent US 10517888
GTAGTGCACTG
>MO616316.1 Sequence 61 from patent US 10513705
GAACTGGGCTG
>MO614943.1 Sequence 4 from patent US 10513702
AAACAAACAAA
>MO612995.1 Sequence 33 from patent US 10509030
GAAACCCAGCA
>MO612992.1 Sequence 30 from patent US 10509030
CAGACTCCGGT
>MO612991.1 Sequence 29 from patent US 10509030
GGAATGAAGGA
>MO612989.1 Sequence 27 from patent US 10509030
AGCTGCTTTTG
>MO612988.1 Sequence 26 from patent US 10509030
GGATTCCGTTG
>MO612986.1 Sequence 24 from patent US 10509030
CCCCTATCACG
>MO612985.1 Sequence 23 from patent US 10509030
ATTAGCATTAA
>MO612983.1 Sequence 21 from patent US 10509030
AACCCATGGAA
>MO612982.1 Sequence 20 from patent US 10509030
TTCAGTTCTCA
>MO612980.1 Sequence 18 from patent US 10509030
CCATCTTTACC
>MO612979.1 Sequence 17 from patent US 10509030
AGACAGTGTTA
>MO612977.1 Sequence 15 from patent US 10509030
TCACAAGTTAG
>MO612976.1 Sequence 14 from patent US 10509030
GGTCTCAGGGA
>MO612974.1 Sequence 12 from patent US 10509030
TCAGACCGAGA
>MO612973.1 Sequence 11 from patent US 10509030
CAAGTGCAATG
>MO612970.1 Sequence 8 from patent US 10509030
TGACTACAACT
>MO612874.1 Sequence 42 from patent US 10508313
CACTGAACAAA
>MO612589.1 Sequence 407 from patent US 10508308
TAGTTCGTAGG
>MO612588.1 Sequence 406 from patent US 10508308
TAGTTTGTAGG
>MO612547.1 Sequence 365 from patent US 10508308
TGTTTCGGAAT
>MO612546.1 Sequence 364 from patent US 10508308
TGTTTTGGAAT
>MO612525.1 Sequence 341 from patent US 10508308
TTGGCGGGTAG
>MO612524.1 Sequence 340 from patent US 10508308
TTGGTGGGTAG
>MO612522.1 Sequence 338 from patent US 10508308
AGTGTGATTTA
>MO612519.1 Sequence 335 from patent US 10508308
AGTGTGATTTA
>MO612515.1 Sequence 331 from patent US 10508308
AGTGCGATTTA
>MO612514.1 Sequence 330 from patent US 10508308
AGTGTGATTTA
>MO612479.1 Sequence 295 from patent US 10508308
TTTTACGGTAG
>MO612478.1 Sequence 294 from patent US 10508308
TTTTATGGTAG
>MO612435.1 Sequence 251 from patent US 10508308
ATGATCGTAGA
>MO612434.1 Sequence 250 from patent US 10508308
ATGATTGTAGA
>MO611654.1 Sequence 217 from patent US 10508298
ACATCACAGGG
>MO609159.1 Sequence 5 from patent US 10507183
GGGATCCTACC
>MO609068.1 Sequence 39 from patent US 10506812
GTTTTTGTACT
>MO609061.1 Sequence 25 from patent US 10506812
AATCATTTGAG
>MO609060.1 Sequence 24 from patent US 10506812
TTTCATTTGAG
>MO578567.1 Sequence 735 from patent US 10501794
ACCTCCTCTGC
>MO565988.1 Sequence 25 from patent US 10501741
CCTGAGGTCTC
>MO559385.1 Sequence 1 from patent US 10494672
CGATCGATCGA
>MO553461.1 Sequence 2 from patent US 10494630
GACTGGAGACN
>MO552276.1 Sequence 1471 from patent US 10494620
TGGGCTGTCAA
>MO550963.1 Sequence 2 from patent US 10494398
GTTAGGGTTAG
>MO550414.1 Sequence 19 from patent US 10493141
CTTTACAAAAC
>MO550413.1 Sequence 18 from patent US 10493141
ATTTTGTAAAA
>MO548402.1 Sequence 75 from patent US 10488412
GTGCTGGTGCT
>MO548375.1 Sequence 48 from patent US 10488412
GTGCGCGCGTT
>MO548373.1 Sequence 46 from patent US 10488412
GAAGGTGGTGA
>MO531175.1 Sequence 4 from patent US 10487328
CCATCATCAAA
>MO527219.1 Sequence 3 from patent US 10480029
TTTTTTTTTTT
>MO527218.1 Sequence 2 from patent US 10480029
AAAAAAAAAAA
>MO527144.1 Sequence 76 from patent US 10480021
NNNNNGGATAC
>MO527142.1 Sequence 52 from patent US 10480021
NNNNNNGCGGG
>MO527141.1 Sequence 51 from patent US 10480021
NNNNNNGCGGG
>MO513126.1 Sequence 6 from patent US 10472626
CAAACACCGAC
>MO513125.1 Sequence 5 from patent US 10472626
ACAACACCAGC
>MO513124.1 Sequence 4 from patent US 10472626
ACAACACCAGC
>MO510877.1 Sequence 5 from patent US 10470446
AGGCTGGAGTG
>MO510876.1 Sequence 4 from patent US 10470446
CACTCCAGCCT
>MO483149.1 Sequence 28 from patent US 10466246
GGTGGGGGTGG
>MO464921.1 Sequence 461 from patent US 10463696
GRTVDGTVVSD
>MO464675.1 Sequence 39 from patent US 10463049
GTTTTTGTACT
>MO464668.1 Sequence 25 from patent US 10463049
AATCATTTGAG
>MO464667.1 Sequence 24 from patent US 10463049
TTTCATTTGAG
>MO463985.1 Sequence 1 from patent US 10457984
ACGTACGACGT
>MO463904.1 Sequence 4 from patent US 10457979
CCCTCTCCTCT
>MO463902.1 Sequence 2 from patent US 10457979
AGAGGAGAGGG
>MO463877.1 Sequence 4 from patent US 10457969
GGTCTCNNNNN
>MO449107.1 Sequence 4 from patent US 10450608
CATCCGCCTTG
>MO449106.1 Sequence 3 from patent US 10450608
AAGGCGGATGT
>MO448877.1 Sequence 2 from patent US 10450595
GAGCAACCGTT
>MO448876.1 Sequence 1 from patent US 10450595
AACGGTTGCTC
>MO448792.1 Sequence 94 from patent US 10450586
TGTCACGATGG
>MO448791.1 Sequence 93 from patent US 10450586
TGTCACGATGG
>MO448790.1 Sequence 92 from patent US 10450586
TGTCANGATGG
>MO448789.1 Sequence 91 from patent US 10450586
TCAACACTGCA
>MO448788.1 Sequence 90 from patent US 10450586
TCAACACTGCA
>MO448787.1 Sequence 89 from patent US 10450586
TCAACNCTGCA
>MO448786.1 Sequence 88 from patent US 10450586
AATTTGAGCTA
>MO448785.1 Sequence 87 from patent US 10450586
AATTTGAGCTA
>MO448784.1 Sequence 86 from patent US 10450586
AATTTNAGCTA
>MO448783.1 Sequence 85 from patent US 10450586
ACTCCGTCTCT
>MO448782.1 Sequence 84 from patent US 10450586
ACTCCGTCTCT
>MO448781.1 Sequence 83 from patent US 10450586
ACTCCNTCTCT
>MO448780.1 Sequence 82 from patent US 10450586
AACACTACCAG
>MO448779.1 Sequence 81 from patent US 10450586
AACACTACCAG
>MO448778.1 Sequence 80 from patent US 10450586
AACACNACCAG
>MO447039.1 Sequence 1018 from patent US 10450568
AATGCTGGCAG
>MO447038.1 Sequence 1017 from patent US 10450568
AATGCTGGCAG
>MO447037.1 Sequence 1016 from patent US 10450568
AATGCTGGCAG
>MO447036.1 Sequence 1015 from patent US 10450568
AATGCTGGCAG
>MO447035.1 Sequence 1014 from patent US 10450568
AATGCTGGCAG
>MO447034.1 Sequence 1013 from patent US 10450568
AATGCTGGCAG
>MO447033.1 Sequence 1012 from patent US 10450568
AATGCTGGCAG
>MO436293.1 Sequence 27 from patent US 10443060
TGGAGGAGACA
>MO435276.1 Sequence 19 from patent US 10442843
GAGNNNNNACV
>MO435124.1 Sequence 69 from patent US 10441653
GGGTTTTTGGG
>MO435114.1 Sequence 58 from patent US 10441653
GGTTTTTTTGG
>MO432275.1 Sequence 1 from patent US 10435742
ACGTACGACGT
>MO403689.1 Sequence 2826 from patent US 10435516
GGTACGTCTTC
>MO396736.1 Sequence 1 from patent US 10428380
ACGTACGACGT
>MO381302.1 Sequence 97 from patent US 10421999
GCCAGCACCAG
>MO377841.1 Sequence 60 from patent US 10421820
CTTGCGTGAGC
>MO376182.1 Sequence 6 from patent US 10420791
GGGATCCTACC
>MO376056.1 Sequence 11 from patent US 10418128
TCGTGTGCTTC
>MO376055.1 Sequence 10 from patent US 10418128
ACTGGGTAACA
>MO373132.1 Sequence 2744 from patent US 10415059
GAAGCTGGAGG
>MO373131.1 Sequence 2743 from patent US 10415059
GAAGCTGGAGG
>MO373112.1 Sequence 2724 from patent US 10415059
TCAACCGGTGG
>MO364483.1 Sequence 135 from patent US 10407722
CCTCCGACCGT
>MO364348.1 Sequence 2 from patent US 10407720
AGACTCCGACT
>MO357876.1 Sequence 1 from patent US 10407459
ACGTACGACGT
>MO357874.1 Sequence 1 from patent US 10407458
ACGTACGACGT
>MO357707.1 Sequence 24 from patent US 10406250
ATCTACATTAT
>MO351334.1 Sequence 11 from patent US 10400289
TGGTGTGTGTG
>MO351331.1 Sequence 1 from patent US 10400289
CAATCCCAATC
>MO350906.1 Sequence 13 from patent US 10400274
CTCTGGGCTTG
>MO350895.1 Sequence 6 from patent US 10400271
ACGCGCGCGCG
>MO344093.1 Sequence 1 from patent US 10399976
AAAGTAGGTCA
>MO344019.1 Sequence 11 from patent US 10398768
CCAAACCATGG
>MO344018.1 Sequence 10 from patent US 10398768
CCACTAGCTGG
>MO344017.1 Sequence 9 from patent US 10398768
CCACCTTTTGG
>MO344016.1 Sequence 8 from patent US 10398768
CCAGATTTTGG
>MO344015.1 Sequence 7 from patent US 10398768
CCAAACAGTGG
>MO341575.1 Sequence 126 from patent US 10393741
CCTTATGCATG
>MO341573.1 Sequence 124 from patent US 10393741
GGTGGTGAGGT
>MO337781.1 Sequence 143 from patent US 10392656
GACTTGATACC
>MO337210.1 Sequence 2 from patent US 10392621
GAANNGNNCCG
>MO336853.1 Sequence 167 from patent US 10392616
CTAAAACNNNN
>MO336852.1 Sequence 166 from patent US 10392616
CTAAAACNNNN
>MO336851.1 Sequence 165 from patent US 10392616
CTAAAACNNNN
>MO336850.1 Sequence 164 from patent US 10392616
CTAAAACNNNN
>MO336633.1 Sequence 1471 from patent US 10392607
TGGGCTGTCAA
>MO332741.1 Sequence 10 from patent US 10392418
GTGGAAGGCGG
>MO332735.1 Sequence 4 from patent US 10392418
GTTAGGGTTAG
>MO332733.1 Sequence 2 from patent US 10392418
CTAACCCTAAC
>MO332161.1 Sequence 71 from patent US 10391098
TCTCAGATGGT
>MO332158.1 Sequence 56 from patent US 10391098
TCCTTCTGATT
>MO332157.1 Sequence 55 from patent US 10391098
CTCTTCCTTTT
>MO332156.1 Sequence 54 from patent US 10391098
ATACTGTCCAA
>MO332155.1 Sequence 53 from patent US 10391098
GGTGCTCAAAC
>MO332154.1 Sequence 52 from patent US 10391098
AGAGTTCAAGG
>MO332152.1 Sequence 50 from patent US 10391098
ATCCACACAAG
>MO332151.1 Sequence 49 from patent US 10391098
CTCTTAATGAT
>MO332150.1 Sequence 48 from patent US 10391098
NNNNTCGCCAA
>MO332149.1 Sequence 47 from patent US 10391098
TGTTTCACCAT
>MO332148.1 Sequence 46 from patent US 10391098
GGTTTGCCAAG
>MO332147.1 Sequence 45 from patent US 10391098
TGTTTCATACG
>MO332144.1 Sequence 42 from patent US 10391098
ATATACCTCAT
>MO332143.1 Sequence 41 from patent US 10391098
TCCTGCATCAT
>MO332142.1 Sequence 40 from patent US 10391098
GTATATGCCAT
>MO332141.1 Sequence 39 from patent US 10391098
TTCTGATTCAT
>MO332140.1 Sequence 38 from patent US 10391098
ACATCTGTCAT
>MO332139.1 Sequence 37 from patent US 10391098
CATTGAGATTT
>MO332138.1 Sequence 36 from patent US 10391098
CTACTGGTCAT
>MO332137.1 Sequence 35 from patent US 10391098
GACTTAATCAA
>MO332136.1 Sequence 34 from patent US 10391098
GGTGCAGTCAT
>MO332134.1 Sequence 32 from patent US 10391098
TGTTAAAGAGC
>MO332133.1 Sequence 31 from patent US 10391098
AATTCGAGCAT
>MO332132.1 Sequence 30 from patent US 10391098
TGTTTGATCAT
>MO332131.1 Sequence 29 from patent US 10391098
ACGCTAATCAT
>MO332130.1 Sequence 28 from patent US 10391098
TTTCCAGCCAT
>MO332129.1 Sequence 27 from patent US 10391098
TTCCCTGCCAT
>MO332128.1 Sequence 26 from patent US 10391098
TTTTGCTCCAT
>MO332127.1 Sequence 25 from patent US 10391098
TCATCTTTGCT
>MO332125.1 Sequence 23 from patent US 10391098
AATGAGGCCAT
>MO332124.1 Sequence 22 from patent US 10391098
TCAAATGAGGC
>MO332123.1 Sequence 21 from patent US 10391098
TCTTTGGCCAT
>MO332122.1 Sequence 20 from patent US 10391098
ATGATACGCAT
>MO332121.1 Sequence 19 from patent US 10391098
CTTAGACATGG
>MO332120.1 Sequence 18 from patent US 10391098
GGCAGACTCGG
>MO332119.1 Sequence 17 from patent US 10391098
CTATTCTCCAA
>MO332118.1 Sequence 16 from patent US 10391098
ACTCGGGACAT
>MO332117.1 Sequence 15 from patent US 10391098
AAATTTATCCA
>MO332116.1 Sequence 14 from patent US 10391098
AATTTATCCAT
>MO332115.1 Sequence 13 from patent US 10391098
CATTTAGTTTG
>MO332114.1 Sequence 12 from patent US 10391098
ATCCATTTAGT
>MO332113.1 Sequence 11 from patent US 10391098
GCTTTTTTCAT
>MO332112.1 Sequence 10 from patent US 10391098
TTGATAGTCAT
>MO332111.1 Sequence 9 from patent US 10391098
AGAAAACCCAT
>MO332110.1 Sequence 8 from patent US 10391098
GCACGTTTCAT
>MO332109.1 Sequence 7 from patent US 10391098
TTATCTACCAT
>MO332107.1 Sequence 5 from patent US 10391098
TTGCCATTAGC
>MO332106.1 Sequence 4 from patent US 10391098
CACAGGAATTC
>MO332105.1 Sequence 3 from patent US 10391098
ATTCTCCTCAT
>MO332104.1 Sequence 2 from patent US 10391098
ATATCGCTCAC
>MO332103.1 Sequence 1 from patent US 10391098
CTTCGATAGTG
>MB464084.1 JP 2018527003-A/4: POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION
AAAAAGCAAAA
>MB464082.1 JP 2018527003-A/2: POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION
TTTTGCTTTTT
>MB459086.1 JP 2018522565-A/342: PROMOTER VARIANTS
GTTCGGATAAA
>MB459076.1 JP 2018522565-A/332: PROMOTER VARIANTS
GTCCGGATAAG
>MB459063.1 JP 2018522565-A/319: PROMOTER VARIANTS
TAGCGGAGATT
>MB459036.1 JP 2018522565-A/292: PROMOTER VARIANTS
TTGATTGTTAA
>MB459026.1 JP 2018522565-A/282: PROMOTER VARIANTS
TGTATTGTTAG
>MB459018.1 JP 2018522565-A/274: PROMOTER VARIANTS
GCTCAGTTGTC
>MB456511.1 JP 2018520683-A/29: MULTI-TARGETED SINGLE ENTITY CONJUGATES
CAGGTAAGTAT
>MB452772.1 JP 2018516569-A/72: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
CTGAGTCGGBN
>MB452763.1 JP 2018516569-A/63: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
CTGAGTCGGBH
>MB452754.1 JP 2018516569-A/54: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
CTGAGTCGGAH
>MB452746.1 JP 2018516569-A/46: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
CTGAGTCGGAG
>MB452717.1 JP 2018516569-A/17: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
GATCGGAAGBN
>MB452712.1 JP 2018516569-A/12: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
GATCGGAAGBH
>MB452707.1 JP 2018516569-A/7: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
GATCGGAAGAH
>MB452703.1 JP 2018516569-A/3: METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
GATCGGAAGAG
>MB452512.1 JP 2018503387-A/108: PROTEIN DELIVERY IN PRIMARY HEMATOPOIETIC CELLS
TTCGAAAGTAA
>MB452385.1 JP 2018509930-A/8: MODELING RIBOSOME DYNAMICS TO OPTIMIZE
TCAGTACGGCG
>MB451580.1 JP 2018511341-A/6: BARCODING SYSTEMS AND METHODS FOR GENE SEQUENCING AND OTHER APPLICATIONS
TCGGTCATTCA
>MB448988.1 JP 2018130124-A/89: METHODS AND COMPOSITIONS FOR SIZE-CONTROLLED HOMOPOLYMER TAILING OF SUBSTRATE POLYNUCLEOTIDES BY A NUCLEIC ACID POLYMERASE
TTTTTTTTTTT
>MB448964.1 JP 2018130124-A/65: METHODS AND COMPOSITIONS FOR SIZE-CONTROLLED HOMOPOLYMER TAILING OF SUBSTRATE POLYNUCLEOTIDES BY A NUCLEIC ACID POLYMERASE
AAAAAAAAAAA
>MB449397.1 JP 2018086010-A/20: Modified Oligonucleotides for Telomerase Inhibition
CTAACCCTAAC
>MB449390.1 JP 2018086010-A/13: Modified Oligonucleotides for Telomerase Inhibition
GTTAGGGTTAG
>MB449383.1 JP 2018086010-A/6: Modified Oligonucleotides for Telomerase Inhibition
GTGGAAGGCGG
>MB447296.1 JP 2018141006-A/5: CLEAVABLE LIPIDS
GGGATCCTACC
>MB445643.1 JP 2018131453-A/10: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
GTGGAAGGCGG
>MB445637.1 JP 2018131453-A/4: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
GTTAGGGTTAG
>MB445635.1 JP 2018131453-A/2: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME
CTAACCCTAAC
>MB443519.1 JP 2018134087-A/6: POLYNUCLEOTIDE MOLECULES FOR GENE REGULATION IN PLANTS
ACGCATAAAAT
>MB443264.1 JP 2018134083-A/51: OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLES
ACAGAAAGACA
>MB442954.1 JP 2018100307-A/5: CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES
GGGATCCTACC
>MB439937.1 JP 2018127459-A/237: NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE
GCTCGAGCGGA
>MB437424.1 JP 2018095653-A/2: Ionizable Cationic Lipids
GGGATCCTACC
>MB471820.1 WO 2019189722-A/6: Method for producing hairpin single-stranded RNA molecules
ACTCTGCTTCG
>MB470516.1 JP 2019187256-A/6: Channel chip for detecting plant molecule
CTCTTCTGTCA
>MB470513.1 JP 2019187256-A/3: Channel chip for detecting plant molecule
CTCCTTTGGCA
>MB431540.1 JP 2019522987-A/146: ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
TTTACCTGGTT
>MB430117.1 JP 2019522972-A/6082: Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
CAATGCCATCC
>MB423690.1 JP 2019521652-A/76: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TCGTCGTTTTT
>MB423689.1 JP 2019521652-A/75: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TGCTGCTTTTT
>MB423665.1 JP 2019521652-A/51: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
GTTTTGTCGTT
>MB423652.1 JP 2019521652-A/38: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TCGTCGTTTTT
>MB423651.1 JP 2019521652-A/37: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TGCTGCTTTTT
>MB423627.1 JP 2019521652-A/13: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
GTTTTGTCGTT
>MB422917.1 WO 2019181946-A/16: Nucleic Acid With Reduced Toxicity
TCCTCAGCAAT
>MB421854.1 JP 2019146561-A/2: Detection of Genetic or Molecular Aberrations Associated With Cancer
TACGTCATGCT
>MB421853.1 JP 2019146561-A/1: Detection of Genetic or Molecular Aberrations Associated With Cancer
ATGCCTGAATC
>LY680812.1 KR 1020190020338-A/864: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACCGCAAGCA
>LY680811.1 KR 1020190020338-A/863: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCGTTCAGCC
>LY680810.1 KR 1020190020338-A/862: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGGATCCTACA
>LY680809.1 KR 1020190020338-A/861: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTTATGTCTC
>LY680808.1 KR 1020190020338-A/860: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCGCATGAACC
>LY680807.1 KR 1020190020338-A/859: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCTATGTCGGA
>LY680806.1 KR 1020190020338-A/858: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCGAATAATCG
>LY680805.1 KR 1020190020338-A/857: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AAGACACCTCG
>LY680804.1 KR 1020190020338-A/856: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GATTGACGCAC
>LY680803.1 KR 1020190020338-A/855: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTAGACGGTCT
>LY680802.1 KR 1020190020338-A/854: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCTATAGGACC
>LY680801.1 KR 1020190020338-A/853: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGGTTACATG
>LY680800.1 KR 1020190020338-A/852: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTGGCTCATG
>LY680799.1 KR 1020190020338-A/851: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GCAGACATTAA
>LY680798.1 KR 1020190020338-A/850: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATTGTGTCCGA
>LY680797.1 KR 1020190020338-A/849: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GGTGCGTTAGT
>LY680796.1 KR 1020190020338-A/848: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGGCCTAGATG
>LY680795.1 KR 1020190020338-A/847: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGTCTAGCCAT
>LY680794.1 KR 1020190020338-A/846: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGAACGACACA
>LY680793.1 KR 1020190020338-A/845: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACCTGGTCAGT
>LY680792.1 KR 1020190020338-A/844: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGAGAACATAA
>LY680791.1 KR 1020190020338-A/843: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GGAATGGACTT
>LY680790.1 KR 1020190020338-A/842: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGGACTGTGTC
>LY680789.1 KR 1020190020338-A/841: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTCAACTCTAC
>LY680788.1 KR 1020190020338-A/840: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTGCCACAGCA
>LY680787.1 KR 1020190020338-A/839: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACTACGAGCTT
>LY680786.1 KR 1020190020338-A/838: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGAACGAGACA
>LY680785.1 KR 1020190020338-A/837: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GGTGATCGTAG
>LY680784.1 KR 1020190020338-A/836: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTCAGTACAAG
>LY680783.1 KR 1020190020338-A/835: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCGTTATACTT
>LY680782.1 KR 1020190020338-A/834: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCAGGAGATAC
>LY680781.1 KR 1020190020338-A/833: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGAGCAGTGA
>LY680780.1 KR 1020190020338-A/832: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCTACCTAAG
>LY680779.1 KR 1020190020338-A/831: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGGATTGCTCA
>LY680778.1 KR 1020190020338-A/830: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CATGAGGCTTG
>LY680777.1 KR 1020190020338-A/829: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGAAGTGTTAC
>LY680776.1 KR 1020190020338-A/828: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GCCTCTTCATA
>LY680775.1 KR 1020190020338-A/827: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTCTAGGACAG
>LY680774.1 KR 1020190020338-A/826: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TGTCAGCGTCA
>LY680773.1 KR 1020190020338-A/825: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCTTAGGTGTG
>LY680772.1 KR 1020190020338-A/824: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATGGATCTGG
>LY680771.1 KR 1020190020338-A/823: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCAGATGAATC
>LY680770.1 KR 1020190020338-A/822: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CACACTACTGG
>LY680769.1 KR 1020190020338-A/821: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GACTTCACGCA
>LY680768.1 KR 1020190020338-A/820: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CAAGGACCGTA
>LY680767.1 KR 1020190020338-A/819: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTTCCAACGTT
>LY680766.1 KR 1020190020338-A/818: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTTGGATCTTG
>LY680765.1 KR 1020190020338-A/817: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TAACGTTACGC
>LY680764.1 KR 1020190020338-A/816: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGTGAACAAC
>LY680763.1 KR 1020190020338-A/815: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CACCAGAATGT
>LY680762.1 KR 1020190020338-A/814: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACCAGCACTAT
>LY680761.1 KR 1020190020338-A/813: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCGTGAAGTG
>LY680760.1 KR 1020190020338-A/812: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTCTTGCCTCA
>LY680759.1 KR 1020190020338-A/811: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTAGAGGTTGG
>LY680758.1 KR 1020190020338-A/810: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AAGTAACGTGG
>LY680757.1 KR 1020190020338-A/809: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AAGCCTGATGT
>LY680756.1 KR 1020190020338-A/808: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATGTAATCGCC
>LY680755.1 KR 1020190020338-A/807: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACCGTTGCCAT
>LY680754.1 KR 1020190020338-A/806: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACCGACTACA
>LY680753.1 KR 1020190020338-A/805: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CGAGATTACAA
>LY680752.1 KR 1020190020338-A/804: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GACACGAGCAA
>LY680751.1 KR 1020190020338-A/803: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GCAATGTTGAA
>LY680750.1 KR 1020190020338-A/802: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTACTCGACGT
>LY680749.1 KR 1020190020338-A/801: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CAGTCACGACA
>LY680748.1 KR 1020190020338-A/800: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TATTACCGTCT
>LY680747.1 KR 1020190020338-A/799: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCGAATAGTCG
>LY680746.1 KR 1020190020338-A/798: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCACGCAACC
>LY680745.1 KR 1020190020338-A/797: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAAGCACACGT
>LY680744.1 KR 1020190020338-A/796: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCGTCAGCTG
>LY680743.1 KR 1020190020338-A/795: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGATCGATGG
>LY680742.1 KR 1020190020338-A/794: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGCCAACATT
>LY680741.1 KR 1020190020338-A/793: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCCTCAGTGAA
>LY680740.1 KR 1020190020338-A/792: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GTACGCTGATC
>LY680739.1 KR 1020190020338-A/791: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCGATACAGAG
>LY680738.1 KR 1020190020338-A/790: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGAACTCGTTG
>LY680737.1 KR 1020190020338-A/789: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CAAGCTTACTA
>LY680736.1 KR 1020190020338-A/788: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCAACGTGCAG
>LY680735.1 KR 1020190020338-A/787: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CAGAAGGTTCA
>LY680734.1 KR 1020190020338-A/786: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GAGTCACAAGG
>LY680733.1 KR 1020190020338-A/785: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTCCAGTTGGC
>LY680732.1 KR 1020190020338-A/784: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GGCTAGCTACT
>LY680731.1 KR 1020190020338-A/783: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CCTTAATGCAT
>LY680730.1 KR 1020190020338-A/782: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACATTCGCACA
>LY680729.1 KR 1020190020338-A/781: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTGCTTATCGT
>LY680728.1 KR 1020190020338-A/780: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TCAGATGTCCG
>LY680727.1 KR 1020190020338-A/779: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTGTCGAACTT
>LY680726.1 KR 1020190020338-A/778: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AACGCCTATAA
>LY680725.1 KR 1020190020338-A/777: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TACCATCGCCT
>LY680724.1 KR 1020190020338-A/776: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ATCCTCGTAAG
>LY680723.1 KR 1020190020338-A/775: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
ACTCCACAGGA
>LY680722.1 KR 1020190020338-A/774: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTGAATATGTG
>LY680721.1 KR 1020190020338-A/773: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGAGTCGAAGC
>LY680720.1 KR 1020190020338-A/772: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
AGAGTCACTGT
>LY680719.1 KR 1020190020338-A/771: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
CTATTCACAGT
>LY680718.1 KR 1020190020338-A/770: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
GCGATAGTCGT
>LY680717.1 KR 1020190020338-A/769: METHOD FOR PRODUCING DNA LIBRARY AND METHOD FOR ANALYZING GENOMIC DNA USING DNA LIBRARY
TTACACTATGC
>LY711209.1 KR 1020190065455-A/62: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTGACGTTCTT
>LY711207.1 KR 1020190065455-A/60: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGACGTTCT
>LY711204.1 KR 1020190065455-A/57: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTTGACGTTC
>LY711203.1 KR 1020190065455-A/56: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGACGTTCT
>LY711196.1 KR 1020190065455-A/49: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTGTCGTTCTT
>LY711194.1 KR 1020190065455-A/47: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGTCGTTCT
>LY711191.1 KR 1020190065455-A/44: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTTGTCGTTC
>LY711188.1 KR 1020190065455-A/41: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGTCGTTCT
>LY711174.1 KR 1020190065455-A/27: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TCTGTCGTTCT
>LY711173.1 KR 1020190065455-A/26: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TCTGTCGTTCT
>LY711162.1 KR 1020190065455-A/15: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTCTGTCGTTA
>LY711160.1 KR 1020190065455-A/13: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TCTGACGTTCT
>LY711159.1 KR 1020190065455-A/12: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
TCTGACGTTCT
>LY711157.1 KR 1020190065455-A/10: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTTGTCGTTC
>LY711155.1 KR 1020190065455-A/8: IMMUNE REGULATORY OLIGONUCLEOTIDE(IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
CTTGTCGTTCT
>LY710136.1 KR 1020190065382-A/18: TCRa HOMING ENDONUCLEASE VARIANTS
AAATCCAGTGA
>LY673921.1 KR 1020190008998-A/171: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY673920.1 KR 1020190008998-A/170: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY673919.1 KR 1020190008998-A/169: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY673918.1 KR 1020190008998-A/168: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>LY704614.1 KR 1020190040098-A/146: Antisense nucleic acids
ACAGTTTGCCG
>LY704612.1 KR 1020190040098-A/144: Antisense nucleic acids
CCTGGAGTTCC
>LY670022.1 KR 1020190015385-A/159: APTAMER-BASED ANALYTE ASSAYS
AGTGTCCTTTG
>LY670021.1 KR 1020190015385-A/158: APTAMER-BASED ANALYTE ASSAYS
AGTGTCCATTG
>LY704188.1 KR 1020190045928-A/26: PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
TCCGCTAGGAA
>LY669662.1 KR 1020190002733-A/51: OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLES
ACAGAAAGACA
>LY666242.1 KR 1020190003985-A/76: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TCGTCGTTTTT
>LY666241.1 KR 1020190003985-A/75: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TGCTGCTTTTT
>LY666179.1 KR 1020190003985-A/13: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
GTTTTGTCGTT
>LY666217.1 KR 1020190003985-A/51: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
GTTTTGTCGTT
>LY666204.1 KR 1020190003985-A/38: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TCGTCGTTTTT
>LY666203.1 KR 1020190003985-A/37: SPHERICAL NUCLEIC ACID TLR9 AGONISTS
TGCTGCTTTTT
>LY663907.1 KR 1020190062290-A/29: miRNA polymer and the method for preparing the same
GTTCTTACAGA
>LY663906.1 KR 1020190062290-A/28: miRNA polymer and the method for preparing the same
ATTTACGAGTC
>LY663895.1 KR 1020190062290-A/17: miRNA polymer and the method for preparing the same
AAACAATACCC
>LY663894.1 KR 1020190062290-A/16: miRNA polymer and the method for preparing the same
GGGTATTGTTT
>LY663890.1 KR 1020190062290-A/12: miRNA polymer and the method for preparing the same
TCCACTCCATA
>LY663887.1 KR 1020190062290-A/9: miRNA polymer and the method for preparing the same
TATGGAGTGGA
>LY658222.1 KR 1020190071950-A/17: Pepetide nucleic acid probe for genotyping age related hearing loss (presbycusis) and Method using the same
CAGCCGGCCCG
>LY691254.1 KR 1020190039969-A/539: RNA FOR CANCER THERAPY
GGGTTTTTGGG
>LY691244.1 KR 1020190039969-A/528: RNA FOR CANCER THERAPY
GGTTTTTTTGG
>LY656335.1 KR 1020190053731-A/7: Cosmetic composition containing extracts of Sorghum bicolor for whitening the skin
CTCTGCTCGCC
>LY682289.1 KR 1020190014125-A/36: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>LY682277.1 KR 1020190014125-A/24: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>MB420479.1 JP 2019520422-A/20: TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
GAATTCTGCAG
>MB420248.1 JP 2019519221-A/81: GENE THERAPY METHODS FOR AGE-RELATED DISEASES AND CONDITIONS
CTGGGCTCAGA
>MB420241.1 JP 2019519221-A/74: GENE THERAPY METHODS FOR AGE-RELATED DISEASES AND CONDITIONS
TGTTTAGTTAT
>MB418457.1 JP 2019519218-A/13: MODULATORY POLYNUCLEOTIDES
CCTGACCCAGT
>MB405863.1 WO 2019151417-A/8: Virus resistant plant and preparation method thereof
AGTGTAACAGC
>MB405861.1 WO 2019151417-A/6: Virus resistant plant and preparation method thereof
AGGGTAACAGC
>MB124444.1 JP 2019106907-A/25: A method for designing probes to detect a Single Nucleotide Polymorphism and a set of probes
TTCCCAGGAAC
>MB124422.1 JP 2019106907-A/3: A method for designing probes to detect a Single Nucleotide Polymorphism and a set of probes
TTCCCGGGAAC
>MB143926.1 JP 2019514372-A/13: KIT AND METHOD FOR DETECTING MUTATIONS IN CTNNB1 AND HTERT, AND USE THEREOF IN HCC DETECTION AND DISEASE MANAGEMENT
GCCCCCTCCGG
>MB143880.1 JP 2019515674-A/7: IMMOBILIZATION-BASED SYSTEMS AND METHODS FOR GENETIC ANALYSIS AND OTHER APPLICATIONS
TCGGTCATTCA
>MO329319.1 Sequence 124 from patent US 10385358
GTTGGACTTTA
>MO329318.1 Sequence 123 from patent US 10385358
GTTGGACTGCC
>MO329317.1 Sequence 122 from patent US 10385358
GTCGGACTTTC
>MO329316.1 Sequence 121 from patent US 10385358
GTTCGACTTTC
>MO329315.1 Sequence 120 from patent US 10385358
GTTGGTCGTTC
>MO329240.1 Sequence 44 from patent US 10385358
GTTGGACTTTC
>MO325595.1 Sequence 6 from patent US 10385338
TAATTGAATCA
>MO325594.1 Sequence 5 from patent US 10385338
TAATCCAATCA
>MO325593.1 Sequence 4 from patent US 10385338
TAATTTAATCA
>MO325592.1 Sequence 3 from patent US 10385338
TAACCCAATCA
>MO325591.1 Sequence 2 from patent US 10385338
TAAYBYAATCA
>MO325590.1 Sequence 1 from patent US 10385338
TAAYYBAATCA
>MO309307.1 Sequence 4 from patent US 10385088
AAAAAGCAAAA
>MO309305.1 Sequence 2 from patent US 10385088
TTTTGCTTTTT
>MO302042.1 Sequence 1 from patent US 10370716
GCCCCCCCAGC
>MO301766.1 Sequence 10 from patent US 10370698
CTCGGCCCGAT
>MO296523.1 Sequence 7 from patent US 10370651
CTACTCCTACC
>MO296521.1 Sequence 5 from patent US 10370651
AACCCAATCCC
>MO296520.1 Sequence 4 from patent US 10370651
ACGTGTCTACC
>MO296518.1 Sequence 2 from patent US 10370651
CGCCCGGACTC
>MO295771.1 Sequence 2464 from patent US 10370453
CCTNNNNNAGG
>MO295768.1 Sequence 2461 from patent US 10370453
CGTCTCNNNNN
>MO295765.1 Sequence 2458 from patent US 10370453
CCANNNNNTGG
>MO295763.1 Sequence 2456 from patent US 10370453
GACNNNNNGTC
>MO295762.1 Sequence 2455 from patent US 10370453
GACNNNNNGTC
>MO295761.1 Sequence 2454 from patent US 10370453
NNNNNGAGACC
>MO295760.1 Sequence 2453 from patent US 10370453
GGTCTCNNNNN
>MO295759.1 Sequence 2452 from patent US 10370453
GCCNNNNNGGC
>MO295752.1 Sequence 2445 from patent US 10370453
GCANNNNNTGC
>MO293883.1 Sequence 357 from patent US 10369216
GGGTTTTTGGG
>MO293873.1 Sequence 346 from patent US 10369216
GGTTTTTTTGG
>MO283969.1 Sequence 827 from patent US 10363266
TAGGGAGCCGT
>MO283951.1 Sequence 809 from patent US 10363266
AGAGCTATTTG
>MO283933.1 Sequence 791 from patent US 10363266
AGCCGTCTTCA
>MO283919.1 Sequence 777 from patent US 10363266
GCTATTTGGTA
>MO283905.1 Sequence 763 from patent US 10363266
GTGCAAATGTT
>MO283895.1 Sequence 753 from patent US 10363266
TTATATACAGG
>MO283885.1 Sequence 743 from patent US 10363266
GTATTCTAGAA
>MO283875.1 Sequence 733 from patent US 10363266
GAATATCTCAT
>MO283865.1 Sequence 723 from patent US 10363266
GTTTAGGGAGC
>MO283851.1 Sequence 709 from patent US 10363266
CCAGAAGAGCT
>MO283837.1 Sequence 695 from patent US 10363266
CAGGACGATGT
>MO283827.1 Sequence 685 from patent US 10363266
CGTGCTGGCGA
>MO283810.1 Sequence 668 from patent US 10363266
CGAGCCCCCAG
>MO283807.1 Sequence 665 from patent US 10363266
ACCCCGCTGCT
>MO283797.1 Sequence 655 from patent US 10363266
GAGCCGTCTTC
>MO283782.1 Sequence 640 from patent US 10363266
CTATTTGGTAG
>MO283767.1 Sequence 625 from patent US 10363266
AGTGCAAATGT
>MO283756.1 Sequence 614 from patent US 10363266
TATATACAGGC
>MO283745.1 Sequence 603 from patent US 10363266
AGTATTCTAGA
>MO283734.1 Sequence 592 from patent US 10363266
AATATCTCATG
>MO283723.1 Sequence 581 from patent US 10363266
TGTTTAGGGAG
>MO283708.1 Sequence 566 from patent US 10363266
CAGAAGAGCTA
>MO283693.1 Sequence 551 from patent US 10363266
ACAGGACGATG
>MO283682.1 Sequence 540 from patent US 10363266
GTGCTGGCGAT
>MO283663.1 Sequence 521 from patent US 10363266
CCGAGCCCCCA
>MO283660.1 Sequence 518 from patent US 10363266
CCCCGCTGCTC
>MO283456.1 Sequence 312 from patent US 10363266
TTATTAATGCC
>MO283455.1 Sequence 311 from patent US 10363266
TTTATTAATGC
>MO283453.1 Sequence 309 from patent US 10363266
GTCTATGACGA
>MO283452.1 Sequence 308 from patent US 10363266
GGTCTATGACG
>MO283450.1 Sequence 306 from patent US 10363266
GGACGCGTATC
>MO283449.1 Sequence 305 from patent US 10363266
TGGACGCGTAT
>MO283447.1 Sequence 303 from patent US 10363266
ACTACCAAATA
>MO283446.1 Sequence 302 from patent US 10363266
CACTACCAAAT
>MO283444.1 Sequence 300 from patent US 10363266
CCCTAAACACT
>MO283443.1 Sequence 299 from patent US 10363266
TCCCTAAACAC
>MO283441.1 Sequence 297 from patent US 10363266
TGGTCCATTCA
>MO283440.1 Sequence 296 from patent US 10363266
CTGGTCCATTC
>MO189770.1 Sequence 1339 from patent US 10344335
CCATCCTTGTC
>MO189768.1 Sequence 1337 from patent US 10344335
GAGGAGGCAGT
>MO188198.1 Sequence 21 from patent US 10344321
AGCTGGTGGCG
>MO188197.1 Sequence 20 from patent US 10344321
GAGCTGGTGGC
>MO188189.1 Sequence 12 from patent US 10344321
TGAACCGGAGG
>MO187984.1 Sequence 8 from patent US 10344319
GGTGGGGGTGG
>MO179290.1 Sequence 2 from patent US 10337055
GTACATAAAGC
>MO168214.1 Sequence 34 from patent US 10337017
CATGACGTTCT
>MO168213.1 Sequence 33 from patent US 10337017
TCATGACGTCT
>MO168208.1 Sequence 28 from patent US 10337017
TTCCTGTCGTT
>MO168183.1 Sequence 3 from patent US 10337017
TCTGACGTTCT
>MO161076.1 Sequence 2 from patent US 10330674
ATATATGTAAG
>MO160814.1 Sequence 173 from patent US 10329628
CAAGCCTTTAT
>MO160507.1 Sequence 6 from patent US 10329615
TTGTGCACAGA
>MO158493.1 Sequence 26 from patent US 10329549
AGAATCCCGAT
>MO158492.1 Sequence 25 from patent US 10329549
AGGATCCCGAT
>MO156818.1 Sequence 16 from patent US 10329542
AGCACCATGCA
>MO155511.1 Sequence 5 from patent US 10325676
CTAAATTCCGG
>MO155509.1 Sequence 3 from patent US 10325676
TCGAATTCCGG
>MO155500.1 Sequence 11 from patent US 10325675
TTGGATATGGG
>MO155326.1 Sequence 8 from patent US 10324092
GGGAAATTCCC
>MO154851.1 Sequence 3 from patent US 10323278
TTTTTTTTTTT
>MO154850.1 Sequence 2 from patent US 10323278
AAAAAAAAAAA
>MO149254.1 Sequence 41 from patent US 10323236
NGACGCTGCTN
>MO149253.1 Sequence 40 from patent US 10323236
NGAGTGAGGAN
>MO149241.1 Sequence 28 from patent US 10323236
NGACGCTGCTN
>MO149240.1 Sequence 27 from patent US 10323236
NGAGTGAGGAN
>MO149227.1 Sequence 4 from patent US 10323236
NGACGGTGCTN
>MO149226.1 Sequence 3 from patent US 10323236
NGAGTGAGGAN
>MO052375.1 Sequence 97 from patent US 10316326
CCTTATATATC
>MO050988.1 Sequence 75 from patent US 10316323
GGAAATCCATT
>MO050598.1 Sequence 111 from patent US 10316318
GATTAGCATTA
>MO050597.1 Sequence 110 from patent US 10316318
GATTAGCATTA
>MO050596.1 Sequence 109 from patent US 10316318
GATTAGCATTA
>MO050595.1 Sequence 108 from patent US 10316318
GATTAGCATTA
>MO050594.1 Sequence 107 from patent US 10316318
GATTAGCATTA
>MO050593.1 Sequence 106 from patent US 10316318
GATTAGCATTA
>MO050592.1 Sequence 105 from patent US 10316318
GATTAGCATTA
>MO050591.1 Sequence 104 from patent US 10316318
GATTAGCATTA
>MO050590.1 Sequence 103 from patent US 10316318
GATTAGCATTA
>MO050589.1 Sequence 102 from patent US 10316318
GATTAGCATTA
>MO050588.1 Sequence 101 from patent US 10316318
GATTAGCATTA
>MO050587.1 Sequence 100 from patent US 10316318
GATTAGCATTA
>MO050586.1 Sequence 99 from patent US 10316318
GATTAGCATTA
>MO050585.1 Sequence 98 from patent US 10316318
GATTAGCATTA
>MO050584.1 Sequence 97 from patent US 10316318
GATTAGCATTA
>MO050583.1 Sequence 96 from patent US 10316318
GATTAGCATTA
>MO050582.1 Sequence 95 from patent US 10316318
GATTAGCATTA
>MO050543.1 Sequence 56 from patent US 10316318
GATTAGCATTA
>MO050509.1 Sequence 21 from patent US 10316318
GATTAGCATTA
>MO050279.1 Sequence 164 from patent US 10316304
TCGNNNNNCGA
>MO049015.1 Sequence 5686 from patent US 10314895
GAGCTAATAAA
>MO048989.1 Sequence 5660 from patent US 10314895
TTTACTTCCTC
>MO048820.1 Sequence 5484 from patent US 10314895
TTATAACACCT
>MO048695.1 Sequence 5352 from patent US 10314895
TAGGATAAGAA
>MO048529.1 Sequence 5174 from patent US 10314895
GAATAGCTATC
>MO048442.1 Sequence 5084 from patent US 10314895
TATATCTACTC
>MO048312.1 Sequence 4949 from patent US 10314895
ATTATTTGAGC
>MO048144.1 Sequence 4772 from patent US 10314895
ATTTTCACAAC
>MO048065.1 Sequence 4692 from patent US 10314895
GATTATCACCT
>MO047972.1 Sequence 4596 from patent US 10314895
AAAATTCCTCC
>MO047906.1 Sequence 4526 from patent US 10314895
AATATTCCTCC
>MO047782.1 Sequence 4398 from patent US 10314895
CCGTGATTAAT
>MO047609.1 Sequence 4221 from patent US 10314895
GGTGATTAACT
>MO047571.1 Sequence 4182 from patent US 10314895
GCGGTGGTATC
>MO047570.1 Sequence 4181 from patent US 10314895
GAGGAATTGAC
>MO047369.1 Sequence 3969 from patent US 10314895
GAGGATGAATT
>MO047351.1 Sequence 3950 from patent US 10314895
AATTGGAAGAT
>MO047254.1 Sequence 3848 from patent US 10314895
AATTAATTAAA
>MO047184.1 Sequence 3775 from patent US 10314895
AGGGTGAAAAT
>MO047149.1 Sequence 3738 from patent US 10314895
AAGCTTGTAGC
>MO047108.1 Sequence 3696 from patent US 10314895
CTTATTTTCAC
>MO047022.1 Sequence 3606 from patent US 10314895
ATTTATTATTT
>MO047017.1 Sequence 3601 from patent US 10314895
GAGTGTTTAGT
>MO046985.1 Sequence 3567 from patent US 10314895
TTTTGATTTGT
>MO046974.1 Sequence 3556 from patent US 10314895
TTTTGATTTGT
>MO046929.1 Sequence 3508 from patent US 10314895
AAAATTAGAAC
>MO046922.1 Sequence 3499 from patent US 10314895
GAGTTGAATAT
>MO046920.1 Sequence 3495 from patent US 10314895
GGAGAATTTTT
>MO046909.1 Sequence 3483 from patent US 10314895
AAGGTGAGAAT
>MO046833.1 Sequence 3395 from patent US 10314895
AATAAAATTTT
>MO046777.1 Sequence 3338 from patent US 10314895
TTGTGAATCAG
>MO046721.1 Sequence 3280 from patent US 10314895
TTCGACCAATT
>MO046525.1 Sequence 3078 from patent US 10314895
GATTTTTAATC
>MO046328.1 Sequence 2881 from patent US 10314895
TAGTGAAACTA
>MO046298.1 Sequence 2851 from patent US 10314895
CTCTTTTAGAG
>MO046186.1 Sequence 2739 from patent US 10314895
TTTTATAAAAA
>MO046052.1 Sequence 2605 from patent US 10314895
TTAAAATTTAA
>MO045904.1 Sequence 2457 from patent US 10314895
TTTATCATAAA
>MO045688.1 Sequence 2241 from patent US 10314895
TTTATTTTAAA
>MO045603.1 Sequence 2156 from patent US 10314895
CTTTTAAAAAG
>MO045449.1 Sequence 2002 from patent US 10314895
TATTTTTAATA
>MO045439.1 Sequence 1992 from patent US 10314895
CTATGGAATAG
>MO045435.1 Sequence 1988 from patent US 10314895
TCCTTAAAGGG
>MO045319.1 Sequence 1872 from patent US 10314895
TAGTTTTACTA
>MO045279.1 Sequence 1832 from patent US 10314895
GATTTACAATC
>MO040663.1 Sequence 132 from patent US 10308949
GCATTAGGTTC
>MO040659.1 Sequence 128 from patent US 10308949
ATGTTCCAAAA
>MO040658.1 Sequence 127 from patent US 10308949
ATGTTCGGTAA
>MO040605.1 Sequence 74 from patent US 10308949
AARTTAGGTAR
>MO275536.1 Sequence 7 from patent US 10358630
TATTAGTAGAA
>MO258077.1 Sequence 21 from patent US 10358459
GTTGAGTGTAG
>MO258076.1 Sequence 20 from patent US 10358459
GTTAGGGTTAG
>MO258073.1 Sequence 17 from patent US 10358459
GTTGAGTGTAG
>MO258072.1 Sequence 16 from patent US 10358459
GTTAGGGTTAG
>MO257584.1 Sequence 14 from patent US 10357478
GGGCTCTGCCA
>MO257582.1 Sequence 4 from patent US 10357478
TGGCAGAGCCC
>MO255597.1 Sequence 18 from patent US 10351909
GGTGTCATGGA
>MO255595.1 Sequence 16 from patent US 10351909
TGAGCGATTCG
>MO255594.1 Sequence 15 from patent US 10351909
CATTAACGGAC
>MB119417.1 WO 2019117192-A/25: A method for designing probes to detect a Single Nucleotide Polymorphism and a set of probes
TTCCCAGGAAC
>MB119395.1 WO 2019117192-A/3: A method for designing probes to detect a Single Nucleotide Polymorphism and a set of probes
TTCCCGGGAAC
>MB118977.1 WO 2019111791-A/8: Antisense oligonucleotides capable of eliminating intron retention in Dystrophin gene
CTGTTGTCCCT
>LY588743.1 KR 1020180083347-A/23: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
TTTGCTTAGAA
>LY588734.1 KR 1020180083347-A/14: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
AAAACATACCA
>LY587568.1 KR 1020180080181-A/7: METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
TAAGCACTTTG
>LY585561.1 KR 1020180005754-A/111: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585560.1 KR 1020180005754-A/110: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585559.1 KR 1020180005754-A/109: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585558.1 KR 1020180005754-A/108: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585557.1 KR 1020180005754-A/107: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585556.1 KR 1020180005754-A/106: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585555.1 KR 1020180005754-A/105: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585554.1 KR 1020180005754-A/104: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585553.1 KR 1020180005754-A/103: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585552.1 KR 1020180005754-A/102: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585551.1 KR 1020180005754-A/101: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585550.1 KR 1020180005754-A/100: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585549.1 KR 1020180005754-A/99: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585548.1 KR 1020180005754-A/98: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585547.1 KR 1020180005754-A/97: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585546.1 KR 1020180005754-A/96: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585545.1 KR 1020180005754-A/95: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585506.1 KR 1020180005754-A/56: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY585471.1 KR 1020180005754-A/21: MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
GATTAGCATTA
>LY617290.1 KR 1020180110195-A/94: TREATMENT OF SODIUM CHANNEL VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ABTISENSE TRANSCRIPT TO SCNA
GCCAGTCACAA
>LY613928.1 KR 1020180127339-A/168: REPLICATIVE TRANSPOSON SYSTEM
GGGCCACTAGT
>LY613927.1 KR 1020180127339-A/167: REPLICATIVE TRANSPOSON SYSTEM
ATCCTATATAA
>LY579694.1 KR 1020180008572-A/65: RAPID CHARACTERIZATION OF CAS ENDONUCLEASE SYSTEMS, PAM SEQUENCES AND GUIDE RNA ELEMENTS
GAGGAAGAGGN
>LY579692.1 KR 1020180008572-A/63: RAPID CHARACTERIZATION OF CAS ENDONUCLEASE SYSTEMS, PAM SEQUENCES AND GUIDE RNA ELEMENTS
ACGGGACTGTN
>LY579211.1 KR 1020180002852-A/65: GUIDE RNA/CAS ENDONUCLEASE SYSTEMS
GAGGAAGAGGN
>LY579209.1 KR 1020180002852-A/63: GUIDE RNA/CAS ENDONUCLEASE SYSTEMS
ACGGGACTGTN
>LY612764.1 KR 1020180104149-A/45: ENHANCED PRODUCTION OF IMMUNOGLOBULINS
GTGCCTGTGCA
>LY578728.1 KR 1020180002776-A/39: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GTTTTTGTACT
>LY578714.1 KR 1020180002776-A/25: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
AATCATTTGAG
>LY578713.1 KR 1020180002776-A/24: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TTTCATTTGAG
>LY612080.1 KR 1020180100697-A/1: BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA
AAAGTAGGTCA
>LY612008.1 KR 1020180098419-A/77: TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
CTCCTTCCTCC
>LY643616.1 KR 1020180137558-A/63: CONSTRUCT AND VECTOR FOR INTRAGENIC PLANT TRANSFORMATION
GTGCGCACATG
>LY607002.1 KR 1020180085055-A/33: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAAACAC
>LY606998.1 KR 1020180085055-A/29: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAGTTCC
>LY606994.1 KR 1020180085055-A/25: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAATTCTAT
>LY606990.1 KR 1020180085055-A/21: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
CGGAAAATACC
>LY606986.1 KR 1020180085055-A/17: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAATATTAC
>LY606982.1 KR 1020180085055-A/13: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATCAC
>LY606978.1 KR 1020180085055-A/9: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATCAC
>LY607003.1 KR 1020180085055-A/34: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
GGAGTTTTCCA
>LY606999.1 KR 1020180085055-A/30: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAGTTTT
>LY606991.1 KR 1020180085055-A/22: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
CGGAAAATCCC
>LY606987.1 KR 1020180085055-A/18: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAATTTAC
>LY606983.1 KR 1020180085055-A/14: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
CGGAAAATCAC
>LY606979.1 KR 1020180085055-A/10: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAAGTCC
>LY607004.1 KR 1020180085055-A/35: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAACTCC
>LY607000.1 KR 1020180085055-A/31: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATTTT
>LY606996.1 KR 1020180085055-A/27: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATTAC
>LY606992.1 KR 1020180085055-A/23: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAACTAC
>LY606988.1 KR 1020180085055-A/19: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
AGGAAAATCAC
>LY606984.1 KR 1020180085055-A/15: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATCAC
>LY606980.1 KR 1020180085055-A/11: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAAATAT
>LY607001.1 KR 1020180085055-A/32: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAATCTCC
>LY606997.1 KR 1020180085055-A/28: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAGTTAC
>LY606993.1 KR 1020180085055-A/24: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
ATAGAATTCCA
>LY606989.1 KR 1020180085055-A/20: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
CGGAAAAAACC
>LY606985.1 KR 1020180085055-A/16: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAATTAC
>LY606981.1 KR 1020180085055-A/12: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAAAATTT
>LY606973.1 KR 1020180085055-A/4: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
HGGAAANNHNH
>LY606974.1 KR 1020180085055-A/5: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
TGGAAATTTGT
>LY606970.1 KR 1020180085055-A/1: COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY
HGGAAWNNHNH
>LY604291.1 KR 1020180088458-A/22: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
GACNNNNNGTC
>LY604287.1 KR 1020180088458-A/15: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
CCTNNNNNAGG
>LY604286.1 KR 1020180088458-A/14: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
GACNNNNNGTC
>MP263248.1 Sequence 70 from Patent EP3501549
GGTTCGAACAG
>MP263177.1 Sequence 16 from Patent EP3492602
TGAGCGATTCG
>MP263176.1 Sequence 15 from Patent EP3492602
CATTAACGGAC
>MP254192.1 Sequence 21 from Patent EP3487992
CCANNNNNTGG
>MP254191.1 Sequence 20 from Patent EP3487992
GCNNNNNNNGC
>MP254188.1 Sequence 17 from Patent EP3487992
CCTNNNNNAGG
>MP254185.1 Sequence 14 from Patent EP3487992
GCANNNNNTGC
>MP254184.1 Sequence 13 from Patent EP3487992
CCNNNNNNNGG
>MP254182.1 Sequence 11 from Patent EP3487992
GCCNNNNNGGC
>MP254180.1 Sequence 9 from Patent EP3487992
ACNNNNGTAYC
>MP254179.1 Sequence 8 from Patent EP3487992
GACNNNNNGTC
>MP302175.1 Sequence 457 from Patent EP3498710
GCTCGAGCGGA
>MP296049.1 Sequence 864 from Patent EP3480319
TACCGCAAGCA
>MP296048.1 Sequence 863 from Patent EP3480319
ATCGTTCAGCC
>MP296047.1 Sequence 862 from Patent EP3480319
TGGATCCTACA
>MP296046.1 Sequence 861 from Patent EP3480319
TGTTATGTCTC
>MP296045.1 Sequence 860 from Patent EP3480319
TCGCATGAACC
>MP296044.1 Sequence 859 from Patent EP3480319
TCTATGTCGGA
>MP296043.1 Sequence 858 from Patent EP3480319
TCGAATAATCG
>MP296042.1 Sequence 857 from Patent EP3480319
AAGACACCTCG
>MP296041.1 Sequence 856 from Patent EP3480319
GATTGACGCAC
>MP296040.1 Sequence 855 from Patent EP3480319
TTAGACGGTCT
>MP296039.1 Sequence 854 from Patent EP3480319
CCTATAGGACC
>MP296038.1 Sequence 853 from Patent EP3480319
GAGGTTACATG
>MP296037.1 Sequence 852 from Patent EP3480319
ATTGGCTCATG
>MP296036.1 Sequence 851 from Patent EP3480319
GCAGACATTAA
>MP296035.1 Sequence 850 from Patent EP3480319
ATTGTGTCCGA
>MP296034.1 Sequence 849 from Patent EP3480319
GGTGCGTTAGT
>MP296033.1 Sequence 848 from Patent EP3480319
AGGCCTAGATG
>MP296032.1 Sequence 847 from Patent EP3480319
AGTCTAGCCAT
>MP296031.1 Sequence 846 from Patent EP3480319
CGAACGACACA
>MP296030.1 Sequence 845 from Patent EP3480319
ACCTGGTCAGT
>MP296029.1 Sequence 844 from Patent EP3480319
CGAGAACATAA
>MP296028.1 Sequence 843 from Patent EP3480319
GGAATGGACTT
>MP296027.1 Sequence 842 from Patent EP3480319
TGGACTGTGTC
>MP296026.1 Sequence 841 from Patent EP3480319
GTCAACTCTAC
>MP296025.1 Sequence 840 from Patent EP3480319
TTGCCACAGCA
>MP296024.1 Sequence 839 from Patent EP3480319
ACTACGAGCTT
>MP296023.1 Sequence 838 from Patent EP3480319
CGAACGAGACA
>MP296022.1 Sequence 837 from Patent EP3480319
GGTGATCGTAG
>MP296021.1 Sequence 836 from Patent EP3480319
CTCAGTACAAG
>MP296020.1 Sequence 835 from Patent EP3480319
CCGTTATACTT
>MP296019.1 Sequence 834 from Patent EP3480319
CCAGGAGATAC
>MP296018.1 Sequence 833 from Patent EP3480319
ATGAGCAGTGA
>MP296017.1 Sequence 832 from Patent EP3480319
ATCTACCTAAG
>MP296016.1 Sequence 831 from Patent EP3480319
TGGATTGCTCA
>MP296015.1 Sequence 830 from Patent EP3480319
CATGAGGCTTG
>MP296014.1 Sequence 829 from Patent EP3480319
AGAAGTGTTAC
>MP296013.1 Sequence 828 from Patent EP3480319
GCCTCTTCATA
>MP296012.1 Sequence 827 from Patent EP3480319
GTCTAGGACAG
>MP296011.1 Sequence 826 from Patent EP3480319
TGTCAGCGTCA
>MP296010.1 Sequence 825 from Patent EP3480319
TCTTAGGTGTG
>MP296009.1 Sequence 824 from Patent EP3480319
TATGGATCTGG
>MP296008.1 Sequence 823 from Patent EP3480319
TCAGATGAATC
>MP296007.1 Sequence 822 from Patent EP3480319
CACACTACTGG
>MP296006.1 Sequence 821 from Patent EP3480319
GACTTCACGCA
>MP296005.1 Sequence 820 from Patent EP3480319
CAAGGACCGTA
>MP296004.1 Sequence 819 from Patent EP3480319
GTTCCAACGTT
>MP296003.1 Sequence 818 from Patent EP3480319
CTTGGATCTTG
>MP296002.1 Sequence 817 from Patent EP3480319
TAACGTTACGC
>MP296001.1 Sequence 816 from Patent EP3480319
GAGTGAACAAC
>MP296000.1 Sequence 815 from Patent EP3480319
CACCAGAATGT
>MP295999.1 Sequence 814 from Patent EP3480319
ACCAGCACTAT
>MP295998.1 Sequence 813 from Patent EP3480319
ATCGTGAAGTG
>MP295997.1 Sequence 812 from Patent EP3480319
CTCTTGCCTCA
>MP295996.1 Sequence 811 from Patent EP3480319
GTAGAGGTTGG
>MP295995.1 Sequence 810 from Patent EP3480319
AAGTAACGTGG
>MP295994.1 Sequence 809 from Patent EP3480319
AAGCCTGATGT
>MP295993.1 Sequence 808 from Patent EP3480319
ATGTAATCGCC
>MP295992.1 Sequence 807 from Patent EP3480319
ACCGTTGCCAT
>MP295991.1 Sequence 806 from Patent EP3480319
TACCGACTACA
>MP295990.1 Sequence 805 from Patent EP3480319
CGAGATTACAA
>MP295989.1 Sequence 804 from Patent EP3480319
GACACGAGCAA
>MP295988.1 Sequence 803 from Patent EP3480319
GCAATGTTGAA
>MP295987.1 Sequence 802 from Patent EP3480319
TTACTCGACGT
>MP295986.1 Sequence 801 from Patent EP3480319
CAGTCACGACA
>MP295985.1 Sequence 800 from Patent EP3480319
TATTACCGTCT
>MP295984.1 Sequence 799 from Patent EP3480319
TCGAATAGTCG
>MP295983.1 Sequence 798 from Patent EP3480319
ATCACGCAACC
>MP295982.1 Sequence 797 from Patent EP3480319
GAAGCACACGT
>MP295981.1 Sequence 796 from Patent EP3480319
ATCGTCAGCTG
>MP295980.1 Sequence 795 from Patent EP3480319
GAGATCGATGG
>MP295979.1 Sequence 794 from Patent EP3480319
GAGCCAACATT
>MP295978.1 Sequence 793 from Patent EP3480319
TCCTCAGTGAA
>MP295977.1 Sequence 792 from Patent EP3480319
GTACGCTGATC
>MP295976.1 Sequence 791 from Patent EP3480319
CCGATACAGAG
>MP295975.1 Sequence 790 from Patent EP3480319
AGAACTCGTTG
>MP295974.1 Sequence 789 from Patent EP3480319
CAAGCTTACTA
>MP295973.1 Sequence 788 from Patent EP3480319
TCAACGTGCAG
>MP295972.1 Sequence 787 from Patent EP3480319
CAGAAGGTTCA
>MP295971.1 Sequence 786 from Patent EP3480319
GAGTCACAAGG
>MP295970.1 Sequence 785 from Patent EP3480319
TTCCAGTTGGC
>MP295969.1 Sequence 784 from Patent EP3480319
GGCTAGCTACT
>MP295968.1 Sequence 783 from Patent EP3480319
CCTTAATGCAT
>MP295967.1 Sequence 782 from Patent EP3480319
ACATTCGCACA
>MP295966.1 Sequence 781 from Patent EP3480319
CTGCTTATCGT
>MP295965.1 Sequence 780 from Patent EP3480319
TCAGATGTCCG
>MP295964.1 Sequence 779 from Patent EP3480319
CTGTCGAACTT
>MP295963.1 Sequence 778 from Patent EP3480319
AACGCCTATAA
>MP295962.1 Sequence 777 from Patent EP3480319
TACCATCGCCT
>MP295961.1 Sequence 776 from Patent EP3480319
ATCCTCGTAAG
>MP295960.1 Sequence 775 from Patent EP3480319
ACTCCACAGGA
>MP295959.1 Sequence 774 from Patent EP3480319
CTGAATATGTG
>MP295958.1 Sequence 773 from Patent EP3480319
AGAGTCGAAGC
>MP295957.1 Sequence 772 from Patent EP3480319
AGAGTCACTGT
>MP295956.1 Sequence 771 from Patent EP3480319
CTATTCACAGT
>MP295955.1 Sequence 770 from Patent EP3480319
GCGATAGTCGT
>MP295954.1 Sequence 769 from Patent EP3480319
TTACACTATGC
>MP275718.1 Sequence 2 from Patent EP3495495
CTAACCCTAAC
>MP274826.1 Sequence 1339 from Patent EP3494985
CCATCCTTGTC
>MP274824.1 Sequence 1337 from Patent EP3494985
GAGGAGGCAGT
>MP272882.1 Sequence 4 from Patent EP3495505
GGGATCCTACC
>MP272216.1 Sequence 16 from Patent EP3494975
GTTAGGGTTAG
>MP272215.1 Sequence 15 from Patent EP3494975
TAGGGTTAGAC
>MP272207.1 Sequence 7 from Patent EP3494975
GTGGAAGGCGG
>MP265147.1 Sequence 562 from Patent EP3502255
GATTAGCATTA
>MP265137.1 Sequence 552 from Patent EP3502255
TGGATTTGCAC
>MP265127.1 Sequence 542 from Patent EP3502255
TGTCACACTCC
>MP256169.1 Sequence 6 from Patent EP3519096
CTAATCGGATC
>MP256168.1 Sequence 5 from Patent EP3519096
GTCAGTCAATG
>MP256167.1 Sequence 4 from Patent EP3519096
ACGTAGGGTCA
>MP256166.1 Sequence 3 from Patent EP3519096
TAGCCTAGTAA
>MP256165.1 Sequence 2 from Patent EP3519096
ACTGTCAGTAG
>MP248060.1 Sequence 24 from Patent EP3478842
GCGGTTGTGCC
>MP234198.1 Sequence 25 from Patent WO2019162699
GTTTTTTTTTC
>MP225128.1 Sequence 52 from Patent WO2019145734
GATCGGATTGA
>MP222626.1 Sequence 10 from Patent EP3490616
CTCGGCCCGAT
>MP215397.1 Sequence 457 from Patent EP3498709
GCTCGAGCGGA
>MP202309.1 Sequence 6 from Patent EP3478650
CTAATCGGATC
>MP202308.1 Sequence 5 from Patent EP3478650
GTCAGTCAATG
>MP202307.1 Sequence 4 from Patent EP3478650
ACGTAGGGTCA
>MP202306.1 Sequence 3 from Patent EP3478650
TAGCCTAGTAA
>MP202305.1 Sequence 2 from Patent EP3478650
ACTGTCAGTAG
>MP200780.1 Sequence 6 from Patent EP3478416
CTAATCGGATC
>MP200779.1 Sequence 5 from Patent EP3478416
GTCAGTCAATG
>MP200778.1 Sequence 4 from Patent EP3478416
ACGTAGGGTCA
>MP200777.1 Sequence 3 from Patent EP3478416
TAGCCTAGTAA
>MP200776.1 Sequence 2 from Patent EP3478416
ACTGTCAGTAG
>MP199578.1 Sequence 9 from Patent EP3480320
TCGACGGATCC
>MP199572.1 Sequence 3 from Patent EP3480320
AATTCCCCGGG
>MP199220.1 Sequence 252 from Patent EP3532642
GCCCCAGGACG
>MP199175.1 Sequence 207 from Patent EP3532642
TGGGAGCCCTG
>MP199034.1 Sequence 66 from Patent EP3532642
AGCAGCTCGAA
>MP198875.1 Sequence 23 from Patent EP3475450
AAAAAAACTAG
>MP198869.1 Sequence 17 from Patent EP3475450
TTTCTAGTTTT
>MP198868.1 Sequence 16 from Patent EP3475450
CTAGTTTTTTT
>MP198867.1 Sequence 15 from Patent EP3475450
CTAGTTTTTTT
>MP193412.1 Sequence 6 from Patent EP3532600
CTAATCGGATC
>MP193411.1 Sequence 5 from Patent EP3532600
GTCAGTCAATG
>MP193410.1 Sequence 4 from Patent EP3532600
ACGTAGGGTCA
>MP193409.1 Sequence 3 from Patent EP3532600
TAGCCTAGTAA
>MP193408.1 Sequence 2 from Patent EP3532600
ACTGTCAGTAG
>MP187800.1 Sequence 131 from Patent WO2019099454
CACAGGTCTCG
>MP187623.1 Sequence 19 from Patent EP3486329
AAAAAAAAAAA
>MP187622.1 Sequence 18 from Patent EP3486329
TTTTTTTTTTT
>MP187621.1 Sequence 17 from Patent EP3486329
AAAAWAAAAAA
>MP187619.1 Sequence 15 from Patent EP3486329
TTTTTTWTTTT
>MP186972.1 Sequence 217 from Patent EP3486318
ACATCACAGGG
>MP265167.1 Sequence 582 from Patent EP3502255
CGTTCGTTCTT
>MP265157.1 Sequence 572 from Patent EP3502255
TCTGATAAGCT
>MP285072.1 Sequence 7 from Patent WO2019110832
CATCGCGCAAT
>MP285071.1 Sequence 6 from Patent WO2019110832
CATCAAGCAAT
>MP281784.1 Sequence 8 from Patent EP3511426
CATCCTCCTCC
>MP272225.1 Sequence 25 from Patent EP3494975
GTTGAGTGTAG
>MP266472.1 Sequence 19 from Patent EP3497114
CTTCCGGGCTC
>MP254718.1 Sequence 19 from Patent EP3518976
ATAAATTATAT
>MP254704.1 Sequence 5 from Patent EP3518976
TGCGGAGTCAT
>MP256574.1 Sequence 59 from Patent EP3519442
TAAAAAAAAAT
>MP224191.1 Sequence 107 from Patent EP3491384
CGGCCGCCACC
>MP221235.1 Sequence 10 from Patent EP3499394
TTAGAGACCTC
>MP189188.1 Sequence 56 from Patent WO2019099629
CAAAGGNANAG
>MB031539.1 WO 2019088179-A/2: Nucleoside Derivatives and the Use Thereof
TTCTTCTTCTT
>MB029494.1 JP 2019511562-A/41: COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES
GCGGTTGTGCC
>MB028054.1 JP 2019509020-A/2: METHODS AND SYSTEMS FOR RAPID DETECTION OF MICROORGANISMS USING INFECTIOUS AGENTS
CTAAATACCCC
>MB003310.1 JP 2017537921-A/15: METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIAS
ACCACCACCAC
>MB023096.1 WO 2019074004-A/6: Method for detecting SNP
TGTTTGAAACC
>MB023094.1 WO 2019074004-A/4: Method for detecting SNP
TGTCTGAAACC
>MB022408.1 WO 2019069720-A/19: Recombinant avian paramyxovirus
AGGGAAAAATA
>MB002421.1 JP 2012519488-A/62: TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
CTCCTTCCTCC
>MB022284.1 WO 2019077887-A/2: Logical engineering of D- and T-arms of tRNA that enhances D-amino acid and beta amino acid incorporation
AGGGGNCCCCT
>MB001256.1 JP 2017535269-A/104: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATGTCAGAGT
>MB001253.1 JP 2017535269-A/101: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TGAGACTGTAC
>MA997131.1 JP 2017533710-A/10: METHODS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING
NNNNGAAGACG
>MA997130.1 JP 2017533710-A/9: METHODS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING
GCTCTTCNNNN
>MB016454.1 JP 2018500878-A/5: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
CCAAACCATGG
>MB016453.1 JP 2018500878-A/4: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
CCACTAGCTGG
>MB016452.1 JP 2018500878-A/3: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
CCACCTTTTGG
>MB016451.1 JP 2018500878-A/2: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
CCAGATTTTGG
>MB016450.1 JP 2018500878-A/1: METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
CCAAACAGTGG
>MB016008.1 JP 2018503403-A/19: Ligation Assays in Liquid Phase
CTACTACCTCA
>MB016007.1 JP 2018503403-A/18: Ligation Assays in Liquid Phase
AACTATACAAC
>MB015061.1 JP 2018503386-A/171: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>MB015060.1 JP 2018503386-A/170: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>MB015059.1 JP 2018503386-A/169: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>MB015058.1 JP 2018503386-A/168: CRISPR HYBRID DNA/RNA POLYNUCLEOTIDES AND METHODS OF USE
AATTTCTACTG
>MA901343.1 JP 2018035196-A/23: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
CTAACCCTAAC
>MA901336.1 JP 2018035196-A/16: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
GTTAGGGTTAG
>MA901335.1 JP 2018035196-A/15: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
TAGGGTTAGAC
>MA901327.1 JP 2018035196-A/7: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
GTGGAAGGCGG
>MB013015.1 JP 2018500892-A/77: Methods And Kits For Theranostic Applications
GGATCACCGGT
>MB012972.1 JP 2018500892-A/34: Methods And Kits For Theranostic Applications
TCCGCTTCGGT
>MB012971.1 JP 2018500892-A/33: Methods And Kits For Theranostic Applications
ATTCGCCCCCC
>MB012970.1 JP 2018500892-A/32: Methods And Kits For Theranostic Applications
TATGCTGTCGG
>MB012969.1 JP 2018500892-A/31: Methods And Kits For Theranostic Applications
AAACCGACAGC
>MB012968.1 JP 2018500892-A/30: Methods And Kits For Theranostic Applications
TTCCTAGCTGC
>MB012967.1 JP 2018500892-A/29: Methods And Kits For Theranostic Applications
CCCGGCCTCCC
>MB012966.1 JP 2018500892-A/28: Methods And Kits For Theranostic Applications
TAGGCGGTTGG
>MB012965.1 JP 2018500892-A/27: Methods And Kits For Theranostic Applications
CCAACTGTAGC
>MB012964.1 JP 2018500892-A/26: Methods And Kits For Theranostic Applications
TTAGGCCAACA
>MB012963.1 JP 2018500892-A/25: Methods And Kits For Theranostic Applications
ATAGAAGGGGC
>MB012962.1 JP 2018500892-A/24: Methods And Kits For Theranostic Applications
TAGGTCGTTCA
>MB012961.1 JP 2018500892-A/23: Methods And Kits For Theranostic Applications
TTGAACGATCC
>MB012960.1 JP 2018500892-A/22: Methods And Kits For Theranostic Applications
TTCATCCGTTC
>MB012959.1 JP 2018500892-A/21: Methods And Kits For Theranostic Applications
ACCTAACAGCC
>MB012958.1 JP 2018500892-A/20: Methods And Kits For Theranostic Applications
TGGCAGTCGGC
>MB012957.1 JP 2018500892-A/19: Methods And Kits For Theranostic Applications
ACGCCGATTGC
>MB012956.1 JP 2018500892-A/18: Methods And Kits For Theranostic Applications
TGTATTCGCCA
>MB012955.1 JP 2018500892-A/17: Methods And Kits For Theranostic Applications
ATCAACCCTGC
>MB012954.1 JP 2018500892-A/16: Methods And Kits For Theranostic Applications
TTACCCAGTGC
>MB012953.1 JP 2018500892-A/15: Methods And Kits For Theranostic Applications
TTCAATGGGCC
>MB012952.1 JP 2018500892-A/14: Methods And Kits For Theranostic Applications
TCGTCTGCGGC
>MB012951.1 JP 2018500892-A/13: Methods And Kits For Theranostic Applications
GGCCCTTCTAC
>MB012950.1 JP 2018500892-A/12: Methods And Kits For Theranostic Applications
TTGTGGATGTG
>MB012949.1 JP 2018500892-A/11: Methods And Kits For Theranostic Applications
TCACATTCACC
>MB012948.1 JP 2018500892-A/10: Methods And Kits For Theranostic Applications
TACCTTCTCCC
>MB012947.1 JP 2018500892-A/9: Methods And Kits For Theranostic Applications
ACACCCTCGCC
>MB012946.1 JP 2018500892-A/8: Methods And Kits For Theranostic Applications
TCTGCCCAGGC
>MB012945.1 JP 2018500892-A/7: Methods And Kits For Theranostic Applications
TCTTTTACGCC
>MB012944.1 JP 2018500892-A/6: Methods And Kits For Theranostic Applications
TTCGCGTCCAG
>MB012943.1 JP 2018500892-A/5: Methods And Kits For Theranostic Applications
ACGGGCCCGGC
>MB012942.1 JP 2018500892-A/4: Methods And Kits For Theranostic Applications
TGCGCACACTC
>MB012941.1 JP 2018500892-A/3: Methods And Kits For Theranostic Applications
TGAGTGTGTGC
>MB012940.1 JP 2018500892-A/2: Methods And Kits For Theranostic Applications
TTAAAGTGACC
>MB012939.1 JP 2018500892-A/1: Methods And Kits For Theranostic Applications
TGGATCTCTGC
>MA900488.1 JP 2018016650-A/162: RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
CTAACTGGGGA
>MA898854.1 JP 2018015008-A/70: TREATMENT OF AMD USING AAV SFLT-1
GGTTCGAACAG
>MA898772.1 JP 2018021076-A/36: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>MA898760.1 JP 2018021076-A/24: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
GTTAGGGTTAG
>MA897848.1 JP 2017225461-A/188: COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS
CTTGCCCAGGC
>MA896936.1 JP 2018007669-A/2: DNA Expression Construct
AAAAACTGGAC
>MA896339.1 JP 2017221221-A/62: TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
CTCCTTCCTCC
>MA989703.1 JP 2017530968-A/15: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
CTTTACAAAAC
>MA989702.1 JP 2017530968-A/14: VIRAL RNA SEGMENTS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
ATTTTGTAAAA
>MA989049.1 JP 2018048203-A/57: Unnatural Reactive Amino Acid Genetic Code Additions
GGTTCGANTCC
>MA878952.1 JP 2019500580-A/7: FLOW SYSTEM AND METHODS FOR DIGITAL COUNTING
ATAGTTGACAC
>MA860080.1 JP 2018536002-A/13: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
GACNNNNNGTC
>MA860076.1 JP 2018536002-A/9: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
CCTNNNNNAGG
>MA860075.1 JP 2018536002-A/8: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER
GACNNNNNGTC
>MA888442.1 JP 2019504646-A/156: REPLICATIVE TRANSPOSON SYSTEM
GGGCCACTAGT
>MA888441.1 JP 2019504646-A/155: REPLICATIVE TRANSPOSON SYSTEM
ATCCTATATAA
>MA885514.1 JP 2019033739-A/1: A method of determining whether the eyelid is double or single
CTCTCTCTCTG
>MM850609.1 Sequence 1 from patent US 10266892
CGATCGATCGA
>MM847178.1 Sequence 32 from patent US 10266824
ATTCAGTTCTC
>MM847177.1 Sequence 31 from patent US 10266824
TAAGTCAAGAG
>MM847091.1 Sequence 70 from patent US 10266822
GTAAGTCTGCC
>MM847089.1 Sequence 68 from patent US 10266822
ATACTTACCTG
>MM845509.1 Sequence 5 from patent US 10266559
GGGATCCTACC
>MM840381.1 Sequence 1 from patent US 10260095
CGATCGATCGA
>MM833816.1 Sequence 113 from patent US 10260070
CGAAAGAAACY
>MM833815.1 Sequence 112 from patent US 10260070
CGAACAAAACY
>MM833814.1 Sequence 111 from patent US 10260070
TGAAAGAAACY
>MM833813.1 Sequence 110 from patent US 10260070
TGAAAAAAACY
>MM833812.1 Sequence 109 from patent US 10260070
AGAANNAAACY
>MM833811.1 Sequence 108 from patent US 10260070
CGAANNAAACY
>MM833810.1 Sequence 107 from patent US 10260070
TGAAANNANCY
>MM833809.1 Sequence 106 from patent US 10260070
HGAANNNANCY
>MM833808.1 Sequence 105 from patent US 10260070
TGAAAGGAACC
>MM833807.1 Sequence 104 from patent US 10260070
CGAAAGAAACT
>MM833806.1 Sequence 103 from patent US 10260070
CGAACAAAACT
>MM833805.1 Sequence 102 from patent US 10260070
AGAATGAAACT
>MM833804.1 Sequence 101 from patent US 10260070
TGAAAAAATCT
>MM833803.1 Sequence 100 from patent US 10260070
TGAAATAAACT
>MM833802.1 Sequence 99 from patent US 10260070
TGAAATAAACC
>MM833801.1 Sequence 98 from patent US 10260070
TGAAAACAACC
>MM833800.1 Sequence 97 from patent US 10260070
TGAAAAAACCT
>MM833799.1 Sequence 96 from patent US 10260070
TGAAAAAACCC
>MM833798.1 Sequence 95 from patent US 10260070
TGAAAAGAACC
>MM833797.1 Sequence 94 from patent US 10260070
TGAAACAAACC
>MM833796.1 Sequence 93 from patent US 10260070
TGAAAGAAACT
>MM833795.1 Sequence 92 from patent US 10260070
TGAAAGAAACC
>MM833794.1 Sequence 91 from patent US 10260070
TGAAAAAAACC
>MO033462.1 Sequence 103207 from patent US 10266881
ATTATGGGAGA
>MM914375.1 Sequence 110 from patent US 10301633
GTCGGGCTCAT
>MM914374.1 Sequence 109 from patent US 10301633
CATAACCCGAA
>MM914369.1 Sequence 104 from patent US 10301633
GTTATTTAATG
>MM914365.1 Sequence 100 from patent US 10301633
AATAATTTTCT
>MM914356.1 Sequence 91 from patent US 10301633
TATTTATTACC
>MM914348.1 Sequence 83 from patent US 10301633
ATCTATGTCGG
>MM914328.1 Sequence 63 from patent US 10301633
GGTAGCCAAAT
>MM914307.1 Sequence 42 from patent US 10301633
CACATCCATAA
>MM914300.1 Sequence 35 from patent US 10301633
GTTCCGGCGCG
>MM914271.1 Sequence 5 from patent US 10301633
TCTGTAAATAA
>MM913905.1 Sequence 17 from patent US 10301626
NRTHNNNNNNY
>MM911872.1 Sequence 425 from patent US 10301620
GCCGAGTTCAC
>MM911041.1 Sequence 30 from patent US 10301605
TGTTTTTTTTT
>MM911026.1 Sequence 15 from patent US 10301605
GTGTGTGTGTG
>MM911023.1 Sequence 12 from patent US 10301605
GTGTGTGTGTG
>MM911020.1 Sequence 9 from patent US 10301605
GTGTGTGTGTG
>MM908475.1 Sequence 173 from patent US 10294532
CAAGCCTTTAT
>MM908080.1 Sequence 1 from patent US 10294521
CTAACCCTAAC
>MM908079.1 Sequence 4 from patent US 10294516
AGTCTCGNNNT
>MM908076.1 Sequence 1 from patent US 10294516
ANNNCGAGACT
>MM907687.1 Sequence 10 from patent US 10294510
CAATCTCATCC
>MM907686.1 Sequence 9 from patent US 10294510
TCTTTATGCTG
>MM907685.1 Sequence 8 from patent US 10294510
GCTGTCTATTG
>MM907684.1 Sequence 7 from patent US 10294510
ATATACAAGCG
>MM907683.1 Sequence 6 from patent US 10294510
GCATTGTTACT
>MM907682.1 Sequence 5 from patent US 10294510
TTTCTTGCTTC
>MM907681.1 Sequence 4 from patent US 10294510
ACAATTCTTCG
>MM907680.1 Sequence 3 from patent US 10294510
GTTTAATTGCG
>MM907679.1 Sequence 2 from patent US 10294510
GAATTTCCTCG
>MM907678.1 Sequence 1 from patent US 10294510
CATCTAAAGCC
>MM906909.1 Sequence 1306 from patent US 10294489
GKGGTTGGGGT
>MM906908.1 Sequence 1304 from patent US 10294489
TTCTCCCCTTT
>MM906540.1 Sequence 936 from patent US 10294489
TTTAWTTTAWT
>MM906374.1 Sequence 770 from patent US 10294489
GGAAGGGGGGG
>MM906210.1 Sequence 606 from patent US 10294489
AAAAACACAAA
>MM906209.1 Sequence 605 from patent US 10294489
CCCMCACACCC
>MM905262.1 Sequence 23 from patent US 10294482
GATGCCGAGCG
>MM902392.1 Sequence 148 from patent US 10294458
ACGCCGTCATT
>MM891857.1 Sequence 366 from patent US 10293058
GGGTTTTTGGG
>MM891847.1 Sequence 355 from patent US 10293058
GGTTTTTTTGG
>MM886296.1 Sequence 173 from patent US 10287639
CAAGCCTTTAT
>MM885947.1 Sequence 173 from patent US 10287637
CAAGCCTTTAT
>MM878929.1 Sequence 11 from patent US 10287574
CTGTCTCTTAT
>MM877503.1 Sequence 14 from patent US 10286086
AAAAAGCAAAA
>MM877501.1 Sequence 12 from patent US 10286086
TTTTGCTTTTT
>MM875438.1 Sequence 19 from patent US 10280455
CTAGCCTCGTA
>MM870563.1 Sequence 62 from patent US 10273525
TGAACAAGGCT
>MM863176.1 Sequence 281 from patent US 10273480
CCAATGTCGCC
>MM863172.1 Sequence 255 from patent US 10273480
GAGGGACGTGC
>MM854559.1 Sequence 172 from patent US 10273291
TGTGCGAGAGA
>MM853929.1 Sequence 13 from patent US 10273269
GGGATCCTACC
>MM853772.1 Sequence 16 from patent US 10272409
GCCCACTACAG
>MM853771.1 Sequence 15 from patent US 10272409
CGCCCACTACA
>MA852270.1 JP 2019022498-A/148: METHODS OF DIFFERENTIATING STEM CELLS BY MODULATING MIR-124
ACGCCGTCATT
>MP150408.1 Sequence 83 from Patent EP3447065
AGGCAACAAAT
>MP150407.1 Sequence 82 from Patent EP3447065
CAGTGATGGTA
>MP150402.1 Sequence 77 from Patent EP3447065
CTTTAGCCATC
>MP150400.1 Sequence 75 from Patent EP3447065
TGCCATTGCAA
>MP150399.1 Sequence 74 from Patent EP3447065
CTCATGCCATT
>MP150396.1 Sequence 71 from Patent EP3447065
ATATGATGCTA
>MP150393.1 Sequence 68 from Patent EP3447065
CCGTAGATGCT
>MP150389.1 Sequence 64 from Patent EP3447065
ACAGGCTCATG
>MP150386.1 Sequence 61 from Patent EP3447065
AGGTTGTCATG
>MP150384.1 Sequence 59 from Patent EP3447065
ATTTTAAAGAG
>MP150587.1 Sequence 36 from Patent EP3446714
GCGGTTTGCGG
>MP150571.1 Sequence 20 from Patent EP3446714
GGTGGTGGTGG
>MP150470.1 Sequence 145 from Patent EP3447065
TGTCCTTCAAT
>MP150468.1 Sequence 143 from Patent EP3447065
CTTCAGCRGAY
>MP150459.1 Sequence 134 from Patent EP3447065
GGCGTAGTGCT
>MP150456.1 Sequence 131 from Patent EP3447065
TGAAGCTTTTG
>MP150455.1 Sequence 130 from Patent EP3447065
GCTATATATTA
>MP150453.1 Sequence 128 from Patent EP3447065
AACTTATAAAG
>MP150450.1 Sequence 125 from Patent EP3447065
GGGATTCTAAA
>MP150448.1 Sequence 123 from Patent EP3447065
TCAACAGTCTA
>MP150446.1 Sequence 121 from Patent EP3447065
TATCTAAGGAA
>MP150445.1 Sequence 120 from Patent EP3447065
TTCTCGAAGAT
>MP150444.1 Sequence 119 from Patent EP3447065
AGAATCAAAAT
>MP150443.1 Sequence 118 from Patent EP3447065
AAAATCTTCTC
>MP150442.1 Sequence 117 from Patent EP3447065
CCTTGAAGAAT
>MP150440.1 Sequence 115 from Patent EP3447065
AAACAACCAAA
>MP150437.1 Sequence 112 from Patent EP3447065
GAATGGATTTT
>MP150436.1 Sequence 111 from Patent EP3447065
TATTAGAAGCT
>MP150435.1 Sequence 110 from Patent EP3447065
ATTGGACAAAT
>MP150434.1 Sequence 109 from Patent EP3447065
ATCTCTTGATA
>MP150433.1 Sequence 108 from Patent EP3447065
TTTCACAAGCA
>MP150425.1 Sequence 100 from Patent EP3447065
TACGCTCACTT
>MP150424.1 Sequence 99 from Patent EP3447065
TCTTCTAGTTG
>MP150419.1 Sequence 94 from Patent EP3447065
CATTGTCTTGT
>MP150416.1 Sequence 91 from Patent EP3447065
TTGTCCAAGTT
>MP150414.1 Sequence 89 from Patent EP3447065
AATCTTTCCGC
>MP150413.1 Sequence 88 from Patent EP3447065
CGCGAGTCCGA
>MP150412.1 Sequence 87 from Patent EP3447065
ATTGAATCTTT
>MP150411.1 Sequence 86 from Patent EP3447065
CAGGCATGGGA
>MP134325.1 Sequence 196 from Patent WO2019038771
CTTTATTCGTT
>MP134315.1 Sequence 186 from Patent WO2019038771
CAAAAAAAAAA
>MP134309.1 Sequence 180 from Patent WO2019038771
CATATATATAT
>MP134303.1 Sequence 174 from Patent WO2019038771
ATTTTTTTTTT
>MP134283.1 Sequence 154 from Patent WO2019038771
GTAATATGTCC
>MP134282.1 Sequence 153 from Patent WO2019038771
CTATATATATA
>MP134273.1 Sequence 144 from Patent WO2019038771
CTATATATATA
>MP134262.1 Sequence 133 from Patent WO2019038771
CTGTATATATA
>MP134254.1 Sequence 125 from Patent WO2019038771
CAAAAAAAAAA
>MP134248.1 Sequence 119 from Patent WO2019038771
CATATATATAT
>MP134240.1 Sequence 111 from Patent WO2019038771
ATTAAAGTGTC
>MP134223.1 Sequence 94 from Patent WO2019038771
GTATATATATA
>MP134179.1 Sequence 50 from Patent WO2019038771
AATATATATAT
>MP132697.1 Sequence 19 from Patent WO2019038544
ATTGGNCCACG
>MP126158.1 Sequence 20 from Patent EP3463483
GAATTCTGCAG
>MP126027.1 Sequence 357 from Patent EP3473266
GGGTTTTTGGG
>MP126017.1 Sequence 346 from Patent EP3473266
GGTTTTTTTGG
>MP125046.1 Sequence 8 from Patent EP3473730
TAGCAGCACGT
>MP125041.1 Sequence 3 from Patent EP3473730
GCATCAGCGAC
>MP124851.1 Sequence 34 from Patent EP3411494
TTATACATCTA
>MP124838.1 Sequence 21 from Patent EP3411494
TTATAGTGATT
>MP124837.1 Sequence 20 from Patent EP3411494
TTTTGATGATA
>MP124836.1 Sequence 19 from Patent EP3411494
TTATAGAGAAG
>MP124835.1 Sequence 18 from Patent EP3411494
TTTAATAAGGT
>MP124834.1 Sequence 17 from Patent EP3411494
TTATAATGGAT
>MP124833.1 Sequence 16 from Patent EP3411494
TTAATTAGGAT
>MP124832.1 Sequence 15 from Patent EP3411494
TTAATTGAGTA
>MP124831.1 Sequence 14 from Patent EP3411494
TTTTAGGTAAA
>MP124830.1 Sequence 13 from Patent EP3411494
TTATGAATCTA
>MP124829.1 Sequence 12 from Patent EP3411494
TTTCTTCATTA
>MP124828.1 Sequence 11 from Patent EP3411494
TTATCTACATA
>MP124826.1 Sequence 9 from Patent EP3411494
TTATACATCTA
>MP124818.1 Sequence 1 from Patent EP3411494
TTATACATCTA
>MP119343.1 Sequence 16 from Patent EP3444341
GCCGTATCCCT
>MP119342.1 Sequence 15 from Patent EP3444341
CGCGCTGTTAT
>MP119341.1 Sequence 14 from Patent EP3444341
CGCGCTGTTAT
>MP118114.1 Sequence 3 from Patent EP3456821
TAAATATTTTA
>MP118111.1 Sequence 23 from Patent EP3456333
CTAACCCTAAC
>MP118104.1 Sequence 16 from Patent EP3456333
GTTAGGGTTAG
>MP118103.1 Sequence 15 from Patent EP3456333
TAGGGTTAGAC
>MP118095.1 Sequence 7 from Patent EP3456333
GTGGAAGGCGG
>MP117138.1 Sequence 28 from Patent WO2019055829
AGCCCAATAAA
>MP117137.1 Sequence 27 from Patent WO2019055829
AGCCCAAGAAA
>MP117134.1 Sequence 24 from Patent WO2019055829
ACCCAAGTGAA
>MP117133.1 Sequence 23 from Patent WO2019055829
CCCAAGGGAAA
>MP117132.1 Sequence 22 from Patent WO2019055829
TCGCATGAGCG
>MP117131.1 Sequence 21 from Patent WO2019055829
TCGCAAGAGCG
>MP114472.1 Sequence 33 from Patent WO2019055234
CTACAGTGAAA
>MP114471.1 Sequence 32 from Patent WO2019055234
GCATGAGTGCG
>MP112015.1 Sequence 82 from Patent WO2019043417
TGAAGAGTTAT
>MP112014.1 Sequence 81 from Patent WO2019043417
AAGCTCCCGTT
>MP112012.1 Sequence 79 from Patent WO2019043417
CTAGTGCACGT
>MP112008.1 Sequence 75 from Patent WO2019043417
AGAATTCCGGA
>MP111999.1 Sequence 66 from Patent WO2019043417
GCGATCGTCGC
>MP111998.1 Sequence 65 from Patent WO2019043417
GCAGATCGTGC
>MP110538.1 Sequence 94 from Patent WO2019043395
CCCGCAGATGA
>MP110536.1 Sequence 92 from Patent WO2019043395
TAGAGGGCAAC
>MP110535.1 Sequence 91 from Patent WO2019043395
TAGAGTATAAC
>MP108216.1 Sequence 2 from Patent EP3448867
AAAAAAAAAAA
>MP108215.1 Sequence 1 from Patent EP3448867
TTTTTTTTTTT
>MP108072.1 Sequence 7 from Patent EP3448886
TTATACATCTA
>MP178826.1 Sequence 1755 from Patent EP3463386
TCGCCCTTCAG
>MP178825.1 Sequence 1754 from Patent EP3463386
CGTCGCCCTTC
>MP178816.1 Sequence 1745 from Patent EP3463386
CGCCCTTCAGC
>MP178814.1 Sequence 1743 from Patent EP3463386
TTCAGCACGCA
>MP178809.1 Sequence 1738 from Patent EP3463386
CCTTCAGCACG
>MP178798.1 Sequence 1727 from Patent EP3463386
GTCGCCCTTCA
>MP178791.1 Sequence 1720 from Patent EP3463386
CCGTCGCCCTT
>MP178776.1 Sequence 1705 from Patent EP3463386
CTTCAGCACGC
>MP178761.1 Sequence 1690 from Patent EP3463386
CGTTTTGTCGT
>MP178747.1 Sequence 1676 from Patent EP3463386
TTGTCGTTTTG
>MP178741.1 Sequence 1670 from Patent EP3463386
GTCGTTTTGTC
>MP178736.1 Sequence 1665 from Patent EP3463386
TCGTCGTTTTG
>MP178735.1 Sequence 1664 from Patent EP3463386
TCGTTTTGTCG
>MP178713.1 Sequence 1642 from Patent EP3463386
TGTCGTTTTGT
>MP178692.1 Sequence 1621 from Patent EP3463386
GTTTTGTCGTT
>MP178687.1 Sequence 1616 from Patent EP3463386
TTTGTCGTTTT
